The Polo-like kinases as recipients and enablers of epigenetic modifications in tumourigenesis by Ward, Rosa alejandra
University of Windsor
Scholarship at UWindsor
Electronic Theses and Dissertations
2014
The Polo-like kinases as recipients and enablers of
epigenetic modifications in tumourigenesis
Rosa alejandra Ward
University of Windsor
Follow this and additional works at: http://scholar.uwindsor.ca/etd
This online database contains the full-text of PhD dissertations and Masters’ theses of University of Windsor students from 1954 forward. These
documents are made available for personal study and research purposes only, in accordance with the Canadian Copyright Act and the Creative
Commons license—CC BY-NC-ND (Attribution, Non-Commercial, No Derivative Works). Under this license, works must always be attributed to the
copyright holder (original author), cannot be used for any commercial purposes, and may not be altered. Any other use would require the permission of
the copyright holder. Students may inquire about withdrawing their dissertation and/or thesis from this database. For additional inquiries, please
contact the repository administrator via email (scholarship@uwindsor.ca) or by telephone at 519-253-3000ext. 3208.
Recommended Citation
Ward, Rosa alejandra, "The Polo-like kinases as recipients and enablers of epigenetic modifications in tumourigenesis" (2014).
Electronic Theses and Dissertations. Paper 5092.
 
 
 
 
The Polo-like kinases as recipients and enablers of epigenetic modifications in     
tumourigenesis   
 
By 
Rosa Alejandra Ward 
 
A Dissertation  
Submitted to the Faculty of Graduate Studies  
Through the Department of Biological Sciences 
in Partial Fulfillment of the Requirements for 
the Degree of Doctor of Philosophy 
 at the University of Windsor 
 
 
 
Windsor, Ontario, Canada 
2014 
 
    ©  2014 Rosa Alejandra Ward  
 The Polo-like kinases as recipients and enablers of epigenetic modifications in 
tumourigenesis 
by 
Rosa Alejandra Ward 
APPROVED BY: 
______________________________________________ 
                                                    A.Parissenti 
Laurentian University 
 
______________________________________________ 
S. Pandey 
Department of Chemistry and Biochemistry 
______________________________________________ 
M. Crawford 
Department of Biology 
 
______________________________________________ 
A. Swan 
Department of Biology 
 
______________________________________________ 
JW Hudson, Advisor 
Department of Biology 
 
 
 
May 15, 2014 
iii 
 
 
Declaration of Co-Authorship / Previous Publication  
Co-Authorship Declaration 
I hereby declare that this dissertation incorporates material that is result of joint 
research, under the supervision under Dr. JW Hudson as follows: 
In all cases, the key ideas, primary contributions, experimental designs, data 
analysis and interpretation and writing, were performed by the author, and the 
contribution of co-authors was primarily through the provision of: 
Chapter 2. Alan Morettin isolated mouse embryonic fibroblasts and performed 
methyaltion specific PCR for all human tissues. Dr. David Shum contributed with 
archived tissue and was consulted for feedback in his area of expertise. 
Chapter 4. Several individuals contributed to this chapter. Dr. Anna Kozarova and 
Dr. Jordan Nantais generated the original mass spectrometry data with input from 
Dr. Otis Vacratsis, that was the springboard for the rest of this project. Gayathri 
Sivakumar contributed the kinases assays and co-immunoprecipitation data 
generated from PRMT5 truncation mutants. Sharon Yong contributed the initial 
PRMT5 localization images and counts. Brayden Labute performed the Western 
blot analysis for p53 levels. 
Chapter 5. This chapter was done in collaboration with oncologists Dr. Sindu 
Kanjeekal and Dr. Caroline Hamm. They both contributed with clinical samples, 
clinical patient data and their expertise where appropriate. Gayathri Sivakumar 
conducted all the in vitro studies within this chapter.  
Chapter 6. I have included work done by Gayathri Sivakumar as part of her 
undergraduate thesis in the Hudson lab 
I am aware of the University of Windsor Senate Policy on Authorship and I certify 
that I have properly acknowledged the contribution of other researchers to my 
thesis, and have obtained written permission from each of the co-author(s) to 
include the above material(s) in my thesis.  
I certify that, with the above qualification, this dissertation, and the research to 
which it refers, is the product of my own work. 
 
II. Declaration of Previous Publication 
iv 
 
 
This dissertation includes 2 original papers that have been previously 
published/submitted for publication in peer reviewed journals, as follows: 
 
Thesis 
Chapter 
Publication title/full citation Publication status* 
Chapter 2 Aberrant methylation of the Polo-like 
kinase CpG islands in Plk4 heterozygous 
mice. BMC Cancer 2011. 11:71 
Published 
Chapter 3 p53-Dependent and cell specific epigenetic 
regulation of the Polo-like kinases under 
oxidative stress. PLoS One 2014. e87918 
Published 
 
I certify that due to the open acces nature of these journals I retain copyright 
ownership and can reproduce these publications in my thesis. I certify that the 
above material describes work completed during my registration as graduate 
student at the University of Windsor. 
I declare that, to the best of my knowledge, my dissertation does not infringe upon 
anyone’s copyright nor violate any proprietary rights and that any ideas, 
techniques, quotations, or any other material from the work of other people 
included in my thesis, published or otherwise, are fully acknowledged in 
accordance with the standard referencing practices. Furthermore, to the extent that 
I have included copyrighted material that surpasses the bounds of fair dealing 
within the meaning of the Canada Copyright Act, I certify that I have maintained 
copyrights and can include this material(s) in my thesis.  
I declare that this is a true copy of my dissertation, including any final revisions, as 
approved by my thesis committee and the Graduate Studies office, and that this 
dissertation has not been submitted for a higher degree to any other University or 
Institution. 
 
 
 
v 
 
 
 
 
ABSTRACT 
 
 
Many highly conserved proteins have evolved specific niches in the cell 
cycle. For the Polo-like kinases (PLKs), these roles include centrosome duplication 
and maturation, the interaction with key DNA damage response proteins, 
cytokinesis, and chromosome separation. The PLKs deliver their effects via 
phosphorylation of their substrates at serine and threonine residues.  Due to their 
importance in the cell cycle, expression of the PLKs is strictly governed. PLK 
deregulation is ubiquitously associated with malignancy. Elucidating how these 
proteins are regulated is key to understanding how their proper function can be 
restored in tumourigenesis. In recent years, the study of epigenetics as an 
additional mechanism controlling gene expression has come to the forefront.  
Epigenetic mechanisms include the addition or removal of methyl groups at the 
DNA and histone levels. My studies describe the regulation of PLK expression at 
the DNA level through the epigenetic mechanism of DNA methylation, the 
microenvironmental alteration of PLK epigenetic marks, and how these 
modifications translate in vivo in the context of carcinogenesis. Furthermore, I 
describe a novel interaction between PLK4, the most structurally divergent of the 
PLKs, and PRMT5, another evolutionarily conserved protein that is responsible for 
the methylation of arginine residues.  Here I propose that the DNA 
hypermethylation of PLK4 promoter, and its subsequent reduction at the protein 
level, contributes to a tumourigenic state. As a signalling protein, the significant 
decrease in PLK4 creates a domino effect destabilizing global epigenetic marks, 
inhibiting the expression of the guardian of the genome, p53, and potentially 
contributing to the upregulation of the pro-mitotic protein, PLK1, the original 
member of the PLKs.  
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CHAPTER 1 
 INTRODUCTION 
The PLKs and the cell cycle 
 
Serine/threonine kinases are essential for cell signalling and progression through 
the cell cycle.  One such group of proteins are the highly conserved Polo-like family of 
kinases (PLKs) [1].  Initially discovered in fruitflies, orthologs of the Drosophila Polo 
can be found from S. cerivisiae, to Xenopus and humans [2]. The PLK family consists of 
five distinct family members in mammalian systems.  Evolutionarily, it has been 
hypothesized that the PLKs were derived from an ancestral member of PLK1, with each 
PLK becoming more specialized, and crucial cell cycle chores segregated among them 
[2]. They have a conserved kinase domain that is essential for their activity and two or 
three polo-box domains which help to bind substrates and aide in PLK localization (Fig. 
1.1) [3]. Their individual expression profiles overlap throughout the cell cycle, however, 
there is no characterized redundancy among them. The PLKs are critical for key cell 
cycle events which include, but are not limited to: centrosome dynamics, the DNA 
damage response, mitotic entry, and cytokinesis (Fig. 1.2) [4]. PLK1-4 all interact with 
p53 with differing outcomes (Fig. 1.3).  
 
PLK1 
Polo-like kinase 1 is likely the founding member of the mammalian PLKs from 
which the remainder of the polo-like kinases evolved from. Its temporal and spatial 
localization within the cell has been well characterized. In adult tissue it is expressed in  
2 
 
 
 
 
 
 
 
Figure 1.1 PLK protein structure and domains. The polo-like kinases in mammals 
consist of five members idnetified to-date. PLK1-PLK4 all have a highly conserved 
kinase domain that exacts phosphorylation on their respective phosphorylation. Human 
PLK5 has a truncated kinase domain (KD), but remains functional. All the PLKs have at 
least two polo-box domains that are required for localization and auto-phosphorylation.  
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actively proliferating cells in the placenta, testes, ovaries, and spleen [5].  PLK1 
expression studies have determined that it is least abundant during the G0 and G1 phases 
of the cell cycle, and so, differentiated cells have little to undetectable PLK1 protein 
levels [5].  The expression of PLK1 increases from late S-phase and peaks in mitosis, 
when PLK1 activity also reaches its apex [6]. PLK1 has multiple functions prior to- and 
throughout mitosis, therefore, its localization is dynamically regulated. A requirement for 
the trasnsition into mitosis is centrosomal maturation, PLK1 plays a crucial role in this 
process by targeting several key centrosomal proteins including α-,β-, and ɣ-tubulins [7]. 
Mitotic entry also requires the activation and nuclear localization of Cyclin B/Cdk1, 
which is accomplished by the simultaneous degradation of Cyclin B/Cdk1 inhibitors, and 
activation of CDC25C. PLK1 is crucial at multiple stages in this process. CDC25C is a 
substrate of PLK1 and is phosphorylated at a nuclear export signal, allowing CDC25C to 
be translocated to the nucleus [8]. Concomitantly PLK1 phosphorylates the Cyclin 
B/Cdk1 inhibitors Wee1 and MYT1, that allows for the binding of E3 ubiquitin ligases 
and their degradation [9]. PLK1 also phosphorylates cyclin B at the centrosomes [10].  
During mitosis, PLK1 localizes to the bipolar spindles, the kinetochores, and the 
cytokinetic bridge [6, 11, 12].  During prophase, PLK1 is required for the dissociation of 
cohesin, a protein complex that regulates the sister chormatid dissociation during cell 
division, via PLK1-dependent phosphorylation, that results in cohesin releasing from 
chromosomes  [13]; PLK1 activates the anaphase promoting complex and the subsequent 
separation of sister chromatids [14]. Post-mitotically, PLK1 is targeted for degradation by 
the anaphase-promoting complex via ubiquitination [15].  PLK1’s essentiality in cell  
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Figure  1.2. The role of the polo-like kinases throughout the cell cycle. The polo-like 
kinases are involved in many important events during the cell cycle from centrosome 
duplication and the DNA damage response to a variety of M-phase events that include 
spindle assembly, anaphase entry, and cytokinesis. This highlights the importance of  
tight regulatio of these hihly conserved serine/threonine kinases. Figure adapted from 
Dai, 2005. Oncogene  
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cycle progression is evidenced by the impact of inactivating mutations of PLK1 orthologs 
in multiple species; in Drosphila (Polo),budding yeast (cdc5), and fission yeast (plo1) all 
resulting in lethality [16-18]. It comes as no surprise, therefore, that in mammals, Plk1 
-/-
 
murine embryos arrest at embryonic day 3.5 and fail to proliferate past the eight-cell 
stage [19]). Although these embryos progressed through S-phase and had no defect in 
DNA synthesis, they did not show markers for mitosis such as phosphorylated H3 or any 
assembled spindles, both required for the mitotic progression [19].  PLK1 is a pro-mitotic 
protein, and unlike the other PLKs, its role in the context of DNA damage is not to 
enhance or activate p53, but in fact to suppress its function. PLK1 suppresses p53 in 
several direct and indirect ways. By directly binding with p53 in its DNA binding region, 
PLK1 inhibits p53’s transactivation activity [20]. Indirectly, PLK1 also induces p53 
degradation by phosphorylating and activating proteins that lead to p53 ubiquitination or 
sumoylation [20]. These targets include Mdm2 and Cdc25C, whose activation leads to 
the dephosphorylation of p53 at S15 resulting in p53 degradation [21]. As well, PLK1 
phosphorylation of the GTSE1 protein, shuttles it to the nucleus where it displaces p53 
into the cytoplasm resulting p53’s degradation [21]. However, p53 is not to be 
underestimated, this repressive relationship is bi-directional. p53 hampers PLK1 
expression at the transcriptional, post transcriptional, and the protein levels. The PLK1 
promoter has several regions that serve as sites for transcriptional regulation. In these 
regions, p21, a target of p53, has been known to repress PLK1 transcription by recruiting 
complexes that bind upstream of the PLK1 promoter start site, additionally, PLK1 also 
has p53 responsive elements where p53 is often recruited after DNA damage [22]. 
FoxM1, a downstream transcriptional activator of PLK1, whose  
8 
 
 
 
 
 
 
 
 
Figure 1.3.  Polo like kinases and the p53 interaction axis. PLKs 1-4 all have 
important interactive relationships with p53 whose deregulation can result in cell cycle 
abnormalities. Of the PLKs, only PLK1 downregulates p53 in its DNA binding domain, 
while PLK3 and 4 play activating roles by phosphorylating S20 and S392 respectively. 
PLK5 has yet to have a characterized interaction with p53.  
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expression levels mirror that of PLK1’s, is also directly repressed by p53 [22, 23]. At the 
RNA level, p53 activates micro-RNA’s that degrade PLK1 transcripts. Lastly, at the 
protein level, p21 activates the RB family of proteins, which in turn target PLK1 for 
transcriptional repression by recruiting the SWI/SNF chromatin remodeling complex that 
leads the histone deacetylation and a more closed chromatin state [21]. PLK1 is a mitotic 
regulator which co-ordinates many important events prior to- and during mitotis, and 
whose relationship with p53 has significant impact on cell cycle progression.  
 
PLK2 
Unlike PLK1, PLK2 expression occurs predominantly in G1 phase of the cell cycle and 
plays a growth regulatory role at G1 and in centriole duplication in S phase [5, 6, 24]. In 
unperturbed cells, PLK2 localizes to the centrosomes and has been implicated in the 
centrosome duplication process during the late G1/S phase; human cells depleted of 
PLK2 did not undergo centriole duplication [24].  PLK2 mRNA levels are induced in 
response to X-ray, UV radiation, and other DNA damaging agents, this stress response is  
mediated through p53 as PLK2 is a direct target of p53 and [25, 26]. Separate studies in 
PLK2
 
depleted cells demonstrated that with low levels of PLK2, cells are sensitized to 
stress and there is an increase in apoptotic cells after exposure to genotoxic stress [26].  
Although catalytically active, PLK2 has a quick turnover rate with a half life of 
approximately 15 minutes [27] and PLK2 expression is not segregated to actively 
proliferating cells, but has a broad tissue distribution with transcripts detected in human 
brain, uterus, mammary gland, and the trachea [28]. Interestingly, PLK2 is differentially 
expressed at a variety of brain regions with the highest expression found in the occipital 
11 
 
and putamen lobes [28]. Recently, the focus of PLK2 research has been in a neurological 
context with several characterized brain-specific targets including α-synuclein, a protein 
associated with Parkinson’s disease and other neurological disorders [29]. Bergeron et al. 
have shown in vivo work demonstrating PLK2 to be directly linked to the phosphorylated 
α-synuclein accumulation in the brain [30]. In keeping with PLK2 as a stress response 
protein, PLK2 levels increase rapidly in post-mitotic neurons and downregulate sustain 
neuronal activity as in the case of seizures [31]. As a result of its activation, PLK2 
localizes to the dendrites of these neurons and is involved in the abatement of synaptic 
strength [32, 33].  However, despite all these roles in the cell cycle and in the brain, 
PLK2 is not an essential cellular protein. In vivo, Plk2
-/- 
cells have a delayed transition 
into S-phase and a longer cell cycle of 25 hours compared to 22 in the wild type cells, 
and Plk2 deficient mice are viable and only display mild growth retardation [34]. It has 
been suggested that although Plk2 has a distinct role in the progression of the cell cycle, 
there may be some functional degeneracy among other Plks that may account for the 
relatively normal phenotype observed in Plk
-/-
  mice [26]. 
 
PLK3 
 Of the PLKs, PLK3 is most similar to PLK2. Like PLK2, PLK3 is an early 
response gene whose transcripts increase in response to mitogenic stimuli in G1 [35]. This 
response has been documented in both murine and a broad spectrum of human cells [5]. 
Although conflicting reports exist with regard to PLK3’s cellular expression, most 
literature indicates that PLK3 levels are generally constant throughout the cell cycle, 
except during mitosis when it is degraded during anaphase [5, 15, 36]. Endogenous PLK3 
12 
 
is found in the cytoplasm, but its localization has also been detected at the centrosomes, 
the nucleus and nucleolus [37, 38]. PLK3 has been implicated in the activation of the 
DNA damage pathway in response to genotoxic stress. DNA damaging agents like 
reactive oxygen species (ROS), can trigger an increase in PLK3 levels [38, 39]. PLK3 
then helps to activate the p53-dependent DNA damage repair pathway by interacting with 
Chk2 and phosphorylating p53 at S20 [5, 38, 39].  PLK3 also plays an active role in the 
G2/M transition by targeting S191 and S198 within the nuclear export signal (NES) of 
Cdc25C thus,promoting its accumulation in the nucleus where it activates cyclinB1/Cdk1 
[40]. Cdc25A is another key phosphatase targeted by PLK3, in this case, PLK3 
phosphorylation of Cdc25A’s C-terminus is associated with priming required for its 
degradation [41]. Although PLK3 has distinct roles in dividing cells, its expression has 
also been detected in terminally differentiated tissues such as human respiratory organs 
including the lungs and bronchus, and in neurons [2]. Similar to PLK2, PLK3 also targets 
α-synuclein and has been implicated in neurological illnesses, though its role in this 
context is less well characterized compared to PLK2 [30, 32].  Interestingly, two separate 
labs have developed a PLK3 mouse model. The Dai group developed a viable PLK3 null 
mouse that, as it aged, developed tumours in multiple sites: kidney, liver, uterus, and lung 
at a rate of 60% compared to 7% in the wild type [42]. They also determined that PLK3 
imparted its tumour suppressive functions through inhibition of HIF1α, since PLK3-/- 
cells displayed deregulated HIF1α levels and activity after hypoxia treatments. The 
second PLK3 mouse model showed no such disparity in tumour formation, and PLK3 
null mice developed tumours at the same rates as their wild type littermates [41]. PLK3 
null MEFs, however, displayed a defect in the G2/M transition and an increase in the 
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polyploid population along with an accumulation of Cdc25A, in keeping with the 
regulatory role PLK3 has on Cdc25A [41]. This data suggests that although PLK3 does 
have relevant roles in the cell cycle, it is not an essential protein for cell cycle 
progression, though its primary functions may be more important in the homeostasis of 
cells such as its increase in activity in response to genotoxic stress.   
 
PLK4 
 PLK4 is the most structurally anomalous of the PLKs. The N-terminus houses its 
kinase domain, while its C-terminus accommodates three polo-box domains with PB1 
and PB2 contiguous to one another and PB3 located at the more distal end of the C-
terminus [43]. It also has three PEST sequences, unique to this PLK, which are required 
for PLK4 degradation [44, 45].  Like the other PLKs, PLK4 has unique cellular functions. 
Although PLK4 is expressed throughout the cell cycle, its expression begins to increase 
during S-phase and peaks at the G2/M. During this time, PLK4 is multi-tasking by 
interacting with cell cycle regulators like CDC25C, and localizing to the centrosomes and 
the cleavage furrow [46-48].  
 PLK4 is absolutely required in centrosome duplication. The centrosome is the 
microtubule organization centre (MTOC), preserving cellular polarity and architecture 
via nucleation of microtubules and their subsequent organization [49].  Duplication of the 
centrosome is licensed to occur once per cell cycle and is intimately coordinated with 
DNA synthesis, mitosis, and cytokinesis [50]. Centrosomes consist of a mother and 
daughter centriole perpendicular to one another, surrounded by pericentriolar material 
(PCM) composed of a variety of proteins like ɣ-tubulin and pericentrin (Fig. 1.4) [51].  
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Both the microtubule nucleation and pro-centriole biogenesis occurs in the PCM [51]. 
Centrosomal scaffold proteins Cep192 and Cep152, recruit PLK4 to the centrosome [52]. 
It localizes to both ends of the centrioles, but at the proximal ends, the site of pro-
centriole formation, PLK4 is required for the initiation of centriole duplication [53, 54].  
Additionally, once established at the centrioles, PLK4 together with Cep152 recruit PCM 
and allow the spindle assembly process to begin [55].  With PLK4 being an essential 
centrosomal protein, its expression must be tightly control, reminiscent of a Goldilocks 
scenario; where down-regulation or over-expression of PLK4 has deleterious effects on 
centriole duplication fidelity, its levels have to be just right. In light of this, PLK4 is 
regulated at multiple levels. At the DNA level, during early G1, PLK4 is transcriptionally 
repressed at cycle-dependent element (CDE) and cell cycle gene homology (CHR) 
elements upstream of its promoter region [57].  In the case of insufficient Plk4, Plk4
+/-
 
murine embryonic fibroblasts (MEFs) display multiple centrosomes and multipolar 
spindle formation [58]. Likewise, PLK4 over-expression in somatic cells is also 
associated with supernumerary centrosomes. Centrosome amplification leads to 
aneuploidy, genomic instability and ultimately, tumourigenesis [59]. This is evidenced in 
aging  Plk4
+/- 
mice, which develop liver and lung tumours at a 15 times higher rate than 
their wild type counterpart [58].  
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Figure 1.4.  Basic centrosome structure.  Centrosomes are made up to two centrioles, 
mother and daugther centrioles. They are orgonally arranged and have interconecting  
fibres between them. This is the centre for microtubule organization and determines cell 
polarity. PCM= pericentriolar material [56].  
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Adequate Plk4 levels also have important roles during development. Plk4 null 
embryos are not viable and arrest at embryonic day 7.5 with a significant proportion of 
embryos arresting before anaphase [47].  One of PLK4’s targets, the transcription factor 
Hand1, is responsible for placentation, as well as cardiac differentiation and 
morphogenesis in the developing embryo [60]. PLK4 phosphorylation of Hand1 induces 
its migration out of the nucleolus and into the cytoplasm, prompting cellular 
differentiation. Inhibition of PLK4 led to Hand1 accumulation in the nucleolus, lack of 
differentiation, and continued proliferation in trophoblast stem cells [60].  Furthermore, 
during early mouse embryogenesis, spindles assemble around chromosomes, since at this 
time there is an absence of centrioles, Plk4 is required for appropriate spindle assembly 
[55].  
PLK4 has also been implicated in the DNA damage response. Some of the 
characterized substrates of PLK4 are known DNA damage response inducers including 
Chk2 and p53 [61]. Cellular exposure to stressors, including etoposide and UV radiation, 
induced an increase in PLK4 protein and activity via phosphorylation by the stress-
activated kinase kinase kinases (SAPKKK)[62] and the NFκB transcription factors also 
function as PLK4 transcriptional activators during stress [63]. With sustained stress, p53 
levels also increased and in turn suppress PLK4 levels [62].  Ko et al 2005 determined 
that PLK4 interacted with p53. In a liver resection model, p53 failed to become activated 
in PLK4
+/-
 mice compared to wild type mice, suggesting that under those conditions, Plk4 
was essential in the activation of p53. This group also determined that PLK4 
phosphorylates p53 at S392, a residue that is phosphorylated in active p53 [64]. Other 
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than protein-protein interactions, p53 also suppresses PLK4 at the transcriptional level 
through histone deacetylases, which enable a closed chromatin structure [65].  
These studies attest to the essentiality of PLK4 in critical events throughout cell 
division and in postgastrulative embryonic development.  
 
PLK5 
 PLK5 is the most recently discovered member of the PLKs. Structurally and 
functionally, it is most like PLK2 and PLK3, however, in humans, PLK5 has stop codon 
in its kinase domain, where mouse Plk5 retains its kinase domain [66]. Interestingly, both 
mouse and human PLK5 have almost identical functions and it appears that the kinase 
domain is not necessary for their functional execution [67]. Plk5 expression is tissue 
specific, being expressed in the brain, eye, and ovary of the mouse. In humans, PLK5’s 
expression is limited to differentiated cells: acini of the parotid glands, the proximal and 
distal tubules of the kidney, and neruonal cells to name a few [67].  In neurons, PLK5 
depletion resulted in attenuated neurite formation and outgrowth [67], indicating PLK5 is 
important in neuronal differentiation. 
  PLK5 primarily localizes to the nucleolus, and has three nucleolar localization 
signals at its amino-terminus [66]. Removal of any of these motifs resulted in mis-
localization of PLK5 [66].  PLK5 also appears to be involved in the response to cellular 
stress with transcripts becoming elevated with exposure to multiple stressors such as 
etoposide, nocodazole, and serum starvation [66, 67]. Ectopic expression of Plk5 was 
also accompanied by elevated levels of p21, G1 cell cycle arrest, and apoptosis all 
occurring in a p53-dependent manner [2, 66, 67]. Despite that no relationship has been 
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established between PLK5 and p53, it is likely that a relationship exists due to the PLKs 
sharing common interacting partners. Further characterization of PLK5 is required to 
fully elucidate its role in the cell cycle.  
 
Cell cycle inhibitors and checkpoints 
In order to maintain genetic content fidelity, eukaryotic cells have evolved 
internal monitoring systems to thwart the duplication of faulty and/or damaged DNA. 
These checkpoints are placed at critical phases of the cell cycle and are composed of 
proteins that are responsible for halting the cell cycle and initiating, either DNA repair, 
apoptosis or cellular senescence in response to intra-or extracellular stressors (Fig.1.5) 
[39].   
 
DNA damage checkpoints 
The cell cycle has several DNA damage checkpoints and the spindle assembly 
checkpoint; these checkpoints collectively safeguard the cell from genomic instability. As 
part of the checkpoint mechanism, multiple components make up the required sensors, 
transducers, mediators, and effectors to disseminate the DNA damage response. Ataxia 
talingiectasia mutated (ATM) and ATR (ATM and rad3 related) proteins act as both 
sensors and transducers of DNA damage, with DNA damage resulting in their 
conformational changes and/or changes in their localization. ATM responds to ionzing 
radiation and double strand breaks, while ATR responds to DNA replication stress [68]. 
As transducers, ATM/R mobilize p53, a tumour suppressor, and the checkpoint kinases 
(Chk)1/2, which in turn act as effectors themselves, or activate effector proteins [69]. 
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Chk1/2 inhibit the function of the Cdc25 phosphatases, which are required in Cdk2 and 
Cyclin B1 activation. p53 in turn, activates the Cdk inhibitor protein (CIP) p21
CIP
, which 
directly binds and inhibits Cyclin D, Cyclin E/A(Fig. 1.5) [70].  
 
Spindle assembly checkpoint  
  The spindle assembly checkpoint is made up of several mitotic arrest deficiency 
proteins (Mad) 1-3 and budding uninhibited by benomyl (Bub) 1-3 proteins which form a 
large mitotic checkpoint complex. Mad2 and BubR1 work synergistically to sequester  
Cdc20, an activator of APC/C early in M phase, while Bub1 phosphorylates Cdc20 [71]. 
This collaboration prevents the early onset of sister chromatid separation prior to the 
adequate attachment of bivalent spindles [72].  
In addition to these checkpoints, there are additional layers of control that can 
suppress cyclin-cdk activity. Several antagonizers specifically target the Cyclin D-
Cdk4/Cdk6 complexes, these are called the inhibitors of kinase 4 family: p15
INK4B 
, 
p16
INK4Aa
 , p18
INK4C
, p19
INK4d
  [73]. The CIP family, other than p21, also includes p27
KIP1
 
and p57
KIP2
, which have a broadened their inhibitory effects to target multiple cyclin-cdk 
complexes [73]. Collectively, these proteins are called tumour suppressor proteins, 
however, in cancer they often deregulated through mutation or inactivation.  
 
The guardian of the genome: p53 
 Often referred to as the guardian of the genome p53 a key tumour suppressor is 
defective in approximately 50% of human cancers. The active p53 protein is a  
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Figure 1.5.  Checkpoints.  There are multiple proteins that can halt the progression 
through the cell cycle in the event of an insult. These protein target the cyclin-cdk 
proteins that are required for cell cycle progression. Modified from Molecular Cell 
Biology 5
th
 Edition. 2004     
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homotetrameric transcription factor which is activated in response to a variety of 
environmental insults and stressors including UV and ionizing radiation, spindle 
assembly defects, reactive oxygen species, and hypoxia [74] [73, 75]. Levels of p53 are 
kept at a low but constant level, with a short half life of 20 minutes [73].  Mouse double 
minute 2(mdm2) is an E3 ubiquitin ligase that binds p53 and targets it for proteolytic 
degradation by ubiquitination. The most well-studied and primary function of p53 is to 
create a barrier by which the emergence of transformed and genomically unstable cells is 
prevented.  p53’s activation, through the interruption of mdm2 binding and subsequent 
protein stabilization can result in two basic outcomes: 1. the cell cycle is arrested and the 
damage is repaired or 2. The damage is too great for cell viability resulting in apoptosis, 
senesence or autophagy.  At the protein level, p53 has important domains that control its 
activation, oligomerization, and DNA-binding specificity (Fig. 1.6) [73]. The most 
frequent mutations found in p53 are point mutations, which make up the majority of the 
15 000 documented mutations in human tumours, many of them occurring in its DNA 
binding domain [76, 77].   These mutations result in defective p53 with an inability to 
bind its downstream targets.  Recently, work on mutant p53 has determined that in some 
cases of breast and malignant skin tumours, p53 mutant proteins go on to form aggregates 
resulting in amyloid oligomers [78]. These aggregates can bind wild type p53 and the p53 
homologues, p63 and p73, creating a dominant negative, prion-like effect on wild type 
p53 [78]. These studies have revealed that deregulation of p53 does not just affect its 
downstream targets, but can sequester remaining wild type p53 and its homologues and 
prevent DNA damage repair.  
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Figure 1.6. p53 protein structure and domains. The tumour suppressor p53 is a 
homotetramer composed of six distinct domains. The transactivation domain (TAD), the 
proline rich region (PRR), the DNA-binding domain, and the tetramerization (TD) and 
regulatory domains (RD).  Portions of this figure have been adapted from Joerger and 
Fersht, 2010.  
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Collectively, these checkpoints, along with their respective effector proteins are 
charged with the genomic intergrity of the cell by responding to DNA damage and other 
stressors, and activating the adequate pathways for repair, apoptosis, or senescence.  
 
Cancer 
 Carcinogenesis is a progressive disease consisting of a variety of contributing 
factors. In their original review, Hanahan and Weinberg proposed that cancer has six 
hallmarks: sustained cellular proliferation, avoidance of growth suppression, resistance to 
cell death, induction of angiogenesis, invasive capacity, and unlimited replicative 
potential [79]. In their most recent review, Hanahan and Weinberg, in addition to their 
original six hallmarks, have proposed new emerging hallmarks of cancer: deregulated 
cellular metabolism, and evasion of immune destruction [80] along with underscoring the 
importance of genomic instability as an enabling characteristic that generates the cellular 
genotypes required to orchestrate the hallmarks of carcinogenesis.  
 
Genomic instability 
 Multistep tumourigenesis is achieved through alterations in the genome that 
confer selective advantages to neoplastic cells. This enables incipient cellular outgrowth 
and eventual dominance in the surrounding tissue.  Genomic instability has been detected 
at all levels in the progression to cancer, from early, pre-cancerous lesions to end stage 
cancers, in some cases even prior to p53 mutation [81]. Genomic instability generates 
mutations through chromosomal re-arrangements and nucleotide sequence alterations.  
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There are two distinct, and sometimes overlapping types of genomic instability: 
microsatellite instability (MIN) and chromosomal instability (CIN) and [73].  
 
Microsatellite Instability 
 Microsatellites are short repetitive elements 1-6 nucelotides in length. They were 
once considered extra, or “junk” DNA, however, these iterations have surfaced as 
important biomarkers in the prognosis and diagnosis of cancers, especially gastric and 
colorectal cancers. Approximately 15% of colorectal cancers present with MIN, though 
most of these cancers show little to no gross chromosomal aberrations [82]. Although 
microsatellites are most predominant in introgenic, non-coding regions, they can be 
hypervariable, harbouring high rates of mutation [73].   These mutations can be single 
point mutations or deletions. One would imagine that these types of mutations in non-
coding regions would be innocuous, however, they can cause frameshift mutations 
leading to reading errors, loss of function, and translational failures in important cell 
cycle regulatory genes; such is the case for ATR and Chk1 genes [83].  Other critical 
genes like BAX, a pro-apoptotic gene, harbour mononucleotide repeat mutations in 
coding regions in more than 25% of gastric cancers [84].  MIN has also been associated 
with hereditary non-polyposis colon cancer (HNPCC) and endometrial cancers [83]. 
These mutations can arise from errors in the mismatch repair mechanism (MMR). The 
MMR mechanism is central to suppressing proof reading errors that arise from DNA 
replication resulting in spontaneous mutations; MMR it is charged with making the 
necessary corrections [85]. In cancers, many of the genes required for MMR also undergo 
mutations related to MIN [83]. Clinically, MIN has been associated with several 
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pathological features such as heredity, gastric cancer staging, and chemosensivity [83, 
85].  
 
Chromosomal Instability 
 More than 90% of solid tumours present with chromosomal abnormalities, with 
gains or losses of whole chromosomes, or structural re-arragements, resulting in 
aneuploidy [82, 86]. Frequently, chromosomal aberrations can target tumour suppressors 
and known oncogenes, whose expression levels are deregulated due to genomic 
variations [86]. Aneuploidy is caused by several factors: compromised surveillance and 
DNA damage response pathways, centrosome amplification, or mis-segration of 
chromosomes due to SAC or APC/C defects [82]. CIN increases with each successive 
cell division creating genetically heterogeneous tumour cells. Several pathological 
indicators are correlated with CIN, such as increase in metastasis, reduced sensitivity to 
chemothepeutic agents, and poor prognosis [86]. 
  Cells experience DNA damage through endogenous and exogenous forms. 
Endogenous DNA damage can be a result of normal metabolism, such as the generation 
of reactive oxygen specicies; whereas exogenous damage can be attributed to UV and IR 
radiation or chemical exposure. Spontaneous DNA damage is managed through the 
activation of ATM/ATR and their downstream effectors Chk1/Chk2. Lowered levels of 
these checkpoint proteins is associated with an increase in chromosomal heterogeneity 
[86]. Both spontaneous and hereditary forms of cancer can harbour loss of function 
mutations in DNA repair proteins. ATM mutations are found specifically in lung 
adenocarcinomas [81].  Breast cancer susceptibility genes 1 and 2 (BRCA1 and BRCA2) 
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are important in repair of double strand breaks with germline mutations of these genes 
leading to an inadequate repair mechanism and the generation of breast and ovarian 
cancers [87]. Unrepaired double strand breaks have deleterious consequences with 
chromosome loss or chromosomal rearrangements. Mutations can also arise from 
proofreading errors during the repair process, as such, mutations in the Msh2 gene, which 
is required for mismatch repair, corresponds with the development of hereditary non-
polyposis colorectal cancers (HNPCC) [85].  
 Likewise, centrosome amplification can create a domino effect, by which the final 
outcome results in aneuploidy and CIN. Centrosome amplification has been correlated to 
tumour grade in a broad range of cancer types both solid and hematological [50]. It is 
well-established that cancer cells often undergo mitosis with supernumerary centrosomes 
forming multi-polar spindles. Multipolar spindles lead to errors in the kinetochore-
microtubule attachment and cause multipolar division. Breast cancer was the first human 
malignancy in which centrosome abnormalities were studied [50]. These tumours 
displayed multiple centrosome defects, in addition to centrosome amplification, they had 
increased centrosome volume, centrosome aggregates, and an accumulation of PCM [88].  
There are several defects that can result in centrosome amplification: 1. Improper 
initiation of centrosome duplication 2. Centrosome re-duplication 3. Failure of 
cytokinesis. The deregulation of several proteins has been directly linked with these 
defects resulting in centrosome amplification. p53 and Aurora Kinase A are prime 
examples. Tarapore and Fukasawa, 2002, showed that p53 is indispensible throughout the 
centrosome cycle; it is required at the initiation of centrosome duplication and 
suppression of centrosome re-duplication [89].  p53
-/- 
MEFs display centrosome 
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amplification and defects in cytokinesis [89]. Defects in cytokinesis can be accompanied 
by lagging chromosomes and incomplete cellular separation, which, in turn also results in 
multinucleated cells with multiple centrosomes and aneuploidy [89].  Unlike p53, Aurora 
A, a serine/threonine kinase is required for centrosome maturation, separation and cell 
progression through mitosis [90]. Its over expression is associated with cytokinetic 
defects and multinucleated cells, this phenotype is evident in human tumours 
overexpressing Aurora A [90].   
A weakened SAC may allow cells to advance into anaphase with unattached or 
misaligned chromosomes. Although infrequent, mutations in several SAC proteins have 
been associated with human cancers. In mice, bi-allelic deletion of many SAC genes, like 
Mad2, BubR1, and Bub3, all result in embryonic lethality, and many haploinsufficent 
mouse models for these genes develop multiple tumour types like lung, colon, and 
hepatocellular carcinomas [82].   
In many instances, these mechanisms are not mutually exclusive, but collectively 
provide several keys pathways making up the portrait of genomic instability throughout 
human cancers.  
 
Epigenetics  
In recent years, epigenetics has become a bigger focus in cancer research. The 
term “epigenetics” was coined by Conrad Hal Waddington as a way of describing the 
interaction between genes and their adaptability to their surrounding environment. More 
recently, the term is used to describe altered gene expressions that are passed on through 
somatic and meiotic cell division without modification to the underlying primary 
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sequence of a gene.  Epigenetics encompasses two distinct modifications that greatly 
impact gene expression. At the DNA level, individual CG sites and regions rich in CG 
dinucleotides, called CpG islands, are targeted by DNA methyltransferase enzymes 
(DNMTs) for the addition of methyl groups to the 5’ position of cytosines leading to 
DNA methylation (Fig. 1.7a) [91].  While at the histone level, histone tails undergo post-
translation modifications which include methylation, acetylation, and phosphorylation 
(Fig. 1.7b) [92]. Methyl CpG binding proteins (MBD) act as important liaisons between 
DNA methylation and histone modification [93]. They bind to hypermethylated promoter 
regions and block the attachment of transcriptional machinery, while simultaneously 
recruiting histone deacetylase-containing complexes to reinforce transcriptional 
repression at the histone level [93].  
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Figure 1.7.  Epigenetic modifications at the DNA and histone level. a) DNA 
methylation is found at CpG dinucleotide sites. A several CpG sites upstream of a gene 
promoter region is called a CpG island. Methylation is not found independently, but 
methyl-binding proteins (MBP) are also attached. b) Histone tail modifications are 
another form of epigenetic mofication leading to changes in gene expression. 
Ac=acetylation, p=phosphorylation, CH3= methylation.  
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DNA methylation in tumourigenesis 
DNA methylation was the first epigenetic mark to be linked to tumourigenesis 
(Lewandowska and Bartoszek, 2011).  DNA methylation is also the most well-studied 
aspect of epigenetics and has several implications in tumourigenesis.  In normal tissues, 
genomes gain global methylation marks with age, consistent with cells achieving a 
differentiated state and a decrease in cellular activity. In contrast, cancer cells display a 
global loss of methylation with increased methylation at gene-specific CpG islands, often 
in tumour suppressor genes [94].  Hypomethylation has been detected in stomach, colon, 
kidney, liver, lung, and pancreatic cancers [95]. Aberrant DNA methylation marks at 
CpG islands have been suggested to be an early event on the cellular trajectory towards 
tumourigenesis.  In 1999, Stephen Baylin and his group determined that colon cancers 
contained a specific DNA methylation profile, they termed this the CpG island 
methylator phenotype (CIMP), since then, many different cancers have become 
associated with specific DNA methylation profiles. These modifications can be used as 
markers for detection of early carcinogenesis, progression of disease, and potential 
predictors of response to chemotherapy [96]. The epigenetic silencing of the CDKN2A 
gene that codes for p16
INK4A
, has significant clinical value. Hypermethylation of 
CDKN2A was detectable in the sputum of patients that developed lung cancer up to three 
years prior to onset of clinical symptoms [96]. Interestingly, irregular DNA 
hypermethylation is detectable in pre-cancerous conditions such as liver cirrhosis due to 
viral infections, or lung inflammation due to smoking [96, 97]. Deregulated DNA 
methylation has also been coupled with an increase in tumour aggressiveness and poor 
patient outcome [97].   
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DNA methylation in normal cellular development 
The importance of DNA methylation is not limited to the tumourigenic context, 
but has extensive functions in normal mammalian growth and development such as X 
choromosome inactivation and genomic imprinting, [98]. During development, zygotes 
undergo large-scale erasure of maternal and paternal DNA methylation (5mC) marks 
through passive replicative dilution, culminating with the inner cell mass having a 
globally demethylated genome [99].   Methylation marks are re-established by DNA 
methyltransferases 3a and 3b (DNMT3a DNMT3b), enzymes responsible for de novo 
DNA methylation along with their co-factor DNMT3L [98], and these new patterns are 
then preserved in successive cell divisions by DNMT1, which is a maintenance 
methyltrasnferase and has an affinity for hemimethylated DNA [100].  Maintenance of 
5mC patterns are important in the developing embryo, with Dnmt1 null murine embryos 
arresting at embryonic day 8.5 [101].  Promoter methylation occurs early in development, 
potentially as a mechanism of defining lineage types. Such is the case in haematopoiesis, 
where 5mC defines the myeloid and lymphoid progenitor lineages [102].  DNA 
methylation is also the final addition to the multi-layer process in the random silencing of 
the extra X-chromosome in female [91].  DNA methylation is employed in the gene 
imprinting process by which a specific parental allele is silenced resulting in mono-allelic 
expression of a gene. In mouse, the gene insulin-like growth factor 2  receptor (Igf2r) is 
maternally expressed, and its ligand insulin-like growth factor 2 (Igf2) is paternally 
expressed [91, 98].  The negative aspects to parent-of-origin monoallelic expression is 
evident in human disease where the parentally expressed region undergoes a mutation or 
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a deletion. Both Prader-Willi and Angelman syndromes are two sides of the same coin; 
Prader-Willi syndrome is characterized by the loss of the paternal chromosome at locus 
15q11-13, and converserly, in Angelman syndrome, the 15q11-13 maternal chromosome 
undergoes deletion [103]. Both of these syndromes are characterized by decreased 
intellectual abilities.  
Epigenetic modifications have indispensable roles in development and DNA 
methylation profiles in tumourigenesis can give valuable insight and act as biomarkers in 
cancer. 
 
Polo-like kinases and tumourigenesis 
  
PLK1 
 PLK1 is a master regulator of mitosis and drives mitotic progression in normal 
cycling cells. Post DNA damage PLK1 has been shown to re-inititate mitosis by 
facilitating proteosomal degradation of p53 through GTSE1 activation, which allows the 
cell to overcome cell cycle arrest and resume division [21]. In the murine cell line NIH 
3T3, increased levels of PLK1 conferred a transformed phenotype capable of producing 
colonies in soft agar assays [104]. Likewise, in normal human fibroblasts, overexpression 
of PLK1 also produced malignant cell transformation; these transformants were also 
capable of producing tumours in nude mice [104].  Functionally, PLK1 is expressed 
differentially between normal and cancer cells. Unlike normal cells, where PLK1 levels 
begin to rise in S- and peak in G2 phase, in cancer cells, PLK1 is expressed early in G1 
and is essential for the G1/S transition [105]. Once in S-phase, PLK1 promotes DNA 
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synthesis by activating the origin of recognition complex 2 (Orc2), a component of the 
DNA replication machinery, prompting DNA replication even in the presence of 
genotoxic stressors [106]. This relationship between PLK1 and Orc2 has translated into 
drug resistance in the treatment of pancreatic cancer [107].  Patients with head and neck 
squamous cell carcinoma, esophageal cancers, or melanomas, exhibited increased levels 
of PLK1 and experienced a shortened 5-year survival compared to those that had low 
levels of PLK1[108]. Elevated levels of PLK1 have also been positively correlated with 
an increased tumour grade in ovarian, endometrial cancers, and gliomas [109-111]. In 
breast cancer, PLK1 levels have been positively associated with estrogen receptors (ER) 
in vivo [112]. While in vitro, PLK1 interacts with ER protein and acts as a  transcriptional 
co-factor activating classical ER targets like Wisp2 [113].  Multiple groups have also 
reported PLK1 deregulation in colorectal cancers, with increased PLK1 associated with 
increased age and tumour progression and poor prognosis [47, 114, 115]. Hepatocellular 
carcinoma and prostate cancers also exhibit a PLK1 over-expression phenotype [23, 116]. 
It may be that upregulation of PLK1 may trigger downstream effects that push the cell 
through the cell cycle regardless of completion of DNA replication, DNA damage, or 
proper microtubule attachments at the kinetochore, generating genomic instability [105]. 
Of course with PLK1 consistently up-regulated in multiple cancer types and its value as a 
prognostic indicator, recent research has concentrated on the development of effective 
PLK1 inhibitors [36, 116-120]. Several small molecule inhibitors targeting PLK1 have 
advanced onto phase I and phase II clinical trials [105]. Perhaps in the future, PLK1 
inhibitors may accompany standard chemotherapy treatments.   
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PLK2 and PLK3 
 PLK2 and PLK3 are both genes that become activated during stress in a p53-
dependent manner. In contrast to PLK1, PLK2 and PLK3 are consistently downregulated 
in several tumour types.  Downregulation of PLK2 through epigenetic means is a 
common event in hematological malignancies including B-cell lymphomas, B-cell 
chronic lymphocytic leukemias, multiple myeloma, acute myelogenous leukemia and 
myelodysplastic syndromes (MDS) [121-123]. In addition, two independent groups 
determined that downregulation of PLK2 is associated with drug resistance in ovarian 
cancers [124, 125]. Syed et al went on to show that PLK2 is epigenetically silenced in 
ovarian cancers with the increase in its promoter methylation associated with 
chemotherapy resistance. It was proposed that PLK2 may serve as a useful biomarker for 
chemotherapy insentivity [124, 126]. It is noted that, DNA hypermethylation of PLK2 is 
not limited to blood neoplasms and ovarian cancers. Epigenetic downregulation of both 
PLK2 and PLK3 has also been detected in hepatocellular carcinoma [23]. PLK3 levels are 
also negatively correlated with lung carcinomas and head and neck squamous cell 
carcinomas, with an low PLK3 levels associated with increased tumourigenicity [108] 
uterine, bladder [20] and breast cancers [127]. The lowered expression of both of these 
proteins may confer a growth advantage to cancer cells by avoiding activation of p53 
 
PLK4 
 Compared to the other PLKs, PLK4’s expression profiles in malignancy is not 
unidirectional. Interestingly both up and down regulation of Plk4 have been implicated in 
malignancy. This may be related to differences in tissue type and/or the cellular makeup 
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of these tumours.  For example, in the liver, PLK4 levels have been reported to be 
significantly downregulated in several independent samplings of HCC [23, 58, 128]. 
Decreased levels of PLK4 in HCC are correlated to increased clinical stage and tumour 
size along with significantly decreased overall survival [128]. The chromosomal location 
where PLK4 resides, 4q.28, frequently undergoes deletion in human HCC, culminating in 
PLK4 loss of heterozygosity [23, 58].  In multiple myeloma, a large proportion of 
samples (40%) assayed exhibited centrosomal amplication as well as low levels of PLK4 
[129]. However, here, low levels of PLK4 and centrosome amplification were correlated 
with a better prognosis [129].  Converse to these examples, PLK4 was found to be 
upregulated in colorectal and breast cancers [114, 130]. In colorectal cancer, similar to 
PLK1, increased PLK4 levels were linked to increased patient age, but not with tumour 
size [114].  In breast cancers, overexpression of PLK4 occurs in the more aggressive 
triple negative breast cancers and its upregulation is associated with poor survival [130]. 
The latter findings, together with PLK4’s unique structural features, has led to the 
development of selective small molecule inhibitors [130] for PLK4. One of these 
inhibitors, deemed compound 50 (designated CFI-400437) was particularly effective at 
suppressing PLK4 and decreasing tumour growth in a xenograft model [130].  Although 
PLK4 has been clearly implicated in malignancies, its role in tumourigenicity is multi-
dimensional and mirrors the protein’s ability to be dynamic, with characteristics of a pro-
mitotic protein as well as a stress and DNA damage response protein. 
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PLK5 
  PLK5 may potentially play a tumour suppressive role in brain tumours. In vivo, 
PLK5 has been shown to be silenced in astrocytomas and glioblastoma multiforme via 
promoter hypermethylation. While ectopic overexpression in cells derived from 
glioblastoma multiforme induced their apoptosis [67].  De Carcer et al. have suggested 
that silencing PLK5 through promoter hypermethylation may provide glioblastoma cells 
with a survival advantage that they may not have if PLK5 was active [67]. PLK5 is a 
newly discovered PLK and has yet to be fully characterized. Although, much of the 
research to date suggests that it may have tumour suppressive qualities and its function 
may play a role in deterring the formation of tumours in the brain.  
With the PLKs being so conserved across taxa and their function intertwined with 
indispensable cell dynamics, it is incumbent that their methods of regulation and 
downstream targets be elucidated.  The purpose of my dissertation was to determine if 
epigenetics played a role in regulating the expression of the PLKs and if this was related 
to a tumourigenic state.  
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Aberrant methylation of Polo-like kinase CpG islands in Plk4 heterozygous mice 
 
Authors: Alejandra Ward, Alan Morettin, David Shum, John W. Hudson 
 
Introduction  
 The Polo-like kinases (Plks) are a highly conserved family of serine-threonine 
kinases, found from unicellular eukaryotic organisms to higher multicellular eukaryotes. 
The mammalian Plks (Plk1-4) have been shown to play major roles in cell cycle 
regulation, centrosome dynamics and the cellular response to stress. Furthermore, 
perturbations in individual Plk protein levels have been associated with malignancies. For 
example, high levels of Plk1 are indicative of a poor prognosis in esophageal, non-small 
cell lung cancer and oropharyngeal carcinomas [1, 2] and have been observed in various 
forms of cancers including gastric, breast, ovarian, endometrial, gliomas, thyroid and 
melanomas.[3] In contrast, Plk3 is down-regulated significantly in carcinomas of the 
lung, head and neck.[4, 5] The Plk2 gene is downregulated in lymphomas and B-cell 
malignancies.[6] In the case of Plk4, over 50% of aged Plk4 heterozygous (Plk4
+/-
) mice 
develop tumours in comparison to only 3% of their wild-type littermates, the major site 
of tumour formation being the liver and lung.[7] In mice, Plk4 is haploinsufficient for 
tumour suppression, while in humans, loss of heterozygosity (LOH) for the Plk4 gene 
was found in 60% of a small sample of human hepatocellular carcinomas (HCC) 
cases.[7] The increased rate of tumourigenesis likely related to the generation of 
aneuploidy, as altered Plk4 levels result in abnormal centrosome numbers, [8] 
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furthermore Plk4 may also play a key role in a DNA damage response pathway consistent 
with its phosphorylation of p53,[7] and Chk2.[9] In general, overexpression of Plk1 is 
typically considered to be oncogenic in nature while the remaining Plks likely function as 
tumour suppressors. 
 Recently it has become evident that the hypermethylation of CpG islands of 
tumour-suppressor genes, histone modification and chromatin remodelling are common 
events in cancers. (for review see [10]) Individual Plk gene epigenetic modifications 
associated with malignancy have previously been documented for Plk2 where its 
methylation-dependent silencing was detected at a high rate in B-cell malignancies and 
Burkitt’s Lymphoma as well as in follicular lymphoma.[11, 12]  The correlation between 
the methylation status of the Plks and malignancy has not been studied in detail. In this 
regard, as noted below, we initially identified a gender disparity for the development of 
HCC in Plk4
+/-
 mice. Previously, the development of HCC was attributed to 
haploinsufficiency for Plk4 rather than via loss off heterozygosity. [7] Given that there is 
accumulating evidence that epigenetic changes are a driving force in the development of 
HCC,  [13] we were interested in determining whether a relationship exists between 
individual Plk epigenetic modifications in the context of Plk4 haploinsufficiency and the 
development of HCC.   
 
Results and Discussion 
Plk methylation status in ageing mice and HCC samples 
Sex specific predisposition to cancer may reflect the underlying effects of the 
methylation patterns of key cancer genes. While the mechanism remains unclear, gender 
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disparity for HCC has previously been established in both humans and mice, where males 
are 3-5 times more likely to develop HCC than females.[14, 15] Therefore, in the present 
study, we examined the rate of HCC in female and male Plk4
+/- 
mice and found that in 
females the rate of HCC was approx 12% (n=32) in comparison to 35% (n=60) in male 
Plk4
+/-
 mice, indicative of a gender disparity for HCC development. An analysis of the 
mouse and human sequence databases revealed that three of four murine and all four 
human Plk genes have CpG rich regions at their 5’ termini suggesting they may also be 
subject to regulation by promoter methylation. We examined the methylation status of the 
promoter region of the Plk genes from DNA extracted from aging mice for normal liver 
and liver tumours, and detected an increase in methylation status of the Plk4 gene in 
22/29 tumours including 16/22 liver tumours studied in male mice (Fig 2.1a). 
Methylation status was confirmed via bisulfite sequencing of the Plk4 CpG island, in 
which 30-40% of the 38 CpG sites analyzed were methylated (Supplementary figure 2.1). 
In contrast to the situation in males, we detected no Plk4 methylation in a small number 
of liver tumours found in females. Interestingly, at 6 months of age, no significant level 
of Plk4 CpG island methylation was detected in either male or female livers (Fig. 2.1b). 
However, at 9 months of age and corresponding to our observed phenotype in aged mice, 
higher levels of Plk4 promoter methylation was detected in male mice in comparison to 
their female littermates (Fig. 2.1c). In total, almost 80% of the HCC samples examined 
were methylated at Plk4 (Fig. 2.1d).  Similar disparities in the methylation status of 
individual genes associated with malignancy were previously found for RASSF1A in 
lung cancer, with males showing higher levels of methylation.[16]   
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The effect of aberrant Plk methylation on expression  
Lower Plk4 levels likely play a role in malignancy by affecting genomic stability through 
a mechanism related to Plk4’s role in centrosome duplication [8] and/or DNA damage 
pathways. [17] We therefore examined the levels of Plk4 transcripts and found that the 
levels were substantially lower in males versus female mice as early as 9 months of age 
(Figure 1e) and were greater than 10 fold lower in livers and liver tumours from aged 
Plk4
+/-
 mice compared to wild type males and females and Plk4
+/-
 females (Fig. 2.1f). 
Similarly, Plk4 protein was also significantly reduced in tumours (Fig. 2.1g). It is noted 
that, while livers from Plk4 
+/-
 mice were grossly normal, they  displayed variable 
amounts of Plk4 transcripts with an average that is significantly lower than found Plk4 
+/+ 
mouse livers. Similarly, at the protein level, in Plk4
+/-
, we see varied amounts of protein. 
It is noted that the Plk4 mice typically develop HCC 18-24 months on with some cases as 
early as 13 months. We suggest that this likely reflects varying stages of progression 
towards the development of HCC; suggesting that reduced levels of Plk4 as a result of 
promoter methylation may precede the appearance of visible tumours. Low levels of Plk4 
have been shown to result in the generation of mono-polar spindles and aneuploidy in 
both cell lines and tissues. [7], [8] This exemplifies the possibility that epigenetic 
modifications may play a role in gender biases for malignancy and corresponds to our 
observation that epigenetic modifications of the Plk4 gene leads to further Plk4 
downregulation, particularly in males. 
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Figure 2.1. Plk4 CpG island methylation and expression levels in elderly Plk4
+/-
 male 
mice and HCC samples. Shown in each case (a-c) is a representative figure of typical 
results based on determination of Plk4 promoter methylation in 6-9 females and males for 
both Plk4 wild type and Plk4
+/-
 genotypes. (a) Methylation status of Plk4 promoter 
regions of genomic DNA extracted from liver tumours in Plk4
+/-
 mice as determined by 
MSP.  U=unmethylated, M=methylated. (b) Plk4 CpG island methylation of liver 
samples from mice aged 6 months and (c) 9 months. (d) Graphical representation 
summarizing percentage of Plk4 promoter methylation in liver tumours from 18-24 
month old Plk4
+/-
 male mice. (e) Relative levels of Plk4 transcripts as determined by 
qPCR. RQ values were normalized to the level of Plk4 transcripts in livers from 9 months 
old Plk4
+/+
 animals. The error bars represent the upper and lower limit of the standard 
error from the mean expression level (RQ). (f) Relative levels of Plk4 transcripts in liver 
tissue and tumours from elderly mice. (g) Level of Plk4 protein in liver tissue extracts as 
determined by Western blot analysis.  Actin levels were used as a loading control. N= 
normal tissue, T= tumour tissue.  
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There is accumulating evidence that the Plk family of proteins often share the 
same targets or signalling pathways, thereby placing their substrates under tighter or 
opposing controls.[18] It was therefore of interest to determine whether Plk4 
haploinsufficiency was also correlated with altered CpG island methylation and 
expression levels for the remaining Plks. Unlike the situation found in haematological 
malignancies, [11]  we found no significant change in either the methylation status or 
expression levels for Plk2 in tumours, aging mice or association with gender (Fig. 2.2a-
b). There were also no discernible changes in Plk3 protein levels (Fig. 2.2c). 
Interestingly, the methylation status for Plk1 was opposite to that for Plk4. Normal tissue, 
regardless of age, showed methylation in the Plk1 promoter region in 80% of the samples 
tested (Fig. 2.3a-b).  However, Plk1 was found to be hypomethylated in 80% of HCC and 
other tumours found in Plk4
+/-
 mice (Fig. 2.3a-b). Furthermore, this loss of promoter 
methylation corresponded to a large increase in Plk1 transcript levels (Fig. 2.3c) and a 
corresponding increase in Plk1 protein level in HCC samples relative to normal liver 
tissue (Fig. 2.3d). While the presence of increased Plk1 protein within tumours is by no 
means novel and is consistent with its potentially oncogenic role in malignancy, our 
findings indicate a novel  
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Figure 2.2. Plk2 methylation of CpG island and protein expression levels for Plk2 
and Plk3 in relation to both age and gender in mice. (a) Levels of Plk2 protein in liver 
tissue extracts as determined by Western blot analysis. (b) Plk2 CpG island methytlation 
status as determined by MSP analysis. (c) Levels of Plk3 protein in liver tissue extracts as 
determined by Western blot analysis. Shown are representative figures of 6-9 females and 
males for both Plk4 wild type and Plk4
+/-
 genotypes. N= normal, T= tumour. Note: we 
did not analyze Plk3 for methylation status as no CpG islands were detectable for the 
Plk3 gene with MethPrimer 
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mechanism for Plk1 regulation in that its expression may be influenced by its promoter 
methylation status, and, our results suggest that the transforming capacity of Plk4 
heterozygosity may be linked to aberrant methylation of Plk1 and Plk4. 
 
Plk methylation status in human HCC samples 
In order to determine if Plk4 methylation status is correlated with the 
development of HCC in humans, we also examined a limited number of human liver 
samples (Supplementary figure 2.2). We found that in normal human hepatic tissue the 
Plk4 promoter region was not methylated in samples taken from patients with no history 
of HCC. In the case of HCC samples we detected Plk4 CpG island hypermethylation and 
downregulation of Plk4 transcript levels as well as barely detectable methylation of the 
Plk1 promoter region. In 3 of 6 samples we found that the corresponding Plk1 transcript 
levels were higher than in the normal control (Supplementary figure 2.2e),  We did not 
detect any changes for Plk2 and Plk3 promoter methylation (data not shown). Since we 
began this aspect of our study, Pellegrino et al. (2010) examined a large cohort of human 
HCC samples and reported Plk2-3 down-regulation in human hepatocellular carcinoma 
correlated with either promoter hypermethylation and/or loss of heterozygosity at the 
Plk2-3 loci. [19] In the case of Plk4 many of the cases displayed loss of heterozygosity 
with no methylation within the Plk4 promoter region. They did not report any analysis for 
the methylation status of Plk1. Their inability to detect methylation changes for Plk4 and 
ours for Plks2-3 may be a reflection of the use of different primers used for methylation 
specific PCR (MSP) which samples a small subset of the potentially methylated residues 
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within a CpG island. Together these results suggest that in general, epigenetic changes 
within the Plks may contribute to malignancy in humans.  
 
Global Methylation status and p53 activity   
In general, global hypermethylation increases with age; however, studies on 
aberrant methylation of genes associated with HCC, like in many other malignancies, are 
characterized by an overall general increase in global hypomethylation along with 
increased rates of hypermethylation of tumour suppressors.[20] We employed an ELISA-
based assay (Epigentek) in order to quantitatively measure genomic methylation. 
Interestingly, we found no significant difference between the 9 month old wild type 
males and age-matched wild type and Plk4 
+/-
 females (Fig. 2.3e). However, consistent 
with what has been shown with age progression, we found an overall increase in the 
global methylation of genomic DNA  in wild type male mice and both Plk4 wild type and  
heterozygous female mice from 9 to 20 months. In contrast, there was a decrease in 
global methylation in Plk4
+/-
 male mice over the same time period (* p<0.05). 
Furthermore, significantly higher levels of global methylation were found in young 
Plk4
+/-
 male mice compared to their wild type littermates (**p<0.001), while the opposite 
is true for the Plk4
+/-
 female mice, where they had significantly lower levels of global 
methylation compared to young wild type females (***p<0.05). . Although, as the 
females age, both genotypes have similar levels of global methylation. These results 
suggest that there is an interplay between gender and Plk4 haploinsufficiency that affects 
global methylation in liver tissue. 
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Figure 2.3. Analysis of Plk1 CpG island methylation status and expression, global 
methylation and expression levels for p53 and p21 in normal and liver tumour tissue 
samples (a) Plk1 CpG island methylation status for HCC samples compared to normal 
tissue  as determined by MSP for aged-matched littermates. U=unmethylated, 
M=methylated. (b) Graphical representation summarizing the percentage of methylated 
Plk1 promoters in both normal liver tissue and tumours.  (c) Plk1 transcript levels in 
normal liver and HCC samples as determined by qPCR. RQ values were normalized to 
the level of Plk1 transcripts in Plk4
+/+
 livers. The error bars represent the upper and lower 
limit of the standard error from the mean expression level (RQ) (d) Plk1 protein levels 
were examined by Western blot analysis. GAPDH protein levels were used as a loading 
control. N = normal, T = tumour. (e) The percent of global methylation of genomic DNA 
extracted from liver was determined by an ELISA assay specific for methylated DNA. 
(*p<0.05), **p<0.001, ***p<0.05, ) The error bars represent the upper and lower limit of 
the standard error (f) p53 and p21 protein levels as detected by Western blot analysis.  
GAPDH levels were used as a loading control. N=normal, T=Tumour.   
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p53 has also been found to be an upstream negative regulator of Plk4 via  histone 
deactylation (HDAC).[21] We therefore examined p53 levels in normal and tumour tissue 
and found that both p53 and p21 were up-regulated in tumour tissue compared to the 
normal tissue (Fig. 2.3f). p53 is also a substrate for Plk4 [22] and p53 levels/activity are 
upregulated as a result of haploinsufficiency in MEFs.[17] These observations suggest 
that increased p53 levels/activity, a consequence of Plk4 haploinsufficiency, may also 
contribute to repressive chromosome structure and the reduced transcript profiles seen in 
aged and tumourigenic Plk4
+/-
 mice.  
 
The effect of chronic alcohol exposure on Plk4 Methylation status in MEFs. 
Alcohol has become an emerging environmental player in the modification of the 
epigenome. [23] In humans chronic alcoholism has been shown to increase availability of 
blood homocysteines, which in turn modifies S’adenosyl methyltransferase (MATs) 
levels, an enzyme responsible for the transfer of methyl groups to DNA. Furthermore, 
these patients showed a significant increase in global DNA methylation by up to 10%. 
[24] There is increasing evidence that alcohol consumption, a known risk for the 
development of HCC, can increase the methylation status of promoters with a subsequent 
decrease in gene expression .[24-26]  In liver cells, the presence of alcohol results in an 
increase in the formation of reactive oxygen species, which are in turn responsible for 
hepatocyte damage, cellular apoptosis, and the tumour promoting effect of ethanol.[27] 
Interestingly, we have preliminary evidence of increased Plk4 methylation in human 
cirrhotic livers with no evidence of viral infection (see supplementary data). This coupled  
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Figure 2.4. The effect of chronic ethanol exposure on murine embryonic fibroblasts 
(MEFs) (a) MEFs were exposed to ethanol for a period of 7 days at which time the 
methylation status of individual Plk CpG islands was determined by MSP analysis. 
U=unmethylated, M=methylated. (b) Plk4 and Plk1 transcript levels in Plk4 wildtype 
(Plk4
+/+
) MEFs were determined after 7 days of ethanol exposure by qPCR. RQ values 
were normalized to the level of transcript found in untreated control MEFs. Standard 
error was calculated based on the  minimum  and maximum values from the mean 
expression levels (RQ) (c) Immunofluorescence analysis Plk4
+/+
 MEFs exposed to 25mM 
and 50mM ethanol for a period of 7 days. Centrosomes were detected by γ-tubulin 
staining and DNA by Hoechst staining. A graphical representation of cells exhibiting 
multiple centrosomes and multinucleation is underneath. Shown are the results of three 
independent experiments in which more than 200 cells were analyzed each time for each 
condition. Error bars indicate standard error. (d) Global methylation analysis of genomic 
DNA from MEFs after 7 days alcohol exposure as determined by MSP analysis of B1 
elements. The error bars represent the upper and lower limit of the standard error from 
the mean.(e) Plk4 transcript levels as determined by qPCR of MEFs exposed to ethanol 
for 7 days in the presence of 5-aza-2’deoxycytidine (AZA), trichostatinA (TSA) and 
valproic acid (VPA). RQ values were normalized to the level of Plk4 transcript in 
untreated control MEFs. The error bars represent the upper and lower limit of the 
standard error from the mean expression level (RQ)  
 
 
63 
 
 
 
 
64 
 
with the associated risk of alcoholism and HCC led us to examine the methylation status 
and expression of the individual Plks in a cell-based model of chronic ethanol exposure 
When wild type MEFs were exposed to a 25-50mM dose of alcohol for 7 days we 
found increased Plk4 promoter methylation and a significant decrease in corresponding 
Plk4 transcript levels (Fig. 2.4a-b). (Note, that in MEFs there was no methylation 
detected for the Plks pre-treatment).  We also observed an increase in Plk1 promoter 
methylation although in this case the change in expression was not significant, displaying 
a large degree of variation. Furthermore, we found a large increase in the proportion of 
cells containing multiple centrosomes or multinucleation (Fig. 2.4c), phenotypes 
correlated with reduced Plk4 levels in Plk4
+/-
 mice.[7]  Additionally, this observation 
mimicked the effect of lower Plk4 levels evident in Plk4
+/-
 MEFs, which display 
increased centrosome numbers and ploidy with passaging. [28, 29]  Unexpectedly, in 
contrast to the situation found in vivo for chronic alcohol exposure, we found no evidence 
for increased global hypomethylation in MEFs. (Fig. 2.4d). However, these results do 
suggest that in MEFs that the Plk4 promoter may be a target for regulation by 
methylation in response to metabolic stress. This idea is supported by the fact that 
chronic alcohol exposure of MEFs has been shown to increase levels of reactive oxygen 
species (ROS), [30] increased levels of p53 and p53 downstream targets such as p21. [31]  
Interestingly, consistent with this p53 has been shown to indirectly repress Plk4 
expression via HDAC in response to stress. [21]. Additionally, while ROS have generally 
been show to induce global hypomethylation,[32] there is increasing evidence that they 
may also induce promoter hypermethylation. For example, both the E-cadherin and 
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catalase promoters have been show to become methylated post ROS exposure. [33, 
34]This is an area for future consideration.  
 
The effect of concurrent drug treatment on MEFs chronically exposed to alcohol. 
Unlike mutations or deletions that lead to the aberrant expression of tumour 
suppressor genes, epigenetic modifications, like DNA methylation, are reversible using 
hypomethylating drugs that inhibit DNA methyltransferase activity and/or inhibit histone 
deacetylases (HDACs). [35] Concurrent alcohol and epigenetic drug treatments revealed 
that 5-aza-2’-deoxycytidine, a DNA hypomethylator and valproic acid, which has been 
shown to be an HDAC inhibitor, partially restored Plk4 transcript levels, while no 
significant differences were seen with trichostatin A (an HDAC inhibitor) treatment (Fig. 
2.4e).   
Modification of the methylation status and corresponding expression levels of 
both Plk4 and Plk1 are likely contributing factors in the development of HCC in both 
mice and humans. This creates interesting possibilities in that epigenetic modifications 
are potentially reversible through the use of demethylating and HDAC inhibiting drugs as 
both prophylactic and therapeutic tools. This may lead to the development of novel 
treatment options for HCC. 
 
Conclusions  
  We determined that a gender disparity exists for the development of HCC in the 
Plk4 mouse model. This disparity was correlated with increased DNA methylation at the 
Plk4 locus and higher risk of developing hepatocelluar carcinomas in aged male Plk4 
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heterozygous mice as compared to female mice. In contrast, we discovered the opposite 
correlation for Plk1 where in normal liver tissue the Plk1 promoter is hypermethylated 
while in tumours, Plk1 CpG islands become hypomethylated and the gene upregulated. 
This represents a novel form of regulation for Plk1 that may have implications for its 
expression in other tumour types. Furthermore, we determined that chronic alcohol 
exposure, well known to be implicated in the development of cirrhosis leading to HCC, 
also leads to Plk4 promoter hypermethylation and downregulation, accompanied by 
defects in the control of centrosome numbers and by the occurrence of multinucleated 
cells. Aberrant Plk4 methylation and expression in chronically exposed MEFs could be 
rescued by treatment with known hypomethylating and/or HDAC inhibiting drugs.    
 
Material and Methods 
Methylation Specific PCR and Global methylation 
DNA from tissue was extracted as follows:  20-60 mg of tissue was digested with 
Pro K at a concentration of 0.5 mg/mL for 48 hrs at 55°C, followed by phenol chloroform 
extraction.  DNA from formalin fixed paraffin embedded tissue was isolated using the 
FFPE DNA isolation kit following manufacturer’s instruction (Qiagen). DNA from cells 
was isolated by trypsinization for 5 minutes, neutralization with media, the cells were 
then spun down at 100g for 5 minutes, then re-suspended with 200 ul of media, followed 
by Pro K treatment. Bisulfite modification was preformed as previously described. [36] 
The DNA was further purified with a Wizard Mini DNA clean up kit (Promega), 
followed by desulfanation with 2M NaOH for 10 min and ethanol precipitation. MSP was 
performed after bisulfite treatment of DNA. Mouse fully methylated genomic DNA 
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(NEB) was used a as a positive control where appropriate.  Primers were designed via 
MethPrimer [37] within the CpG islands of each individual Plk gene (see Table 1). 
Global methylation levels for liver tissue were determined by the MethylFlash 
Methylated DNA Quantification Kit (Epigentek), an ELISA-based colourimetric assay. 
The assay was done according to the manufacturer’s instructions, using 100 ng of 
genomic DNA. The Wallac Victor3 1420 multilabel counter was used to measure the 
assay at 450nm. Relative quantification was determined by normalizing the readings to 
the positive control provided with the kit.  In ethanol treated mouse embryonic fibroblasts 
global methylation was assessed by determining the methylation status of B1 elements 
with MSP as previously described. [38] Briefly, there are 30, 000 copies of the 163 base 
pair element dispersed throughout the mouse genome. Each element contains 6 CpG 
dinucleotides. The methylation status of these elements is also responsive to DNA 
methyltransferase inhibitors like Azacytidine and therefore they are excellent indicators 
of global methylation. In order to determine the percentage of B1 element methylation 
densitometry was performed with analysis via the Syngene Gene tools version 3.07 
software. Statistical analysis on the normalized results were performed using Statsoft 
Statistica v7.0.61.0 using a one-way ANOVA t-test where p< 0.05 was significant.  
Tissue Samples 
 All murine samples were obtained from our breeding colony, with all protocols 
with animals were as approved by the University of Windsor Animal Care Committee 
according to the Canadian Council on Animal Care guidelines.  Plk4
+/-
 mutant mice on a 
129Sv/CD1 background were obtained as described [28] and backcrossed with CD1 mice 
to establish a colony of Plk4 wild type and Plk4 heterozygous
 
littermates. Mice were 
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maintained under normal light cycle and on regular chow. All tissue samples were 
obtained from aged matched littermates. For murine hepatocellular carcinoma (HCC) 
samples, it is noted that Plk4
+/-
 mice develop a high rate of liver and lung tumours by 18-
24 months of age [7] and thus the analysis was performed on spontaneously occurring 
hepatocellular carcinomas.  
 
Cell lines 
 Mouse embryonic fibroblasts (MEFs) were harvested from Plk4 wild type CD1 
mice at day 12.5 post coitum  as described previously in [28]  and  cultured with DMEM 
supplemented with 20% FBS (Sigma), 1% penicillin G sodium 10 000 U/mL and 
streptomycin sulphate 10 000 ug/mL, and 0.5% gentamycin 10mg/mL.   
 
Western blot analysis 
Protein from fresh tissue was extracted using the Trizol reagent (Invitrogen) 
according to manufacturer’s suggestions.  Cell lysates were obtained from cells harvested 
followed by lysing using lysis buffer (50mM Tris-HCl pH 7.4, 150mM NaCl, 1mM 
EDTA, 0.5% Triton X) with EDTA free protease inhibitor cocktail tablets (Roche).  20 
ug of protein were subjected to immunoblotting.  Primary antibodies used were as 
follows: p53 (Sigma), Plk1 (Abcam), p21 (Santa Cruz), GAPDH (Cell Signaling), and 
Actin (Sigma). Secondary antibodies used were anti-rabbit (Amersham) and anti-mouse 
horse radish peroxidase (HRP) (Sigma).   
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Analysis of gene expression 
RNA was extracted from cells and tissues using the RNAeasy kit (Qiagen) according to 
manufacturer’s recommendations. First Strand cDNA synthesis kit using Superscript II 
according to the manufacturer’s instructions.  Quantitative real time PCRs (qPCR) were 
conducted in an ABI 7300 instrument using 250 ng of cDNA with TaqMan Gene 
Expression Assays (Applied Biosystems) for mouse Plk1 and Plk4.  Rodent GAPDH 
probe was used as an internal control. Relative quantity (RQ) values were generated by 
the ABI 7300 system SDS software. The error bars represent the upper and lower limit of the 
standard error from the mean expression level (RQ) as analyzed by the SDS software with the 
ABI 7300 instrument. The error bars are calculated based on 95% confidence limits.    
Immunofluorescence 
 Post treatment, MEF cells were fixed in 3.7% paraformaldehyde and probed with 
a mouse γ-tubulin primary antibody (Sigma) followed by an anti-mouse alexa fluor 568 
secondary antibody (Invitrogen).  The cells were then briefly incubated in Hoescht 
33342. Adherent cells  were analyzed with a Zeiss Axioskop 2 mot plus microscope and 
Northern Eclipse imaging software. Conditions for immunofluorescence were as 
described by Hudson et al, (2001). [28] 
 
Ethanol and Drug treatments 
Wild type MEFs were exposed to 25 mM and 50mM of EtOH per day for 7 days. 
Trichostatin A, 5 aza-2’-deoxycytidine, and valproic acid were administered concurrently 
at concentrations of 1nM, 10 nM, and 0.5 mM respectively. Plates were sealed with 
parafilm to prevent evaporation. 
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Table 1.  
     Mouse primer sequences:  
 
Target Gene 
Sense Primer Sequence 
Antisense Primer sequence 
Plk1 U 
5’aca aac acc tct ttt ata tct aca tc 3’ 
5’tgg ttt gag tat tag ttg att ttg g 3’ 
Plk1 M 
5’acg aac acc tct ttt ata tct acg tc 3’ 
5’gtt ggt tcg agt att agt cga ttt c 3’ 
Plk2 U 
5’ caa act tta ccc aaa acc tac tcac 3’ 
5’ata ggg tta gtt tgg atg ttt gtt t 3’ 
 Plk2 M 
5’ aaa ctt tac cca aaa cct act cg 3’ 
5’ggt tag ttc gga cgt ttg ttc 3’ 
Plk4 U 
5’cac act ctc cac ttc tta aaa aca a 3’ 
5’ att tta tta tta gtg ttt gtg tta tgg 3’ 
Plk4 M 
5’aca ctc tcc act tct taa aaa cga a 3’ 
5’ aat tta tta tta gcg ttc gcg tta c 3’ 
B1 Element U 
5’-taa cct caa act caa aaa tcc acc-3’ 
5’gtt ggg tgt agt ggt ata tat ttt taa ttt ta 3’ 
B1 Element M 
5’ctcgaactcaaaaatccgcc 3’ 
5’ gtc ggg cgt agt ggt ata tat ttt t 3’ 
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Supplementary Materials and Methods:  
 
Human Primers 
 
Primers for methylation specific PCR were determined by MethPrimer and are as shown 
in Supplementary Table 1 (Human).  
Human HCC samples 
 Human HCC samples were obtained from both the Ontario Tumour Bank and the 
Alberta Tumour Bank. All protocols were approved by the individual tumour banks and 
the University of Windsor Research Ethics Board. 
 
Analysis of gene expression 
RNA was extracted from tissues using the RNAeasy kit (Qiagen) according to 
manufacturer’s recommendations. First Strand cDNA synthesis kit using Superscript II 
according to the manufacturer’s instructions.  Quantitative real time PCRs (qPCR) were 
conducted in an ABI 7300 instrument using 250 ng of cDNA with TaqMan Gene 
Expression Assays (Applied Biosystems) for human Plk1 and Plk4.  Human GAPDH 
probe was used as an internal control. Relative quantity (RQ) values and error bars were 
generated by the ABI 7300 system SDS software. The error bars represent the upper and 
lower limit of the standard error from the mean expression level as analyzed by the SDS software 
with the ABI 7300 instrument. The error bars are calculated based on 95% confidence limits.    
 
  
Bisulfite Sequencing PCR 
 Bisulfite sequencing PCR (BSP) for Plk4 CpG islands was done by bisulfite 
converting 2ug of genomic DNA, as described previously (30) followed by PCR 
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amplification upstream of the Plk4 promoter region with BSP Primers as follows: 
5’GCGCTACGGTCAGTCGTACACTGACC3’, 
5’GAGGTTGAGGTTTAGTTTGGTT3’, 5’ AAAT T TTCTAAACTCCCTCCCT 3’. 
BSP primers were determined with the methyl-primer software package (ABI). PCR 
products were gel purified using the Qiaquick gel extraction kit (Qiagen) and analysed by 
direct sequencing or subcloned into the p-GEM-T-easy cloning vector (Promega). 
Sequence analysis was performed using the ABI 3730 with sequencing chemistry BDT 
version 3.1 We initially performed direct sequencing of 5 independent  PCR 
amplifications for each tumour sample to identify methylated CpG sites in individual 
tumours. The sites were  confirmed  by a cloning method in which 10 subclones were 
picked for sequencing for each tumour sample. Individual CpG sites were considered to 
be positive for methylation where a minimum of 60% of the subclones displayed a 
methylated nucleotide. 
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Supplementary Table 1. 
   Human primer sequences for MSP: 
Gene 
Sense Primer Sequence 
Antisense Primer Sequence 
Plk1 U 
5’ tag tga ttg tag gga agt tgg t 3’ 
5’aca taa atc cac taa aac ctc c 3’ 
Plk1 M 
5’ gta aat cca cta aaa cct cc 3’ 
5’ gta gtg att gta ggg aag ttg 3’ 
Plk2 U 
5’cac ccc aca acc aac caa aca 3’ 
5’ gga tgg ttt tga agg ttt ttt t 3’ 
Plk2 M 
5’ ccc acg acc gac cga acg c 3’ 
5’ acg gtt ttg aag gtt ttt tcg c 3’ 
Plk3 U 
5’agt aaa ttt agg tag tgt tat 3’ 
5’ aaa ccc aac caa aaa aac a 3’ 
Plk3 M 
5’aat tta ggt agc gtt acg cgc 3’ 
5’ccg acc gaa aaa acg aac gc 3’ 
Plk4 U 
5’cca aac tct aac cta aat tct cca a 3’ 
5’ att att agt tta gtt tgg atg gta agt gg 
Plk4 M 
5’caa act cta acc taa att ctc cga a 3’ 
5’tat tag ttt agt tcg gac ggt aag c 3’ 
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Supplementary figure 2.1. Analysis of the methylation status of the murine Plk4 CpG 
promoter CpG island by bisulfite sequencing for genomic DNA isolated from both 
normal liver and HCC tissue samples. More than 30% of the CpG sites upstream of the 
Plk4 promoter region showed methylation in tumour samples (T), while little to no 
methylation was detected in age-matched wild type controls (WT). Fully methylated 3T3 
DNA (NEB) was used as a positive control. Circles represent CG sites within the 
sequence. Shaded circles depict a methylated state, while open circles lack methylation.  
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Supplementary Figure 2.2 Plk4 CpG island methylation and expression levels in human 
liver samples. (a) Plk methylation status of genomic DNA extracted from normal human 
liver tissue was determined by MSP. Fully methylated human genomic DNA (NEB) was 
used as a positive control for methylation. The negative PCR control lacked DNA 
template. U=unmethylated, M=methylated (b) In contrast the analysis of cirrhotic 
adjacent tissue by MSP displayed increased levels of Plk4 methylation suggesting that 
methylation of Plk4 may be an early event in the transition of cirrhosis to HCC. (c) 
Shown is representative image of both the Plk4 and Plk1 methylation status in human 
HCC tumour samples as determined by MSP. Only two of the samples had 
hypomethylation within the Plk1 promoter region, suggesting that loss of Plk1 
methylation may be a later event.  U=unmethylated, M=methylated (d) Human HCC 
samples were analysed for Plk expression by qPCR. There was more than a 20 fold 
decrease in Plk4 transcript levels in tumours in comparison to normal liver tissue, while 
(e) Plk1 transcript levels were elevated in several of the tumour samples compared to the 
control.  RQ values were normalized to the level of Plk4 transcripts in normal livers.  
Transcript levels for tumours 2, 8, and 9 were not assessed as they were archival 
specimens with poor quality RNA.  Human GAPDH was used as an internal control.  
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Chapter 3 
p53-dependent and cell specific epigenetic regulation of the Polo-like kinases under 
oxidative stress 
Authors: Alejandra Ward and John W. Hudson 
Introduction 
The polo-like kinases (PLKs) have been implicated in a variety of solid and 
hematopoietic tumours, which include B-cell lymphoma, hepatocellular carcinoma 
(HCC), head and neck squamous carcinoma, colorectal cancers, and most recently 
gallbladder cancer, just to name a few [1-5].  Moreover, their deregulation is often 
associated clinically with poor prognosis, such as the case of PLK1 overexpression in 
non-small cell lung carcinoma and head and neck squamous carcinoma, or 
downregulation of Plk4 in HCC [3, 6, 7].  Recently, we and others, have determined that 
the polo-like kinases, which are cell cycle regulated serine/threonine kinases, are 
susceptible to aberrant DNA methylation in many of the tumour types described above 
[1, 8-10].  Aberrant promoter methylation of PLK1-4 have been implicated in 
hepatocellular carcinoma [9, 10], while PLK2 promoter hypermethylation has been 
detected in hematologic malignancies such as acute myeloid leukemia and B-cell 
lymphoma, as well as in ovarian cancers [1, 8, 11].  Interestingly, the recently discovered 
PLK5, has tumour suppressor properties, and it is often hypermethylated in glioblastoma 
[12]. Given that these kinases, which are highly conserved among species, play crucial 
roles in important cell cycle events such as spindle pole assembly, the DNA damage 
response, G2/M transitions, and cytokinesis [6, 13, 14], proper regulation of these 
proteins is essential for the maintenance of genomic integrity and the prevention of 
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genomic instability. Therefore, the underlying question is what is prompting the aberrant 
epigenetic regulation of the polo-like kinases in a variety of cancer types?   
  It has been established that the microenvironment plays a significant role in the 
initiation and progression of tumourigenesis. The cellular microenvironment provides a 
platform from which bidirectional molecular cues can be exchanged.  This topographical 
information can direct cellular phenomena which include growth, cellular differentiation, 
and division. The aberrant alterations in the microenvironment can confer 
tumourigenicity through direct genetic mutations, but more so via epigenetic plasticity 
[15, 16].  Oxidative stress, in the form of reactive oxygen species (ROS) and hypoxia, are 
components of the tumour microenvironment, and have been shown to be causative 
agents of abnormal, epigenetically-induced gene expressions in a variety of tumour types 
[17-19].  Studies have also revealed that several tumour suppressors and cell cycle 
regulators such as p14ARF, p16INK4a, and BRCA1 are susceptible to epigenetic 
silencing through DNA hypermethylation or histone modification in the presence of 
oxidative stress [19, 20]. The purpose of this study was to examine the susceptibility of 
individual PLK regulation through epigenetic modifications in response to oxidative 
stress in the form of either ROS or hypoxia.  Here we have determined that the polo-like 
kinases are indeed epigenetically modified in the presence of oxidative stress, though in a 
cell type-dependent and p53-dependent manner. Furthermore, we have determined that 
Plk4 heterozygosity may play a role in the epigenetic regulation of Plk1 in response to 
oxidative stress. 
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Results and Discussion 
Plks are subject to epigenetic modification under hypoxic conditions in normal and 
tumour-derived cells in vitro  
Hypoxia has been established as a characteristic of the solid tumour 
microenvironment and has been shown to promote cell migration and cell transformation 
[21, 22]. The primary mediator of the cellular response to hypoxia is hypoxia inducible 
factor 1α (Hif1α) which is responsible for the transcriptional regulation of several key 
genes, such as vascular endothelial growth factor (VEGF) [23] and metabolic 
components such as nitric oxide (NO) which are important for the cellular adaptation to a 
hypoxic environment [24].  More recently, Hif1α has been shown to indirectly modify 
epigenetic marks on histone tails leading to varying levels of transcriptional activation 
and repression through histone deactylatase (HDAC) recruitment and modification of the 
H3K9 methylation marks [25].   
We have previously shown that Plk4 heterozygosity increases the susceptibility of 
Plk4 promoter methylation in an in vivo murine HCC model [10], therefore we wanted to 
determine whether Plk4 heterozygosity  impacted Plk promoter methylation under 
oxidative stress. First, wild type (Plk4
+/+
) and heterozygous (Plk4
+/-
) murine embryonic 
fibroblasts (MEFs) were cultured in a hypoxia chamber flooded with 2% oxygen and 
incubated for 18 hours in order to determine whether the exposure of cells to hypoxia 
results in the modification of Plk gene expression through epigenetic means. After the 
treatment, methylation specific PCR (MSP) was performed in order to examine the 
methylation status of the Plks.  We did observe Plk4 promoter methylation upon hypoxia 
treatment, regardless of genotype (Fig. 3.1a).  Furthermore, corresponding Plk4  
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Figure 3.1. Aberrant methylation of plk1 and plk4 promoter regions in MEFs under 
hypoxic stress. (a) DNA extracted from mouse embryonic fibroblasts grown under 
hypoxic conditions was bisulfite treated and then assessed for promoter methylation of 
Plk1 and Plk4 using methylation specific PCR; U=unmethylated, M=methylated. Fully 
methylated NIH 3T3 DNA was used as a positive control (+M), no template was added to 
the negative control (-M). (b) Plk4 transcripts were assessed using qPCR. Transcript 
levels were normalized to the wild type untreated sample. All qPCR data is representative 
of the mean value of three independent experiments and error bars represent +/- SD. (c) 
Western blot analysis to examine protein levels of Plk1 and Plk4 post hypoxic treatment. 
(-) represents the lysates from untreated cells, (+) lysates from cells were grown in the 
presence of hypoxia. (d) Densitometric analysis normalized to the levels of the wild-type 
untreated cells. Error bars represent +/- SD from three independent experiments. (e) The 
fold change of plk1 transcripts normalized to the respective untreated transcripts. (f) The 
percent of Plk1 protein expression relative to the untreated wild-type cells. * denotes 
significance with p<0.05. (g) RNA extracted from MEFs along with real-time PCR was 
used to determine Hif1α transcripts post hypoxia treatment. 
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transcripts were decreased by approximately 12-fold compared to the untreated in both 
Plk4
+/+ 
and Plk4
+/-
 MEFs under hypoxic conditions (Fig. 3.1b).  Interestingly, Plk4 
transcript and protein levels post hypoxia treatment in the Plk4
+/+ 
MEFs were comparable 
to the levels normally found in Plk4 heterozygous cells. Moreover, treated Plk4 
heterozygous MEFs displayed even further depleted Plk4 protein levels by approximately 
10% compared to the untreated counterpart (Fig. 3.1c,d). This suggests that the Plk4 
promoter region may be targeted for methylation under hypoxic conditions.  Next, we 
sought to determine whether the modification to the epigenetic marks that we observed 
were specific to Plk4, or if the other Plks were also undergoing a similar response.  
Interestingly, hypoxia treatment of wild-type MEFs resulted in hypermethylation of the 
Plk1 promoter region (Fig. 3.1a) with a corresponding seven-fold decrease in transcript 
levels (Fig. 3.1e) and a 20% decrease in protein levels when compared to non-treated 
controls (Fig. 3.1f). Considering that Plk1 was methylated prior to treatment in Plk4
+/-
 
MEFs, it was not surprising to see that there was no change in the methylation status of 
Plk1 promoter with hypoxia (Fig. 3.1a). In contrast, there was a moderate increase in the 
corresponding Plk1 transcripts (Fig. 3.1e).  Examination of Plk1 protein levels in 
untreated Plk4
+/-
 MEFs revealed almost 40% higher Plk1 levels compared to the wild 
type cells prior to treatment (Fig.1f). Moreover, post-treatment, Plk4
+/-
 MEFs showed 
approximately a 10% increase in Plk1 protein levels compared to the untreated (Fig. 
3.1f). As a positive control, Hif1α transcript levels were assessed post treatment to ensure 
the cells were responding to hypoxic conditions (Fig. 3.1g).  
Previous research has shown that p53 is both necessary and sufficient in 
transcriptionally repressing Plk1 [26].  In a regenerating liver model, Plk4 heterozygosity 
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resulted in decreased p53 protein levels and activity compared to the wild-type model as 
evidenced by decreased p21 levels and phosphorylated Ser15 on p53 [2], suggesting that 
Plk4 heterozygosity is insufficient for proper  p53 activation. This also suggests a model 
in which Plk1 expression in wild-type MEFs exposed to hypoxia is in part regulated by 
promoter methylation, resulting in repression of transcription and lower protein levels. 
The different response for Plk1 in Plk4
+/- 
MEFs, is likely related to the fact that Plk4
+/- 
MEFs display increased genomic instability along with a lack of active p53 during stress 
[2]. Thus, the normal regulatory mechanisms necessary to down-regulate Plk1 protein 
levels are, in part, absent. This combination of lower Plk4 and increased Plk1 likely 
results in promoting the cellular transition through G2/M, and further propagating 
genomic instability and aneuploidy resulting in DNA damage caused by Plk4 
haploinsufficiency [2], a contributing factor to tumourigenesis.  It also further suggests 
that Plk4 needs to be at normal levels in order to maintain appropriate Plk1 levels.   
 
ROS-induced epigenetic downregulation of the Plks in MEFs 
Oxidative stress in the microenvironment is not limited to hypoxic conditions. 
Oxidative stress can also be caused by an increase in free radicals producing reactive 
oxygen species (ROS). Furthermore, ROS have been shown to promote tumourigenesis 
through several biological processes which include cell proliferation,  metastasis, and 
evasion of apoptosis [27].   Exposure of cells to high levels of ROS have also been 
implicated in the hypermethylation of tumour suppressor genes such as runt-related 
transcription factor 3 (RUNX3) [28]. Moreover, ROS exposure, as a result of hydrogen 
peroxide treatment, has been shown to recruit DNA methyltransferases (DNMT) 
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complexes to areas in the genome that are CG-rich, which could include the CpG islands 
upstream of the Plk promoter regions [29].  Additionally, in our previous work, we 
demonstrated that wild type MEFs that were chronically exposed to ethanol (EtOH) 
treatment, displayed a hypermethylated  Plk4 promoter region resulting in a phenotype 
that resembles that seen in Plk4
+/-
 cells with multi-nucleation and multiple-centrosome 
formation [10]. Inherent to ethanol metabolism is the production of high levels of ROS 
[30] therefore, suggesting that ROS may also impact Plk promoter methylation.  In order 
to examine whether Plk1 and Plk4 epigenetic marks were susceptible to modification as a 
result of high levels of ROS, we subjected Plk4
+/+
 and Plk4
+/-
 MEFs to reactive oxygen 
species (ROS) by exposing them to hydrogen peroxide (H2O2) at a 200um dose for a 
period of 18 hours. This level of ROS is known to induce DNA damage and p53 activity 
[31].  Methylation specific PCR (MSP) revealed that the Plk4 promoter became 
hypermethylated in the presence of ROS (Fig. 3.2a). Both  Plk4
+/+
 and Plk4
+/-
 MEFs 
displayed a decrease in Plk4 transcripts of more than 10-fold (Fig. 3.2b) and subsequent 
Western blot analysis revealed a significant decrease in Plk4 protein in both MEF 
genotypes by approximately 50% (p<0.05) relative to the untreated cells (Fig. 3.2c,d). 
These results are similar to what we observed under hypoxic conditions, and suggest that 
as part of the stress and DNA damage response, Plk1 and Plk4 may normally become 
downregulated via promoter methylation likely in order to arrest cell division. It is noted 
previous work by Ko et al. revealed that low levels of Plk4 results in a delay in cell cycle 
progression [2], and we have shown that lower levels of Plk4
 
results in cells aggregating 
at the G2/M transition of the cell cycle [32].     
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Figure 3.2. Modification of plk1 and plk4 epigenetic marks with ROS exposure in 
MEFs. (a) MSP analysis shows the promoter methylation of plk1 and plk4 pre- and post-
ROS treatment; U=unmethylated, M=methylated. Fully methylated NIH 3T3 DNA was 
used as a positive control (+M), no template was added to the negative control (-M). (b) 
Plk4 transcript levels determined by qPCR. All transcripts were normalized to the wild 
type untreated control. All qPCR data is representative of the mean value of three 
independent experiments and error bars represent +/- SD. (c) Plk1 and plk4 protein levels 
examined via Western blot analysis, actin was used as a loading control. (-) represents the 
lysates from untreated cells, (+) lysates from cells grown in the presence of ROS (d) Plk4 
protein expression levels determined by densitometry. All densitometry data is 
representative of three independent experiments and the error bars represent +/- SD. * 
denotes significance with a p<0.05. (e) Plk1 transcripts of cells treated with ROS, the 
transcripts were normalized to the respective untreated samples. (f) The relative plk1 
protein levels post treatment was normalized to the wild-type untreated samples. Levels 
determined by densitometric analysis of Western blot images. (g) An ELISA-based p53 
activity assay. Relative activity was determined by normalizing values to the untreated 
samples. This data represents the mean value obtained over three independent 
experiments and error bars denote the +/- SD. (h) p53 protein levels in MEFs post 
treatment as determined by Western blot analysis. (i) Densitometry was performed on 
three independent experiments and all data has been normalized to the respective 
untreated. The mean expression is presented with error bars denoting +/- SD. * denotes 
significance with a p<0.05.  
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Plk1 promoter methylation and levels in Plk4
+/+
 MEFs were responsive to increased ROS 
in a similar manner to that seen with hypoxia, in which Plk1 was downregulated (Fig. 
3.2a). Plk1 transcripts were decreased by approximately 12-fold, which was reflective of 
the promoter hypermethylation (Fig. 3.2e). This was correlated with visibly reduced 
protein levels post ROS exposure by almost 40% (Fig. 3.2c,f).  Although there appeared 
to be no visible change at the promoter region via MSP analysis, Plk1 transcripts were 
elevated in the heterozygous MEFs in the presence of ROS with transcripts almost 15-
fold higher compared to the untreated (Fig. 3.2a,e). Moreover, Plk1 protein expression 
levels were also 10% higher in ROS-treated heterozygous MEFs compared to the 
untreated counterparts and 100% higher compared to the treated wild-type MEFs 
(p<0.05) (Fig. 3.2c,f). In contrast to Plk4 and Plk1, Plk2 promoter methylation as well as 
Plk2 and Plk3 protein levels displayed no detectable changes in either cell type in 
response to hypoxia and upon exposure to reactive oxygen species (Supplementary figure 
3.1a,b). Note that, we did not examine Plk3 promoter methylation as the gene in mouse 
lacks CpG islands.   
The experimental results observed for Plk1 and Plk4 epigenetic regulation in 
MEFs as a response to ROS were similar to those obtained under hypoxic conditions, 
suggesting that an adequate response to stress and the DNA damage  may be  impaired in 
Plk4
+/- 
MEFs and that lower Plk4 protein levels have an indirect impact on the epigenetic 
regulation of Plk1. This model is supported by the observations that upon DNA damage, 
p53 is activated and subsequently represses Plk1 [33, 34].  Previous work has determined 
that p53 interacts with and is a substrate of Plk4; and in the Plk4
+/- 
 mouse model, partial 
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hepatectomy failed to activate p53 within the first 24 hours post-surgery, unlike the wild-
type counterparts which displayed p53 activation almost immediately [2, 35].  
Given these observations, it was therefore of interest to determine whether p53 
was activated in Plk4
+/- 
MEFs post ROS treatment. We performed an ELISA-based p53 
activity assay with MEF nuclear extracts post H2O2 treatment.  Plk4
+/+
 cells had an 
increase in p53 protein levels by almost 50% and an increase in p53 activity by almost 6-
fold relative to the untreated cells (Fig. 3.2g-i). Unexpectedly, in Plk4
+/-
 MEFs, p53 
activity was not elevated, but was comparable to the untreated counterparts (Fig. 3.2g). 
This corresponded to the lack of a significant change in p53 protein levels for the Plk4
+/-
 
MEFs (Fig. 3.2h,i). Our observations suggest that Plk4 heterozygosity and the subsequent 
low Plk4 protein levels are insufficient to activate p53 during genotoxic stress caused by 
ROS, resulting in an upregulation in the pro-mitotic protein, Plk1.  Interestingly, in our 
previous examination of HCC in Plk4
+/- 
 mice, we also observed elevated Plk1 protein in 
tumours,  but not in normal liver tissue [10]. Human studies have found that loss of 
heterozygosity for PLK4 occurs in 45-60% of HCC cases examined together with an 
increase in Plk1 protein levels [2, 9].  PLK4 LOH may be an early event in the 
progression to carcinogenesis. Here we show that a combinatorial effect of Plk4 
heterozygosity, together with micro-environmental stressors such as hypoxia and ROS, 
result in the upregulation of Plk1.  
 
Promoter methylation of the Plks in HCC tumour cells 
 Li et al. 2005 demonstrated that PLK4 mRNA is regulated in a p53-dependent 
manner in lung carcinoma cells and osteosarcoma-derived cells exposed to etoposide 
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[36]. The levels of PLK4 transcripts were most affected at 6 and 24 hours post treatment 
[36].   Thus, p53 plays a role in the transcriptional downregulation of PLK4 through 
histone deacetylation upon exposure to DNA damaging agents [36]. Recently, Nakamura 
et al. also showed that sustained genotoxic stress via etoposide and UV resulted in the 
attenuation of PLK4 in a p53-dependent manner [37]. In addition, p53 is known to be an 
important player in the epigenetic downregulation of another tumour suppressor, ras-
associated domain family 1 (RASSF1A), by directly binding to the promoter of RASSF1A 
and recruiting DNA methyltransferase 1(DNMT1) along with accessory proteins to the 
promoter region [38]. Moreover, p53 interacts and cooperate with DNMT1 in the 
methylation of the PLK4 target, CDC25C, in the presence of DNA damage [39] and also 
interacts with DNMT3a, which is responsible for de novo methylation [40]. This suggests 
that p53 likely also regulates the Plks through an epigenetic mechanism. We were 
therefore interested in determining whether the promoter methylation of the Plks, which 
we observed in MEFs under hypoxia and ROS treatment, was dependent on the presence 
or absence of p53.  We employed the hepatocellular carcinoma (HCC) derived cell lines, 
HepG2 and Hep3B to answer this question.  HepG2 cells exhibited an increase in PLK4 
promoter methylation post hypoxia, but not Hep3B cells (Fig. 3.3a). In the case of HepG2 
cells there was an increase in the detectable level of methylation accompanied with a 
corresponding 2-fold decrease in PLK4 transcripts (Fig. 3.3b) compared to the untreated 
as well as a 5% decrease in protein levels (Fig. 3.3c,d) . For Hep3B cells, under hypoxic 
conditions, the increase in promoter methylation did not translate into significant changes 
at transcript and proteins levels (Fig. 3.3c,d). In this case, protein levels of PLK4 did not 
show a significant difference, although transcript levels were slightly decreased  
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Figure 3.3. Hypoxia-induced modification of PLK promoter methylation in HCC 
cells. (a) Promoter methylation status of the plks examined in HCC-derived cells HepG2 
and Hep3B; U=unmethylated, M=methylated. Fully methylated HeLa DNA was used as 
a positive control (+M), no template was added to the negative control (-M). (b) Post 
hypoxia, PLK4 transcripts were assessed via qPCR in RNA extracted from HCC cells. 
All qPCR data is representative of the mean value of three independent experiments and 
error bars represent +/- SD. (c) PLK protein levels were examined post treatment from 
whole cell lysates. Actin was used as a loading control. (-) represents lysates from 
untreated cells, (+) lysates from cells grown in the presence of hypoxia. (d) 
Quantification of protein levels using densitometry. Levels have been normalized to the 
respective untreated controls. Data is representative of the mean value of three 
independent experiments and error bars represent +/- SD. (e) The fold change of PLK1 
transcripts as determined by qPCR. Values normalized to the respective untreated 
sample. (f) PLK2 and PLK3 analyzed and fold changed determine by normalization to 
the respective untreated samples. (g) Hif1α transcripts post hypoxia were determine by 
real-time PCR using a Taqman probe. 
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(Fig. 3.3c,d). As HepG2 cells contain a functional p53 whereas as Hep3B cells lack a 
functional p53 [41], these results once again suggest the involvement of p53 in the 
epigenetic regulation of PLK4.   
   Likewise, for PLK1, the change in methylation status was similar to that seen 
with hypoxia treatment in MEFs. Before treatment, HepG2 cells displayed some 
methylation for the PLK1 promoter (Fig.3a). Post hypoxia, the PLK1 promoter region 
became hypermethylated (Fig. 3.3a). In addition, transcript levels were decreased by 
almost 2.5-fold (Fig.3e) and accompanied by a slight decrease in protein levels (Fig. 
3.3c). Hep3B cells, on the other hand, showed no distinct change in the methylation 
status of PLK1 promoter region compared to the untreated (Fig. 3.3a). Moreover, PLK1 
transcript and protein levels in treated Hep3B cells were not significantly impacted by 
hypoxia treatment (Fig. 3.3c,e).    
 Human PLK3, unlike its murine homolog has two CpG islands in its promoter 
region. We used two sets of primers in order to assay for any changes in methylation 
status for PLK3. With both, MSP published primers based on the first 200 base pairs of 
the upstream CpG island [1] and an additional set of MSP primers downstream, we 
detected no overt change in promoter methylation for PLK3 in either HepG2 or Hep3B 
cells (Fig. 3.3a). This suggests that the regulation of PLK3 under hypoxic conditions is 
not p53 dependent and is likely not regulated by an epigenetic mechanism in this context.  
 Likewise, for PLK2, there was no dramatic change in promoter methylation, for 
either HepG2 and Hep3B cell lines. This indicates that PLK2 and PLK3 do not undergo 
aberrant changes to their promoter methylation in response to hypoxia.   
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As an experimental control, we assessed the transcript levels of HIF1α to 
determine whether these cells were responding to hypoxic stress under the same hypoxic 
conditions as used with the MEFs. With hypoxia, HIF1α transcripts were elevated by 
more than 1.5 times in both cell lines (Fig. 3.1g), indicating that the cells were indeed 
responding to low oxygen levels and the change in HIF1α transcript levels were similar 
to previously reported hypoxia treatments in HCC cells  [42]. 
 
Plk  promoter methylation in HCC with ROS treatment 
 HepG2 and Hep3B were cultured in the presence of hydrogen peroxide at a 
concentration of 200um and activation of p53 by ROS was confirmed via an ELISA-
based p53 activity assay and Western blot analysis. As expected, we found a 6-fold 
increase in p53 activity in HepG2 cells in the presence of ROS, while no change in 
activity was detected for Hep3B (Fig. 3.4a).  The increase in activity also corresponded to 
an increase in p53 protein levels in HepG2 cells, while in agreement with Hep3B p53 
status, no p53 protein was detected in Hep3B cells (Supplementary figure 3.1c). 
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Figure 3.4. Modification of PLK promoter methylation marks in HCC cells exposed 
to ROS. (a) A p53 activity assay was performed to confirm activation of p53 with 
genotoxic stress caused by ROS. The percent activity is the average of three independent 
experiments with error bars representing the +/- SD. (b) MSP analysis of plk promoter 
methylation; U=unmethylated, M=methylated. Fully methylated HeLa DNA was used as 
a positive control (+M), no template was added to the negative control (-M). (c) Plk1 
transcript levels were examined and normalized to the respective untreated samples. All 
qPCR data is representative of the mean value of three independent experiments and are 
normalized to the untreated samples. Error bars represent +/- SD. (d) Western blot 
analysis of PLK protein levels. Actin was used as a loading control. (-) represents the 
lysates from untreated cells, (+) lysates from cells were grown in the presence of ROS. 
(e) The fold change in plk4 transcripts from cells exposed to ROS. (f) Quantification of 
PLK4 protein levels. Data is representative of three independent experiments and the 
error bars represent +/- SD. * denotes significance with a p<0.05. (g,h) PLK2 and PLK3 
change in transcripts as determined by real time PCR.  
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PLK1 became hypermethylated in HepG2 post ROS exposure, while in Hep3B the level 
of detectable methylation decreased in comparison to that initially present in untreated 
cells (Fig. 3.4b).  Subsequent examination of the transcript and protein expression for 
PLK1 were correlated with their respective promoter methylation status. Specifically, in 
HepG2, PLK1 transcripts and protein were significantly reduced, whereas in Hep3B, 
PLK1 transcripts were almost 4-fold higher compared to the untreated control and protein 
expression was also elevated (Fig. 3.4c,d). Here we show that PLK1 downregulation in 
response to DNA damage in p53-wild type cells is also accompanied by promoter 
hypermethylation and this hypermethylation can be induced by ROS whereas the 
opposite scenario is observed for the p53 null cells.    
 PLK4 promoter methylation patterns also paralleled what we have observed with 
PLK1, where HepG2 had a qualitative gain in PLK4 promoter methylation (Fig. 3.4b) 
accompanied by a 6-fold decrease in transcripts and a 40% decrease in protein expression 
(Fig. 3.4d-f).  This is in direct opposition to what we observed in Hep3B cells, which had 
no observable gain of methylation for PLK4, but more importantly, there was an increase 
in transcripts  and protein by 5-fold and 30% respectively compared to the untreated cells 
(Fig. 3.4d,e).  
This data indicates that PLK1 and PLK4 promoter methylation is p53-dependent 
and that ROS may play an important role in the regulation of both of these genes. This 
correlates with recent work by Nakamura et al. which determined that under stress and 
DNA damage in colorectal cells, PLK4 is initially activated, but its expression is 
abrogated over time in p53-wild type cells followed by an increase in p53 levels. In p53-
null cells, PLK4 protein levels persisted over the same period of time [37].   
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 Previous examination of PLK2 expression has shown that it can be induced by 
p53 during DNA damage and stress via p53 directly binding to its consensus sequence 
within the PLK2 promoter [43, 44].  More recently, PLK2 transcript levels have been 
used as predictors in determining the genotoxicity of potential hepatocarcinogens [45]. 
So, it was not surprising to see that post ROS treatment of HepG2 cells, PLK2  lost 
promoter methylation (Fig. 3.4b) along with a 2-fold increase in PLK2 transcript (Fig. 
3.4g) and protein levels (Fig. 3.4d).   In Hep3B cells, PLK2 displayed a gain of 
methylation at its promoter region after ROS exposure (Fig.4b), correlated with 
decreased protein levels, suggesting that in the absence of p53, the PLK2 promoter region 
becomes hypermethylated in HCC in the presence of ROS (Fig. 3.4d).  
 PLK3 activity is also known to become upregulated in the presence of H2O2. This 
increase in activity   leads to the phosphorylation of p53 at serine 20 in human fibroblast 
cells [31]. Therefore, we would expect PLK3 levels to increase in response to ROS 
treatment.  Although PLK3 promoter methylation remained largely unchanged between 
the untreated and the ROS exposed cells (Fig. 3.4b),   PLK3 transcripts (Fig. 3.4h) and 
protein levels (Fig. 3.4d) were elevated in ROS treated HepG2 cells. However, in the 
absence of p53, PLK3 transcripts and protein levels were not significantly changed with 
ROS treatment (Fig. 3.4h,d).    
 Here we show that in HCC cells, PLKs 1,2, and 4 become epigenetically modified 
in the presence of ROS, and that this regulation is in part, p53 dependent. Moreover, in 
Hep3B cells, which lack p53, the upregulation of the PLKs needed for DNA damage 
repair, PLK2 and PLK3, are impaired in the presence of ROS. This is also accompanied 
by an increase in PLK1 and PLK4 in p53 null cells.  In the clinical setting, PLK1 and 
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PLK4 have been found to be jointly upregulated in colorectal cancers compared to the 
normal mucosa in almost 80% of the cases examined [4].  Furthermore, upregulation of  
PLK4 leads to centrosome amplification and multipolar spindle formation resulting in 
aneuploidy, which is a signature of many solid tumours [46].  In addition, it is important 
to note that more than 50% of colorectal cancers harbour p53 mutations [47]    
 
Plk promoter methylation in osteosarcoma-derived cells 
These results raised the question whether these modifications were a general 
phenomenon or were these epigenetic modifications specific to tissue or cell type?  
Previous literature suggested that certain gene-signatures that are found in HCC cells are 
not found in other cell types such as colon carcinomas [42]. We chose to replicate our 
experiments with hypoxic conditions and in the presence of ROS using osteosarcoma 
derived cells within the same p53 context.  We employed the p53-wild type cells U2-OS 
and the p53 null cells Saos-2 [41].  First, we examined the promoter methylation and 
expression of the PLKs in the sarcoma-derived cells under hypoxic conditions. 
Interestingly, in osteosarcoma cells, PLK1 promoter regions became hypomethylated in 
both U2-OS and Saos-2 cells (Fig. 3.5a) followed by upregulation of the accompanying 
transcripts and protein levels compared to the untreated cells (Fig. 3.5b,c).  This suggests 
that hypoxia-induced modifications to the promoter methylation of PLK1 in the above 
mentioned cell lines is not p53 dependent. Conversely, when examining the PLK2  
promoter methylation under hypoxic conditions,  U2-OS cells displayed a loss of  
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Figure 3.5. Examination of PLK promoter methylation in sarcoma-derived cells 
grown in the presence of oxidative stress. (a) PLK promoter methylation was 
determined by methylation-specific PCR; U=unmethylated, M=methylated. Fully 
methylated HeLa DNA was used as a positive control (+M), no template was added to the 
negative control (-M). (b) Fold change in plk1 transcripts. All qPCR values have been 
normalized to the respective untreated samples. Here the mean value of three independent 
experiments are depicted with error bars representing the +/- SD. (c) PLK1 and PLK2 
protein levels in U2-OS and SAOS-2 cells treated with hypoxia and ROS. GAPDH was 
used as a loading control. (-) indicates lysates extracted from untreated samples, (+) 
represents lysates extracted from cells exposed to either hypoxia or ROS. (d,e) PLK2 and 
PLK3 transcripts as determined by qPCR. ND= not detectable. (g) Transcript changes for 
PLK4 in cells exposed to ROS and hypoxia. (h) PLK4 protein levels in sarcoma cells 
treated with hypoxia and ROS (+) compared to the untreated counterpart (-). GAPDH 
was used as a loading control. (i) PLK4 protein levels quantified with densitometry 
analysis of the Western blot images. The histogram is representative of the mean from 
three independent experiments with error bars showing the +/- SD. * denotes significance 
with a p<0.05. 
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promoter methylation (Fig. 3.5a) followed an almost 2-fold increase in transcripts (Fig. 
3.5d), while a only a slight change in protein level was observed (Fig. 3.5c); Saos-2 cells 
on the other hand, had no distinct change in promoter methylation (Fig. 3.5a), however, 
qPCR analysis revealed a decrease in PLK2 transcripts by almost 5-fold resulting in a 
slight decrease in protein (Fig. 3.5c,d). A study by Matthew et al. (2009) revealed that 
PLK2 has an active and p53-dependent role in the cellular response to hypoxia by 
indirectly restraining the mTOR signaling pathway during hypoxia, so it was expected 
that we would see an increase in PLK2 in U2-OS and not Saos-2 [48]. When examining 
the remaining PLKs, PLK3’s promoter region did not appear to change in response to 
hypoxia, in either cell type and transcript and protein levels did not differ from the 
untreated (Fig. 3.5a,e,f), similar to what we have seen in the MEFs and HCC cells. In 
Saos-2 cells, the PLK4 promoter region became hypermethylated in the presence of 
hypoxia (Fig. 3.5a) followed by a decrease in PLK4 transcripts by nearly 4-fold 
compared to the untreated (Fig. 3.5g), which resulted in a moderate decrease in protein 
levels (Fig. 3.5h).  In U2-OS, the PLK4 promoter region was initially methylated prior to 
treatment, but with hypoxia treatment, there was a loss of detectable methylation, though 
this did not translate into significant changes at the transcript or protein levels (Fig. 
3.5a,g-i). The examination of sarcoma cells illustrates that hypoxia can differentially 
impact the PLK promoter methylation patterns between cell types, and that p53 may not 
have the same impact on the epigenetic regulation of the PLKs in all cells. HIF1a 
transcript levels were examined and were found to be elevated by 1.5-2 fold in both cell 
types (Supplementary figure 3.2a). 
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 ROS treatment of sarcoma cells resulted in very different pattern of methylation 
than that seen in HCC cell lines.  Confirmation of ROS-induced increased in p53 activity 
was carried out via Western blot analysis and with a p53 activity assay , which showed an 
increase in p53 activity in U2-OS cells by almost 9-fold, whereas no change was detected 
with SAOS-2 (Supplementary figure 3.2b,c). Unlike HCC cells, in both osteosarcoma 
cell lines, PLK2 became hypermethylated (Fig. 3.5a) accompanied by undetectable 
transcripts and significantly decreased protein levels (Fig. 3.5c,d). Although PLK3 
promoter methylation did not increase with treatment, transcripts and protein levels were 
also undetectable in either cell type (Fig. 3.5e,f). This suggests that PLK2 and PLK3 are 
differentially regulated in osteosarcoma cell lines compared to HCC cell lines. The PLK1 
promoter region also did not display a change in promoter methylation, remaining 
hypermethylated in both cell lines similar to our observations in HCC and
 
MEFs (Fig. 
3.5a). Real-time PCR did reveal a slight decrease in PLK1 transcripts (Fig. 3.5b) and 
protein levels in SAOS-2 cells, but not in U2-OS cells (Fig. 3.5c). However, when 
examining PLK4, we noticed a dramatic loss of promoter methylation in Saos-2 cells in 
response to ROS, but not in U2-OS cells (Fig. 3.5a).  Along with promoter 
hypomethylation in Saos-2 there was a minor increase in transcripts (Fig. 3.5a,g). PLK4 
protein levels were also elevated in treated Saos-2 cells by more than a 10%; whereas 
U2-OS cells displayed a decrease in PLK4 protein by almost 20% compared to the 
untreated, similar to the response observed in HCC cells (Fig. 5h,i). This suggests that 
regardless of cell type, PLK4 continues to be sensitive to ROS-induced promoter 
hypermethylation within a functional  p53 context.  
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Global methylation and DNMT levels 
 In general, cells exposed to oxidative stress also experience shifts in global 
methylation patterns that can be associated with modifications to local methylation 
patterns at gene promoter regions [49, 50]. As part of our epigenetic analysis of the Plks, 
we wanted to determine if the modifications we observed at Plk-specific promoter 
regions were associated with a general increase in global methylation and whether any 
change varied between p53 wild type and p53 null cells. Here we examined the whole 
genome methylation of DNA from cells subjected to either ROS or hypoxia treatment.  
With hypoxia, both Plk4 wild type and heterozygous MEFs had a slight decrease in 
global methylation compared to the untreated samples by approximately 15% (Fig. 3.6a). 
This is similar to what Shahrzad et al. demonstrated in melanoma cells, under anoxia, 
global methylation decreased between 15-20% [49].  We also observed a similar trend 
with HCC and osteosarcoma cells, with a 15-40% decrease in global methylation (Fig. 
3.6b,c).  There was little difference in global methylation between the hypoxia treated  
p53 wild type and p53 null cells although, in three independent experiments, Hep3B cells 
displayed a greater loss of global methylation in comparison to HepG2 (Fig. 3.6b).  DNA 
methylation is maintained by DNA methyltransferases (DNMTs) which are enzymes that 
catalyze the transfer of methyl groups to cytosines which are 5’ to guanine [51]. DNMT1 
is responsible for maintenance methylation during replication, and DNMT3a and 
DNMT3b drive de novo methylation [51].  It was therefore of interest to determine 
whether the changes in global methylation were also accompanied by differences in 
protein levels of the DNMTs.  
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 DNMT1 and 3b protein levels have both been shown to become downregulated 
with hypoxia  along with a decrease in DNMT activity which would lead to an overall 
decrease in global methylation marks [52]. We examined the levels of the DNMT’s in 
both wild type and Plk4 heterozygous MEFs and found that this was also the case, where 
DNMT1 and DNMT3b protein levels decreased with hypoxia (Fig. 3.6d).  When 
examining DNMT3a, protein levels were elevated in Plk4 heterozygous MEFs prior to 
treatment and remained elevated post hypoxia treatment, but the wild type MEFs did not 
display this change in DNMT3a levels (Fig. 3.6d).  It was previously reported that p53 
wild type and p53 null colorectal cells, post hypoxia exposure, have increased transcript 
levels of DNMT3a, with a greater increase observed in p53 null colorectal cells [52]. 
Also, in an in vivo study done by Park et al., a p53 heterozygous and null mouse model 
revealed elevated levels of DNMT3a compared to the wild type littermates prior to any 
tumour development [53]. This suggests that DNMT3a is deregulated in Plk4
+/- 
MEFs in 
a manner similar to that seen in p53 null cells. This also correlates to the decrease in p53 
activity that we have observed in Plk4
+/- 
MEFs and re-enforces the importance of the 
Plk4-p53 relationship and interaction axis.  
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Figure 3.6. Analysis of global methylation in MEFs, HCC and osteosarcoma cells 
and DNMTs levels in MEFs.  An ELISA-based global methylation assay was performed 
to determine changes in global methylation levels due to oxidative stress as a result of 
hypoxia and ROS exposure. The histograms are representative of three independent 
experiments and the error bars depict the +/- SD. (a) In MEFs the values have been 
normalized to the untreated wild-type cells. (b,c) The values have been normalized to the 
respective untreated samples. (d) Western blot analysis was used to determine the levels 
of the DNMTs from whole cell lysates extracted from untreated (-) and treated (+) MEF 
cells.   
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ROS treated Plk4
+/-
 MEFs
 
also displayed an increase in global methylation (Fig. 3.6a), 
similar to what we observed in the HCC and osteosarcoma cancer cells (Fig. 3.6b,c). This 
was in contrast to global methylation levels in the Plk4 wild type MEFs which decreased 
with ROS (Fig. 3.6a).  This once again suggests that Plk4 heterozygosity results in 
deregulation of the response to oxidative stress. 
Conclusions 
 The contributions to tumourigenesis are complex and multi-factorial. Oxidative 
stress has been acknowledged as one such contributor in the path to carcinogenesis.  
Previous studies have shown that the PLKs are subject to regulation through post-
translational modifications [54, 55].  Our observations here show that the Plks, whose 
proper regulation is essential for cell cycle fidelity, become deregulated in the presence of 
both hypoxia and ROS through epigenetic modifications to their respective promoter 
regions. However, the deregulation that we have observed is cell-specific, resulting in 
methylation patterns that are similar, like those between MEFs and HCC, and patterns 
that differ like those observed in sarcoma-derived cells.  The promoter methylation of 
PLK4 is also correlated with the status of p53 in the cell. Plk4 haploinsufficiency, 
together with oxidative stress-induced epigenetic deregulation can inadvertently lead to 
the upregulation of Plk1.  Based on our observation and the current literature, we propose 
a model in which p53 likely leads to downregulation of transcription for PLK1 and PLK4 
in the presence of cellular stress by either recruiting or cooperating with DNMT1, 
DNMT3a and/or histone deacetylases (HDACs); this leads to an increase in promoter 
hypermethylation and hence changes in expression [36-40]  (Fig. 3.7a).  In the absence of 
p53, cellular stress would lead to the upregulation of pro-mitotic PLKs (PLK1 and PLK4) 
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resulting in a push through the G2/M checkpoint that would contribute to genomic 
instability and tumourigenesis (Fig. 3.7b) 
The methylation status of the PLKs could also be used as an indicator of oxidative 
stress at the cellular level. These modifications to PLK epigenetic marks may even be an 
early event in the multi-stage process leading to tumourigenesis, given that we have 
observed detectable changes 18 hours post-treatment.  Furthermore, promoter 
hypermethylation of the PLKs is a common event in a variety of cancers, including blood 
neoplasms, hepatocellular carcinoma, and ovarian cancer. Aberrant promoter 
methylation, induced specifically via microenvironemtal cues, could be another 
contributor to carcinogenesis [1, 8-11].  Currently, PLK1 has been the most targeted PLK 
for drug development [56-58], however, promoter hypermethylation is a reversible 
phenomenon for which there are drugs already in clinical use [59] that could be used as 
prophylactic agents or could help reverse hypermethylation-induced downregulation of 
the remaining four tumour suppressing PLKs in combination with traditional therapies.  
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Figure 3.7. A potential role for p53 in the silencing of the PLKs as a result of 
oxidative stress. Previous data has established that p53 can regulate both PLK1 and 
PLK4 expression through protein-protein interactions. Here we have incorporated our 
observations into the known mechanisms of the p53-PLK regulatory axis (a.) Our data 
suggests that when oxidative stress upregulates p53 activity, this can lead to downstream 
effects that can potentially induce the epigenetic silencing of the PLKs. In wild type p53 
cells, these mechanisms can include the recruitment and/or collaboration with epigenetic 
modifiers such as  DNMT1, DNMT3a or histone deacetylases (HDACs). (b) However, 
oxidative stress in the absence of p53, these vital inhibitory interactions carried out 
through the p53 pathway are abolished. PLK1 and PLK4 expression thus carries on 
unhindered, potentially pushing the cell through the G2/M transition point with 
unrepaired DNA damage, resulting in genomic instability and aneuploidy, both of which 
are hallmarks of cancer.  
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Materials and Methods 
Ethics Statement 
All animal procedures were carried out in accordance with animal care protocols 
approved by the University of Windsor Animal Care Committee under the guidelines of 
the Canadian Council on Animal Care. 
Tissue Culture 
Mouse embryonic fibroblasts (MEFs) were harvested from Plk4
+/+
 and Plk4
+/-
 embryos 
at day 12.5 post coitus, as described in Ko et al, 2005 [2]. The procedure was carried out 
in accordance with animal care protocols approved by the University of Windsor Animal 
Care Committee under the guidelines of the Canadian Council on Animal Care. The 
MEFs were maintained in DMEM supplemented with 20% fetal bovine serum and 1% 
penicillin G sodium/streptomycin sulphate at 10,000ug/mL, and 0.5% gentamycin 
10mg/mL. Cell lines were purchased from ATCC, U2-OS and Saos-2 cells were 
maintained in McCoy’s media supplemented with 10% FBS. Hep3G2 and Hep3B cell 
lines were grown in MEM with 10% FBS. All the cell lines were kept in a 37˚C incubator 
with 5% CO2. During hypoxic treatment, cells were grown in a hypoxia incubator 
chamber (STEMCELL Technologies Inc.) flooded with 2% CO2 at a rate of 10L/min for 
8 minutes then incubated for 18 hours at 37˚C. Reactive oxygen species were generated 
using 200um H2O2 for 18 hours; treated cells were grown in standard culture conditions.    
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Methylation Specific PCR 
DNA was extracted from cells prior and post treatment using ProK digestion buffer 
(0.5mg/mL) followed by phenol chloroform extraction.  Genomic DNA was subjected to 
bisulfite conversion as described in Herman et al. [60]. Post-bisulfite treatment, the DNA 
was purified using the Wizard mini DNA clean-up kit (Promega), desulfanated with 
NaOH and ethanol precipitated.  MSP was performed with primers designed for 
individual Plks using the MethPrimer program [61]. For sequences please see Ward et al. 
[10]. Positive controls of fully methylated NIH 3T3 mouse DNA and HeLa human DNA 
(NEB) were also included in all experiments.    
 
Western blot analysis 
Whole cell lysates were extracted using a lysis buffer (50mM Tris-HCl pH 7.4, 150mM 
NaCl, 1mM EDTA, 0.5% Triton X) with an EDTA-free protease inhibitor cocktail (Bio 
Basics Inc.) 20ug of total protein was used to perform Western blot analysis. Primary 
antibodies were purchased accordingly, anti-PLK2, anti-PLK3, and anti-DNMT3b (from 
Santa Cruz), anti-PLK1, anti-PLK4, anti-GAPDH, and anti-DNMT3A (from Cell 
Signalling), and anti-DNMT1 and anti-Actin (from Sigma). For secondary antibodies, 
anti-rabbit (from Cell Signalling) and anti-mouse HRP (from Sigma) were used. Bands 
were visualized by ECL (Thermo Scientific) and blots were acquired on an Alpha 
Innotech Multimage™ Light Cabinet and densitometry analysis was carried out using 
OptiQuant software Version 5.0.   
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Real time PCR 
RNA from treated cells was extracted using the RNeasy® mini kit (Qiagen). RNA 
extraction was performed according to manufacturer’s protocols.  Reverse transcription 
was carried out using the First Strand cDNA synthesis kit (Invitrogen) according to 
manufacturer’s instructions.  Real time PCRs were carried out on an ABI 7300 machine 
using Taqman gene expression probes for  mouse Plk1, Plk4, and HIF1α; and human 
PLK1-PLK4, and HIF1α (Applied biosystems). GAPDH was used as an internal control 
in ROS qPCR, but not in hypoxia qPCR due to GAPDH transcripts also being affected by 
hypoxia treatment [62]. Hypoxia transcript values were normalized by addition of 100ng 
of total cDNA to each reaction and ΔCT for treated samples were calculated from the 
untreated CT values as per [57]; additional calculations were performed according to the 
Taqman assay manual.  
 
p53 activity assay 
The Human/Mouse Active p53 DuoSet® IC (R&D Systems) assay was carried out 
according to the manufacturer’s protocol. Briefly, cells were grown to 80-90% 
confluence and the nuclear fraction of protein was extracted and sandwich ELISA assay 
was used to determine p53 activity.   
 
Global methylation assay 
The global methylation of genomic DNA was determined by using 100ng of ProK 
extracted gDNA in a sandwich ELISA colourimetric assay (Epigentek). The assay was 
carried out according to manufacturer’s instructions. 
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Statistical analysis 
All Western blot analysis, transcript levels, and global methylation assays are represented 
as the mean +/- standard deviation. These data were evaluated using Statsoft Statistica 
software version 7.1 using One-way ANOVA analysis. Significance represents a p<0.05.  
All results are representative of three independent experiments.  
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Supplementary figure 3.1. Assessment of plk2 and plk3 levels in treated MEFs and 
p53 levels in HCC cells. (a) Methylation status of Plk2 in treated MEFs was determined 
by MSP. (b) Western blot analysis of Plk2 and Plk3 protein in untreated (-) and treated 
(+) MEFs. GAPDH was used as a loading control. (c) p53 protein levels determine via 
Western blot analysis in untreated (-) and treated (+) HCC cells. GAPDH was used as a 
loading control.  
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Supplementary figure 3.2. Examination of Hif1α transcripts along with p53 levels 
and activity in treated osteosarcoma cells. (a) Transcript levels of Hif1α were 
determined by qPCR and normalized to the respective untreated samples. The histogram 
is representative of the mean from three independent experiments with errors bars 
showing +/- SD. (b) p53 protein levels in untreated (-) and treated (+) U2-OS and SAOS-
2 cells. (c) The activity of p53 pre- and post-treatment from nuclear extracts of 
osteosarcoma cells. The values were normalized the respective untreated samples. Error 
bars represent the +/- SD from three independent experiments.  
 
 
 
 
 
126 
 
 
 
 
 
 
 
 
127 
 
Chapter 4 
PRMT5, a novel PLK4 interacting partner is deregulated in Plk4 heterozygous 
MEFs 
Authors: Alejandra Ward, Gayathri Sivakumar, Sharon Yong, Anna Kozarova, Jordan 
Nantais, Otis Vacratsis, John W. Hudson 
Introduction 
The highly conserved polo-like kinase family is essential for a variety of cellular 
phenomena which include centrosome dynamics, spindle pole formation, mitotic and 
anaphase entry, as well as involvement in the DNA damage response [1-4].  Of the five 
members discovered to-date, PLK1-4 are the most well characterized of these 
serine/threonine kinases.  Congruent with the promiscuity of these types of kinases, 
multiple interacting proteins have been identified for PLK1-4. Among these interacting 
partners, PLK1 and PLK3, and PLK4 have been shown to interact with key cell cycle 
proteins such as CDC25C [5-8] and cyclin B1[9].  As well, PLK1-PLK4 all interact with 
DNA damage response proteins Chk2 and p53 [6, 8, 10, 11] with varying biological 
outcomes  [12, 13].  Most recently, PLK2 has been implicated in a variety of neurological 
pathways including the phosphorylation of α-synuclein in yeast and mammals [14], and 
regulating the activity of the guanosine triphosphatases, Ras and Rap, in neurons [15].  
PLK4’s primary function is in centrosome duplication with several of its identified 
targets involved in this process. This includes GCP6, a member of the ɣ-tubulin ring 
complex, an essential component of the centrosome, and the SCF-FBOXW5 E3 ubiquitin 
ligase which helps prevent centrosome overduplication [16, 17].  Deregulation of PLK4 
protein levels in both humans and mice leads to multiple centrosomes and multipolar 
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spindle formation resulting in genomic instability and is associated with tumourigenesis 
[18, 19]. During development, murine embryos which are Plk4
-/-
 fail to progress past 
embryonic day 7.5 [20]. PLK4 also has been implicated in cell-fate determination 
through its regulation of Hand1, which, when phosphorylated by PLK4, signals  for 
trophoblast stem-cell differentiation [21].  Plk4
+/-
 mice develop hepatocellular 
carcinomas and lung tumours at a rate 15 times higher than their wild type littermates as 
they age [19].  Deregulation of PLK4 has been reported in several human tumour types 
including colorectal cancers, hepatocellular carcinoma, and most recently, the highly 
aggressive triple negative breast cancers [13, 22-24]. Recent studies from our lab have 
revealed that downregulation of Plk4 levels has downstream impacts on normal 
epigenetic modifications in vitro and in vivo [23, 25].  Plk4
+/- 
MEFs have higher levels of 
DNA methyltransferase 3A (DNMT3A), an enzyme responsible for de novo methylation, 
before and after oxidative stress [25]. Furthermore, Plk4
+/- 
mice display significantly 
higher global methylation when they are young compared to their wild type counterparts, 
and eventually go on to develop hepatocellular carcinoma, where Plk4 itself is further 
downregulated through DNA hypermethylation [23].    It is therefore of importance to 
identify PLK4 downstream targets in order to fully understand the essential functions of 
PLK4 and how this may impact epigenetic modifications.  Here we report the 
characterization of a novel interaction between PLK4 and protein arginine 
methyltransferase 5 (PRMT5), an epigenetic modifier. In addition, we also show Plk4 
heterozygosity directly impacts the levels, activity, and localization of PRMT5.  
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Results and Discussion 
Characterizing the interaction between Plk4 and PRMT5  
In order to enhance the detection of novel PLK4 interacting partners, we used a 
Flag-tagged mass spectrometry (MS) approach. The resulting mass spectra were analyzed 
for any peptide peaks which had particularly strong signals and these were chosen for 
analysis by tandem-MS (MS-MS). PRMT5 was identified in these peaks.  Concerns with 
non-specific binding of PRMT5 in co-immunoprecipitations have been previously 
documented in the literature [26]. Nishioka and Reinberg noted that Flag-M2 agarose 
beads could non-specifically bind PRMT5 in pull down assays [26]. Therefore, to 
validate our mass-spectrometry findings, we performed a co-immunoprecipitation with a 
PRMT5 antibody against the endogenous protein using G-sepharose beads. Our co-
immunoprecipitation indeed showed Flag-PLK4 was interacting with PRMT5 under 
these conditions (Fig. 4.1a).  To further eliminate the possibility that this interaction may 
be due to non-specific Flag binding, the experiment was repeated using endogenous 
protein from whole cell lysates of HEK 293T cells. The interaction still persisted in 
unsynchronized cells (Fig. 4.1b). PLK4 is the largest of the PLKs with an N-terminal 
domain housing its kinase activity, a unique central region termed the cryptic polo box 
which encompasses two tandem polo-box domains, and the C-terminus with a third polo-
box domain [27].  This tri-polo-box architecture facilitates PLK4 activities such as 
oligomerization, autophosphorylation and substrate targeting [27].   Cep152, an essential 
centrosome protein, recruits PLK4 to the centrioles and binds to PLK4’s cryptic polo-box 
domain, though it does not interact at the N-terminal domain and is not a substrate of 
PLK4 [28]. However, PLK4’s interaction with GCP6 and Ect2 only requires the N-
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terminal domain of PLK4 and both are substrates of PLK4 [16, 29].  As a first step in 
determining the nature of the interaction between PLK4 and PRMT5, we used various 
PLK4 mutants.  Initially, we examined the interaction at the N-terminal domain of PLK4 
by using Flag-PLK4K41M kinase dead (KD), Flag-PLK4T170D kinase active (KA), and 
Flag-PLK4ΔPB (lacking polo-box domains) mutants (Fig. 4.1c).  Based on our co-
immunoprecipitations, all of the N-terminal mutant constructs interacted with PRMT5 
(Fig. 4.1d) while there was no detectable interaction for the C-terminal domains, Flag-
PLK4R1 (only the cryptic polo-box) and Flag-PLK4Pb (only the polo-box domain) (Fig. 
4.1d).  Flag-YVH1, a phosphatase, was used as an additional control for non-specific 
binding (Fig. 4.1c).  Note, we had previously determined that this protein did not interact 
with Plk4 [7, 8].  
PRMT5 is an epigenetic modifier which can methylate both histone and non-
histone proteins at arginine residues, and as a type II arginine methyltransferase, it 
catalyzes the symmetric transfer of methyl groups onto arginine [30, 31].  PRMT5 can 
mediate transcriptional repression at the histone level by methylation of histone tails at 
H3R8 and H4R3, [32] which in turn, recruit the DNA methylating proteins, DNA 
methyltranferase 3A (DNMT3A), and histone deacetylase 1 (HDAC1) to increase 
transcriptional downregulation at the DNA level. The function of PRMT5 is not limited 
to histone modification, but it has also been shown to play a role in the regulation of cell 
growth proteins like Epidermal Growth Factor Receptor (EGFR) and TNF-related 
apoptosis inducing ligand (TRAIL), by suppressing their functions [33, 34]. PRMT5 is 
essential for embryonic development as PRMT5 null mouse embryos are embryonic 
lethal between E3.5-E6.5 [35].   
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Figure 4.1. PRMT5 interacts with PLK4’s N-terminal domain. (a) PRMT5 Co-
immunoprecipitations using HEK 293T cells were conducted in order to determine if 
PLK4 interacts with PRMT5. The cells lane represents un-transfected whole cell lysates; 
Flag represents cells transfected with Flag empty vector. (b) Schematic diagram showing 
the   sites modified on PLK4 to obtain mutants. KD represents the kinase dead mutant 
where lysine 41 was converted to methionine. KA is the kinase active mutant with 
threonine converted to aspartic acid. ΔPB encompasses the entire kinase domain without 
the polo box domains. R1 represents what was once called the cryptic polo-box domain, 
but now is known to harbour 2 polo-box domains. PB is just the third and C-terminal 
polo-box domain only. (c) To characterize the interaction between PRMT5 and PLK4, 
transiently transfected N-terminal mutants were pulled down with PRMT5 antibody. (d) 
A PRMT5 co-immunoprecipitation with lysates from transiently transfected C-terminal 
domain truncation mutants. (e) The co-immunoprecipitation was performed on 
endogenous PLK4 proteins using the PRMT5 antibody. The first lane has a negative 
control with beads immunoprecipitated with mouse IgG only. IgG label at 55 kDa 
represents the heavy chain of the antibody. (f) Endogenous PLK4 co-
immunoprecipitation was performed with PRMT5 antibody with lysates from p53 null 
cells.   
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Additionally, PRMT5 has a role in the DNA damage response by activating p53 during 
genotoxic stress via arginine methylation [36, 37].   Interestingly,  Ko et al., determined 
that PLK4 interacts with p53 [19] an observation that suggested to us that perhaps the 
PLK4 and PRMT5 interaction required p53, or p53 may be acting as an intermediary in 
binding. We thus performed endogenous co-immunoprecipitation of PRMT5 from cell 
extracts of the p53-null cell lines Hep3B which is derived from a hepatocellular 
carcinoma, as well as with Saos-2, an osteosarcoma-derived cell line [38]. In these p53 
null cells, the PLK4-PRMT5 interaction persisted and was evident in both cell types (Fig. 
4.1f), indicating that p53 was not required for the interaction.  
Prmt5 is a bonafide substrate of Plk4 
Since PRMT5 interacted with PLK4 specifically at its N-terminal region, which houses 
PLK4’s kinase domain, we next sought to determine whether PRMT5 may be a potential 
substrate of PLK4. Flag-tagged versions of human wild-type (Flag-Plk4), kinase active 
(Flag-Plk T170D) and kinase dead (Flag-Plk4 K41M) were expressed in HEK-293 cells 
and after affinity purification were subsequently used in in vitro kinase assays to test the 
ability of PLK4 to phosphorylate bacterially expressed GST-PRMT5 fusion protein. Our 
results demonstrated PRMT5 was targetted by both wild type and kinase active forms of 
PLK4, thus indicating that PRMT5 is a substrate of PLK4 (Fig. 4.2a). Moreover, our 
kinase assay also indicated that kinase activity of PLK4 is required for the 
phosphorylation of PRMT5 since the kinase-inactive mutant of PLK4 did not 
phosphorylate PRMT5 (Fig. 4.2a). As expected auto-phosphorylation of both full length 
and kinase active forms of PLK4 were also observed (Fig. 4.2a) and Plk4 did not 
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phosphorylate the residual GST-tag or purified GST protein, thus confirming that the 
phosphorylation of PRMT5 by PLK4 was specific for PRMT5 (Fig. 4.2b).  
Identification of the Plk4 interacting region within Prmt5  
PRMT5 exists as a tetramer and the oligomeric interactions between dimer pairs 
are propelled by comprehensive associations between the Triosphosphate isomerase 
(TIM) barrel at the amino-terminal lobe of one monomer and the carboxy-terminus β-
barrel of another [39]. In addition, the N-terminus of PRMT5 is essential for the binding 
of the co-factor methylosome protein 50 (MEP50) to form the integral unit of the protein 
methyltransferease complex. This moiety can in turn collaborate with a myriad of partner 
proteins, creating a pool of multimeric complexes with unique substrate selectivity and 
functionalities [40, 41]. Gu et al. (2012) have previously identified the presence of three 
nuclear exclusion signals in PRMT5 with one in the N-terminal and two in the C-terminal 
region.  Depending on the cell type, PRMT5 has discrete subcellular localizations and 
consequently, altered functions. It is speculated that the dynamic regulation of its 
localization may be dependent on post-translational modifications [42]. The amino-
terminal of PRMT5 provides a platform for substrate interaction through MEP50, while 
the carboxy-terminal domain encompasses the salient catalytic core possessing the S-
adenosylmethionine (AdoMet)-dependent arginine methyltransferase activity of PRMT5 
[40]. Undoubtedly, the active site of PRMT5 is key to its functions in several cellular 
processes, including the modulation of signaling pathways and gene expression. 
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Figure 4.2. PRMT5 is a novel substrate of PLK4. (a) Kinase assays were performed to 
ascertain whether PLK4 phosphorylates PRMT5. HEK 293T cells were transiently 
transfected with Flag empty vector and Flag-tagged PLK4 constructs, including wild type 
(PLK4), kinase active (KA), and kinase dead (KD) mutants. 293T lysates transfected 
with the indicated constructs were immunoprecipitated with anti-Flag antibody and 
incubated with bacterially expressed, GST-cleaved PRMT5 in the presence of [ɣ-32P]. 
The assay was visualized by autoradiography. Immunoblots show the loading of PLK4 
constructs and PRMT5. (b) In vitro kinase assay conducted with GST protein alone is 
shown as control. (c) A schematic representation of PRMT5 full-length protein and 
truncation mutants.  (d) Co-immunoprecipitation of truncation mutants with Flag-PLK4 
identifies the PRMT5 domains which interact with PLK4.  
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In order to map the region in PRMT5 that interacts with PLK4, we generated Myc-tagged 
deletion mutants for human PRMT5. The truncation mutants were generated to target 
three distinct domains on PRMT5.  The first is a ΔN-terminal (amino acids 1-291)-
PRMT5, a deleted arginine methyltransferase domain  ΔMTD (amino acids 365-369)-
PRMT5, which causes the protein to lose its enzymatic activity, and a ΔC-terminal 
(amino acids 292-637)-PRMT5 (Fig. 3.2c).  Surprisingly, results from the 
immunoprecipitations displayed PLK4 interaction with all three mutated constructs of 
PRMT5  (Fig. 3.2d). As a way to exclude the possibility of non-specific binding of Myc 
tag with Flag-PLK4, we also performed a Co-IP assay where HEK 293Ts were co-
transfected with Myc-SPY1 and Flag-PLK4. Again, Flag antibody was used to co-
immunoprecipitate proteins and no interaction was observed between Myc-tagged SPY1 
and PLK4 (data not shown). To dissect the implication of PLK4’s association with 
multiple domains of PRMT5, we performed an in silico analysis using  NetPhos 2.0 
server [43] to predict Serine/Threonine phosphorylation sites on PRMT5. Nine Ser and 
two Thr residues have potential for such post-translation modifications within the N-
terminus, while the C-terminus possesses four Ser and four Thr phosphorylatable sites. It 
is widely known that many substrates need to be phosphorylated at multiple sites in order 
to modulate localization or function [44]. It may be possible that distributive 
phosphorylation events may be essential for the nature of the signaling network between 
PLK4 and PRMT5.  We are currently using a mass spectrometry-based approach to 
determine the site(s) targeted by PLK4. As both domains of PRMT5 contain putative 
nuclear exclusion sequences, all of which are in close proximity to phosphorylatable 
Ser/Thr residues, it is possible that phosphorylation of these specific regions by PLK4 is 
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an impetus to produce the changes in localization patterns innate to PRMT5. Moreover, 
distal binding interactions between the kinase and substrate can further alter substrate 
activity through allosteric regulation and induce changes in sub-cellular localization [45]. 
  
Prmt5 does not arginine methylate Plk4 
 PRMT5 orchestrates the arginine methylation of a repertoire of proteins to 
modulate important biological processes such as growth, proliferation, and 
differentiation. We assessed whether the interplay between PRMT5 and PLK4 could 
potentially be bi-directional. In silico analysis revealed that PLK4 had a putative site for 
arginine methylation between residues 353-361 [46]. Using a symmetric arginine 
dimethylation antibody, we performed a co-immunoprecipitation to determine whether 
PLK4 is able to co-purify with this dimethyl arginine antibody. PLK4 was undetectable 
in the immunocomplex, suggesting that under these conditions PRMT5 does not confer 
any post-translational arginine methylation marks on PLK4 (data not shown). This 
suggests that the interaction between PLK4 and PRMT5 may be unilateral. While PLK4 
is able to phosphorylate PRMT5, PRMT5 may not necessarily mediate arginine 
methylation of PLK4. 
 
Plk4 heterozygosity results in aberrant localization of PRMT5 
Plk4 has been well established as a master regulator of centrosome duplication, 
and localizes to this and other important mitotic structures including the midbody and the 
cleavage furrow [29, 47]. Therefore, it was important to determine to which of these 
subcellular areas PRMT5 localized to. Previous literature has established that PRMT5 
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localizes both to the cytoplasm and the nucleus, however, ectopic expression of GFP-
PRMT5 in HEK 293 cells resulted in PRMT5 being expressed predominantly in the 
cytoplasm with regions of increased staining [42, 48],  which were suggestive of 
centrosomal localization. The cellular compartment in which PRMT5 inhabits has a 
direct impact on its function and activity.  Distinct partitioning of PRMT5 results in a 
cellular dichotomy, where nuclear localization of PRMT5 has been associated with a 
decrease in arginine methyltransferase activity, while cytoplasmic localization is 
associated with an increase in cellular proliferation [42].  This has been documented in 
several cell types:  in colorectal tumour tissue, there is a greater proportion of PRMT5 
localizing to the nucleus of tumour cells compared to the normal cells, while in prostate 
cancer cells, PRMT5 localization in the cytoplasm was associated with an increase in 
cellular proliferation [42, 49].  Initially, since the predominant site of localization for 
PLK4 is the centrosomes [47] we performed immunofluorescence on NIH 3T3 cells with 
ɣ-tubulin to stain for centrosomes and anti-PRMT5 staining for endogenous PRMT5.  
We found that in these cells, PRMT5 was detected in dot-like patterns in the nucleus, 
with some generalized staining in the cytoplasm, and, more specifically, PRMT5 was 
also found to have a strong signal on the centrosomes (Fig. 3.3a). We examined this 
phenotype further in primary cells in the context of Plk4 levels by utilizing both wild type 
and heterozygous Plk4 mouse embryonic fibroblasts (MEFs).  Perhaps, low levels of Plk4 
could perturb the centrosomal localization of PRMT5?  For example, one of PLK4’s 
substrates, Ect2 is required for appropriate cytokinesis; in the context of Plk4 
heterozygosity, during late mitosis, Ect2 fails to localize to the midbody and does not 
activate RhoA, a necessary protein for completion of cytokenesis [29]. In wild type  
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Figure 4.3. Plk4 heterozygosity impacts Prmt5 localization. Mouse fibroblasts were 
used to examine the endogenous localization of Prmt5. Hoechts 33342 was used to stain 
the nucleus, ɣ-tubulin to examine the centrosomes, and Prmt5 antibody was used to 
examine endogenous localization of Prmt5. (a) Initially NIH 3T3 mouse fibroblasts were 
employed to examine the localization of Prmt5. In some instances, Prmt5 also localized 
to the centrosomes. (b) Primary wild type (WT) mouse embryonic fibroblasts (MEFs) 
show the co-localization of Prmt5 to the centrosomes. (c) Plk4 heterozygous MEFs were 
used to determine if varying levels of Plk4 also impacted Prmt5 localization. (d-e)  
Plk4
+/-
 MEFs were transiently transfected with Flag empty vector, full length PLK4, and 
the KD PLK4 mutant. (f) The distribution of Prmt5 localization was quantified in WT 
and HET MEFs by counting a minimum of 200 cells. The cell counts for the transfected 
cells were obtained by counting a minimum of 100 cells positive for Flag staining. Error 
bars represent the standard deviation from three independent experiments. * represents a 
p<0.001.  
 
 
 
 
 
141 
 
 
142 
 
MEFs, PRMT5 was also detected in the nucleus and the cytoplasm, but PRMT5 also co-
localized to the centrosomes in more than 85% of the cells examined (Fig. 4.3b,g). By 
contrast, in Plk4
+/-
 MEFs, we found that on average, that approx. 10% of the cells 
examined had PRMT5 localizing to the centrosome (Fig. 4.3c,g) with the majority of 
PRMT5 localized to the nucleus in Plk4
+/-
 MEFs (Fig. 4.3c,g). In order to further 
establish a role for Plk4 levels in PRMT5’s localization patterns, we examined whether 
Plk4 over-expression in Plk4 heterozygous MEFs would alter or rescue expression the 
pattern.  We observed that PRMT5 co-localized with ectopically expressed PLK4 in 
Plk4
+/- 
 MEFs at the centrosomes in approximately 80% of the cells examined, suggesting 
that re-introducing normal PLK4 levels is sufficient to rescue the predominant nuclear 
localization of PRMT5 in Plk4
+/- 
MEFs (Fig. 4.3e,g). Furthermore, transfection with the 
kinase dead-PLK4 mutant resulted in a partial rescue, though not to the same degree as 
the full length PLK4 rescue (Fig. 4f,g).  The PRMT5 localization in Plk4
+/- 
MEFs 
transfected with Flag-vector alone remained primarily in the nucleus similar to un-
transfected cells (Fig. 4.3d,g).   
 
Plk4 heterozygosity is insufficient for normal PRMT5 activity 
It is known that cellular localization impacts PRMT5 function. With the aberrant 
localization of PRMT5 in Plk4
+/- 
MEFs, it raised the question of how else does Plk4 
heterozygosity impact PRMT5?   To answer this question, we examined protein levels of 
PRMT5 in Plk4
+/+ 
 and  Plk4
+/- 
MEFs via Western blot analysis.  Interestingly, we found 
that in the Plk4
+/-
 MEFs, PRMT5 levels were dramatically decreased compared to the 
wild-type cells regardless of whether the MEFs were from an early or late passage (Fig. 
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4.4a). This indicates that PRMT5 down-regulation is correlated with lower levels of Plk4. 
Decreased levels of PRMT5 that persist through later passages indicates that this is an 
inherent phenotype of Plk4 heterozygous cells and it is not merely a transitory event (Fig. 
4.4a).  PRMT5 protein levels were 50% lower in Plk4 heterozygous MEFs than Plk4 wild 
type MEFs (Fig. 4.4b), which is directly proportional to the Plk4 protein levels found in 
these Plk4 genotypes [13]. This suggests PRMT5 levels are tethered to that of Plk4 
protein levels and that Plk4 may have an upstream regulatory role on PRMT5 levels.  
Previous studies have shown that PRMT5 levels are correlated with its activity, 
significantly effecting the arginine methylation of its downstream targets [49-51]. In 
agreement with this, the examination of whole cell lysates for symmetric arginine 
methylation revealed that Plk4
+/- 
MEFs had almost no detectable arginine methylated 
proteins (Fig. 4.4e,f) [52]. PRMT5 catalyzes the formation of symmetric dimethyl 
arginine residues in proteins), indicating that along with depletion of PRMT5 proteins, 
Plk4
+/- 
MEFs also had a decrease in PRMT5 activity.  Plk4 heterozygosity indirectly 
results in insufficient global symmetric protein arginine methylation patterning, due to 
Plk4 interacting with and potentially playing a role in both the localization of PRMT5 
and its levels.    
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Figure 4.4. Plk4 heterozygosity decreases Prmt5 protein level and activity. Whole 
cell lysates from Plk4
+/+ 
and Plk4
+/-
 MEFs were extracted and examined for Prmt5 levels. 
(a) Prmt5 levels from Plk4
+/+ 
MEFs at passage 3 (p3)
 
were used as a normal comparison 
for the Prmt5 protein levels obtained from Plk4
+/-
 MEFs at passage 3 and 11 (P3, P11). 
(b) Prmt5 levels from MEFs treated with reactive oxygen species in the form of H2O2 
were examined for changes in protein levels between genotype and treatment. (c) 
Densitometry was used to quantify the differences in Prmt5 protein between Plk4
+/+ 
and 
Plk4
+/-
 MEFs. * represents a p<0.001. The error bars represent the standard deviation 
obtained from three independent experiments.  (d,e) Whole cell lysates from Plk4
+/+ 
and 
Plk4
+/-
 MEFs were examined via Western blot analysis for global symmetric arginine 
methylation marks. GAPDH was used a loading control. 
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Plk4 heterozygosity impacts PRMT5’s role in DNA damage: a model for PLK4 and 
PRMT5 cooperation in the activation of p53 
 
In order to further characterize the impact of Plk4 heterozygosity on PRMT5 
activity, we examined the activity of one of PRMT5’s targets, p53. PRMT5 methylates 
several arginine residues on p53, which, during genotoxic stress, are necessary for p53 
stability, activity, and specificity [36, 37]. In addition, ectopic knockdown of PRMT5, at 
similar levels to what we have observed in Plk4
+/- 
MEFs, resulted in decreased p53 
stability and activity [36, 37].  Previously, we have shown that the DNA damage induced 
by ROS in Plk4
+/- 
MEFs did not translate into an increase in p53 activity compared to the 
wild type counterparts [25].  We therefore sought to examine p53 levels post-DNA 
damage using UV as the damaging agent since it is a genotoxic stressor that activates the 
p53 response and previous PRMT5 studies have used UV to examine the p53 response 
[37].  p53 levels increased with increased UV dosage in the wild-type MEFs as one 
would be expect (Fig. 4.5a). On the other hand, in Plk4
+/- 
MEFs, p53 levels started out 
high, as previously reported (Morettin et al, 2009) and then, decreased with increased 
dosages of UV (Fig. 4.5a), indicating a loss of p53 stability. The p53 activity of nuclear 
extracts from treated MEFs also displayed a 20% decrease in p53 activity in Plk4
+/-
 
MEFs in comparison to untreated MEFs, while the wild-type counterparts displayed a 
15% increase in p53 activity with UV exposure (Fig. 4.5b).  The role of p53 during DNA 
damage is to either mediate DNA damage repair pathways, or, if the damage is too great, 
to activate the apoptotic pathway in order to prevent DNA lesions from being propagated 
in the next round of cell division (Reviewed in Yoshida and Miki, 2009).We next looked 
at levels of phosphorylated histone H2AX (γH2AX), which become 
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Figure 4.5. Lowered levels of Prmt5 inhibit p53 activation during DNA in a Plk4 
heterozygous context. MEFs were subjected to 0-40 mJ/UV and the DNA damage 
response was assessed. (a) Western blot analysis for p53 and ɣ-H2AX post DNA damage 
in Plk4
+/+ 
and Plk4
+/-
 MEFs. (b) An ELISA-based p53 activity assay was used to 
determine p53 activity with cellular exposure to UV radiation. Nuclear extracts from 
MEFs were used. (c) Flow cytometry was conducted to determine the distribution of cells 
throughout the cell cycle post UV damage of MEFs. (d) The distribution of cell 
populations in the Sub-G0 phase of the cell cycle. The data is representative of three 
independent experiments and error bars are the standard deviation of the mean. 
*represents a p<0.001.  
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generally increases in response to DNA damage [53, 54].  In Plk4
+/+
 MEFs, ɣH2AX 
levels peaked at 40mJ/UV dose, while in Plk4
+/- 
MEFs, γH2AX was initially high and 
protein levels became depleted with increasing dosage of UV (Fig. 4.5a), suggesting that 
Plk4
+/- 
MEFs have an impaired DNA damage repair pathway.  We examined the 
proportion of MEFs post-UV treatment undergoing apoptosis using flow cytometry. As 
expected, after 8 hours post 40 mJ/UV exposure, Plk4
+/+
 MEFs displayed an increase in 
the sub-G0 population compared to the untreated cells by 12%, suggestive of apoptosis 
(Fig. 4.5c), whereas, Plk4
+/- 
MEFs showed no such increase in the sub-G0 population 
compared to the untreated counterparts, indicating that there may be an inadequate p53-
mediated apoptotic response to DNA damage (Fig. 4.5c). These results are similar to 
those obtained by Michael Ko, where UV treated MEFs were examined via flow 
cytometry [55]. He observed that with 100 J/m
2
 UV, Plk4
+/- 
MEFs displayed half the 
number of apoptotic cells compared to the wild type cells [55].  PRMT5 methylation of 
p53 arginine residues 333, 335, 337 has been shown to impact p53 activity and 
localization during DNA damage  [37]. With Plk4
+/-
 MEFs displaying a decrease in 
PRMT5 protein and a general decrease in global PRMT5-mediated arginine methylation 
marks, this may result in a lack of the arginine dimethylation required for appropriate p53 
activity during DNA damage.  Furthermore, PLK4 has been also been shown to interact 
with and phosphorylate p53 at S392 [19, 55] and in liver resection studies in Plk4
+/-
 mice, 
p53 failed to become activated, providing evidence that normal levels of Plk4 are also 
necessary for the activation of p53.  Given the dynamic nature of the centrosome, where a 
variety of proteins either reside, or transitionally inhabit the pericentriolar material, it has 
been proposed that the centrosome may be a control centre for the initiation of the DNA 
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damage response [56].  Indeed, several DNA damage response proteins localize to the 
centrosome, including Chk2, BRCA1 and p53 [57-59]. During the normal progression of 
the cell cycle, at the G2/M transition, p53 localizes to the centrosomes in an ATM 
dependent manner via phosphorylation of S15 and monitors the integrity of the mitotic 
spindles [58]. With PLK4 levels peaking at the G2/M transition and PRMT5 interacting 
and co-localizing to the centrosomes, this now provides a spatial and temporal platform 
by which PLK4, PRMT5 and p53 could interact.  We surmise that this tripartite grouping 
could be acting collaboratively to disseminate the appropriate response to DNA damage 
prior to the onset of mitosis (Fig. 4.6).     
Here, we demonstrated that PLK4 is required for the normal function of PRMT5 
through direct interaction, phosphorylation, and co-localization at the centrosomes as 
well as maintenance of normal PRMT5 levels. Interestingly, in data from our lab 
obtained from human hematological malignancies, PLK4 and PRMT5 followed a 
comparable pattern, where downregulation of PLK4 via promoter methylation, was also 
associated with lower levels of PRMT5 (Ward et al, Chapter 5 dissertion).  Moreover, it 
may be that the opposite scenario is also true; over-expression of PLK4 has been detected 
in breast and colon cancers and is associated with poor prognosis [18, 24]; Independent 
studies have, likewise, determined that PRMT5 overexpression in these same tumour 
types is also associated with poor outcome [49, 60]. Together with our results, these 
studies suggest that PRMT5 expression may be proportionally tethered to PLK4 levels 
and this directly impacts normal PRMT5 activity.  Some of the processes that are  
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Figure 4.6.  Potential mode of action by which PLK4 haploinsufficency results in an 
altered DNA damage response.  (a) During the normal cell cycle ATM (Ataxia 
telangiectesia mutated) phosphorylates p53 at S15 where it then shuttles to the 
centrosome, acting as an overseer of the  mitotic spindle assembly, and promptly 
dephosphorylated [59].  If DNA damage occurs during this time, PLK4 together with 
PRMT5 act collaboratively to arginine methylate and phosphoryate the respective 
residues that will allow p53 to shuttle into the nucleus and activate the appropriate 
downstream targets. (b) In the context of Plk4 haploinsufficiency, although p53 is still 
phosphorylated by ATM, it does not remain at the centrosome and phosphorylation of 
S15 is not lost. Together with low levels of Plk4 and Prmt5, p53 cannot have the post-
translational modifications on the R333,335,337 and S392, required for it to exert its 
cellular protective function, allowing the cell through mitosis with damaged DNA and 
into the next cycle of cell division, which can ultimately result in tumourigenesis.  
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regulated by arginine methylation include transcriptional regulation by histone 
modifications, RNA processing, DNA repair, and signal transduction [30].  PRMT5’s  
downstream targets include E2F-1, Hif1α, and NF-κβ. [49-51]. The deregulation of all of 
these proteins along with their associated pathways, confers pro-survival effects at the 
cellular level and have all been implicated in tumourigenesis.  The regulatory role of 
PLK4 on PRMT5 reinforces the importance of PLK4’s upstream role as an anti-tumour 
protein. Furthermore, in previous studies, the PLKs have been the recipients of epigenetic 
modifications displaying aberrant promoter methylation in a variety of tumour types 
including ovarian cancer, hepatocellular carcinoma, and hematological malignancies [22, 
23, 61, 62]. However, this is the first study that shows a role reversal, in which PLK4 acts 
as an upstream regulator of epigenetic modifications.  Much of the investigation 
surrounding Plk4 deregulation in malignancy has been associated with centrosomal 
aberrancies and the ensuing aneuploidy and genomic instability [19, 23]; here we 
demonstrate that deregulation of PLK4 is not limited to centrosome abnormalities, but in 
fact, has downstream impacts on critical epigenetic modifications and the DNA damage 
response.  
Currently, the prevailing research suggests that PRMT5 may be an ideal 
therapeutic target in cancers since its expression or localization is deregulated in many 
malignancies [33, 63-65]. Although, much is known about its structure and function, 
other than as a JAK2 substrate, little is known about its upstream regulators.  As a future 
initiative, in tumours where PRMT5 is de-regulated, perhaps examining the upstream 
PLK4 levels may provide more insight into PRMT5 deregulation and subsequent 
therapeutic design efforts can be more refined.  
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Materials and Methods 
 
SDS-PAGE stains and Mass spectrometry 
Silver-Stain Protein Staining Procedure for SDS-PAGE Gels 
Following SDS-PAGE, the gel containing samples was treated in de-staining 
solution (25% ethanol, 10% glacial acetic acid) for one hour. The gel was then washed 
three times in 50% ethanol and subsequently, the gel was pre-treated in thiosulfate 
solution (1.3 mM sodium thiosulfate) and washed. Next, the gel was impregnated with 
silver nitrate solution (11.8 mM silver nitrate, 7.5x10
-4
% v/v formaldehyde). Developer 
solution (28.3 mM sodium carbonate, 5.0x10
-4
% v/v formaldehyde, 2.6x10
-2 
mM sodium 
thiosulfate) was then used to develop the solution for anywhere between one and ten 
minutes. After incubation, the gel was washed and the developing reaction was stopped 
with de-staining solution. Post de-stain, the gel was maintained in 1% glacial acetic acid. 
The visible bands were excised and rehydrated in siliconized microcentrifuge tubes 
(please note that all water used in this section was mass spectrometry grade). Water was 
then removed from all excised bands and replaced with 100 μL of de-stain solution (15 
mM potassium ferrocyanide, 50 mM sodium thiosulfate). After de-staining, the bands 
were incubated in 50 mM ammonium bicarbonate and subsequently, charged with 200 μL 
of acetonitrile repeatedly until the pieces reached a white opacity. The samples were then 
dried using a Savant Speed Vac Plus SC110 A then re-hydrated in trypsin digestion 
buffer (50 mM ammonium bicarbonate, 13 ng/μL Promega modified trypsin) to cover 
each gel piece (≈20μL). The samples were incubated for 30 minutes on ice. If after 30 
minutes the gel pieces had absorbed all of the digestion buffer, additional ammonium 
bicarbonate (50 mM stock) was added until the original volume was re-established. Each 
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microcentrifuge tube was then sealed using Parafilm, and incubated at 37
o
C and 220rpm 
shaking for 30-60 minutes.  After digestion, the remaining supernatant was incubated in 
protein extraction solution (60% acetonitrile, 1% formic acid) at 37
o
C and 220rpm 
shaking for 45 minutes. The resulting digestion buffer and protein extractions were then 
concentrated by volume reduction to ≈10μL using the Savant Speed Vac Plus SC110 A at 
room temperature. In order to perform analysis by MALDI-TOF, 1μL of sample was 
spotted into each well of the MALDI plate, followed by 1μL of matrix solution (53 mM 
alpha cyano-4-hydroxy cinnaminic acid) which was then spotted on top of the sample. 
The samples were allowed to dry for several hours, followed by MALDI-TOF analysis. 
The resulting mass spectra were analyzed for any peptide peaks which had particularly 
strong signals and these were chosen for analysis by tandem-MS (MS-MS). Through the 
use the bioinformatic program Protein Prospector (The Regents of the University of 
California) as well as the SwissProt database it was possible to estimate the identity of 
PRMT5. 
Cell culture 
Human embryonic kidney 293T cells were cultured in Dulbecco’s modified Eagle’s 
media (DMEM) supplemented with 10% fetal bovine serum (FBS). Primary Mouse 
embryonic fibroblasts (MEFs) were harvested at embryonic day 12.5 under sterile 
conditions and in accordance with the University of Windsor’s and the Canadian Animal 
Care guidelines.  MEFs were cultured in DMEM supplemented with 20%FBS, 1% 
penicillin/streptomycin, and 0.5% gentamicin. MEFs used for experiments were between 
passages 2-5 unless otherwise stated. All cells were maintained at 37˚C with 5% CO2. 
Transient transfections in HEK 293T cells were carried out using 10 μg of respective 
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purified plasmid DNA (Qiagen Maxiprep kit) and 1 mg/mL polyethylenimine (Sigma).  
MEFs were transfected using the Qiagen Effectine
TM
 transfection kit. The transfections 
were carried out according to manufacturer’s recommendations. In order to establish 
inducible cell lines, T-REx
TM
 HeLa cells were used and the standard growth media 
composed of Minimum Essential Medium (MEM), 2 mM L-glutamine, and 10% FBS, 
was supplemented with 5 μg/mL blasticidin 24 hours post-transfection. Following this, 
inducible colonies were established by maintaining transfected cells in growth medium 
with 5 μg/mL blasticidin and 500 μg/mL ZeocinTM.  Once inducible cell lines were 
established, Flag-PLK4 expression was induced using tetracycline at a final concentration 
of 1 μg/mL.  
To carry out the co-transfection of two plasmids, a total of 13 μg of combined plasmid 
DNA was introduced to cells along with polyethylenimine in serum-free media. After 4-6 
hours post-transfection, serum-free media was replaced with complete media. Protein 
lysates were collected 24 hours post-transfection.   
Western blot analysis 
Protein analysis was carried out using Western blot analysis. Whole cell protein was 
extracted using a lysis buffer (50mM Tris-Cl, 150mM NaCl, 1% Triton-X, 0.1% SDS) 
supplemented with EDTA-free protease inhibitor cocktail (Roche).  40 µg of total protein 
was used for Western blot analysis. The primary antibodies used were obtained 
accordingly, anti-PLK2 and anti-PLK3, (Santa Cruz); anti-ɣ-H2AX, anti-PLK4, anti-
PRMT5 and anti-GAPDH (Cell Signalling); anti-flag (Sigma-Aldrich); anti-symmetric 
arginine methylation (Novus biologicals). For secondary antibodies, anti-rabbit HRP 
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(Cell Signalling) and anti-mouse HRP (Sigma) were used.  Bands were visualized by 
ECL using the SuperSignal West Femto maximum sensitivity detection kit (Thermo 
Scientific), blots were acquired on an Alpha Innotech Multimage™ Light Cabinet and 
densitometry analysis was carried out using ImageJ software Version 1.47.    
 
Co-immunoprecipitations 
M2-agarose with anti-flag antibody (Sigma-Aldrich) and G-sepharose (GE Healthcare 
and Life Sciences) beads for immunoprecipitations were prepared as follows: 15 μL of 
beads for each plate of cells lysed were washed 2x using wash buffer (50mM Tris-Cl pH 
7.4, 150mM NaCl, and 0.025% Triton-X) and equilibrated with lysis buffer followed by 
the addition of the respective cell lysates. In some cases, stringent washes with 50 mM 
Tris-Cl pH 7.4, 500 mM NaCl, 0.1% SDS, and 0.1% Triton-X were required to reduce 
any non-specific interactions during the co-immunoprecipitation process. 
Immunocomplexes were flushed of protein contaminants by washing at least 5 to 7 times. 
For cell lysates obtained from inducible cell lines the lysates and beads were incubated at 
4
o
C for 2-3 hours with gentle rocking. Protein from transient transfections was incubated 
with beads at 4
o
C for 16 hours.  
p53 activity assay 
An enzyme-linked immunosorbent assay (ELISA) was performed in order to determine 
p53 activity. The ELISA was carried out according to manufacturer’s protocol (R&D 
Systems) using 30 ug of nuclear extracts from MEFs grown to 90% confluency. 
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UV treatments and Flow cytometry 
MEFs were UV treated using a Spectrolinker
TM
 XL-1000 UV Crosslinker (Spectronics 
Corporation) at specified doses ranging from 10-40 mJ/UV and cell lystaes collected 
directly after treatment. For flow cytometry analysis, UV treated cells were collected at  8 
hours post UV exposure and fixed in ice cold 80% ethanol and incubated on ice for an 
hour. Cells were permeabilized with PBS+ 0.1% triton X-100 solution and stained with 
propidium iodide. Cell cycle analysis was performed on a Cytomic FC 500 flow 
cytometer (Beckman Coulter). 
Plasmid Clones 
Wild-type human PRMT5 was cloned into the pCMV Myc vector by PCR amplification 
of PRMT5 from pANT7_cGST vector (DNASU) using forward primer 5’- 
TAGAATTCGGATGGCGGCGATGGC-3' and reverse primer 5'-
ATAAGATCTCTAGAGGCCAATGGTATATGAGC-3' which also introduced EcoRI 
and BglII restriction sites, respectively. Myc-tagged PRMT5 deletion expression vectors 
were created by mutagenesis of the full length Myc PRMT5 vector using QuikChange 
multi-site directed mutagenesis kit (Stratagene). The following primers were used for 
ΔMethyltransferase domain, ΔC-terminal, and ΔN-terminal Prmt5, respectively: 5’-CTG 
ATG GTG CTG CCA CTA GTG AAC GCT TCC C-3’, 5’–CAG AAC CGT CCT TGA 
GAG ATC TCT CGA GGT-3’, and 5’ –GAG GCC CGA ATT CGG CCA CCT AAT 
GCC TAT-3’. For kinase assay experiments, recombinant GST-PRMT5 was cloned from 
pANT7_cGST vector (DNASU) using forward primer 5’-TAG GAT CCA TGG CGG 
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CGA TGG C-3’ and reverse primer 5’-ATG AAT TCC TAG AGG CCA ATG GTA 
TAT GAG C-3’ containing BamHI and EcoRI restriction sites, respectively.   
 
Expression and Purification of GST-Fusion Protein 
GST-PRMT5 was expressed in E.coli BL21 DE3 (Stratagene) cells by induction with 1 
mM of IPTG (isopropyl-β-D-1-thiogalactopyranoside) at 30ºC for 4 hours. After 
collecting bacterial pellets, cells were lysed in a buffer containing 50 mM Tris-HCl pH 
7.5, 100 mM NaCl, 0.1 mM EDTA, 0.1% Triton X-100, 2 mM DTT, and protease 
inhibitor pellet (Roche). After incubation on ice for 20 min, lysates were subjected to 
sonication. Following centrifugation at 12,000 rpm for 30 min, the supernatant was 
incubated with glutathione S-transferase beads on a nutator for 2h at 4ºC. The beads were 
washed once with five column volumes of cell lysis buffer and twice with wash buffer 
(50 mM Tris-HCl pH 7.5, 100 mM NaCl, 1 mM dithiothreitol). Glutathione-agarose 
bead-conjugated GST fusion proteins were washed with five column volumes of cleavage 
buffer (100 mM NaCl, 50 mM Tris pH 7.5, 2.5 mM CaCl2, 1 mM dithiothreitol) in order 
to prepare the protein for GST cleavage by thrombin. After this washing step, 10 units of 
thrombin (Sigma Aldrich) were added per mg of fusion protein into one column volume 
of fresh cleavage buffer and left on a nutator overnight at 4°C. Stock solutions of 
thrombin (1 unit/µl) were prepared in sterile PBS and stored in a -80°C freezer. Soluble 
cleaved fusion protein was eluted from the filtrate by washing with elution buffer (50 
mM Tris HCl pH 7.5, 100 mM NaCl, 10 mM glutathione). Following purification, eluted 
protein was cleansed of contaminating salts and proteins and concomitantly concentrated 
using Amicon Ultra centrifugal filters (Millipore). As a negative control for kinase 
assays, empty GST protein was also expressed by inducing at room temperature 
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overnight with the addition of 1 mM IPTG. GST protein was purified and concentrated as 
mentioned above.  
 
Kinase Assays   
Following lysis of cells 24 hours post-transfection, whole cell lysates were collected and 
incubated with 1 µg of anti-Flag antibody (Sigma) and 20 µl of calibrated Protein G 
Sepharose beads 4 Fast Flow (GE Healthcare Life Sciences) at 4°C overnight. Immuno-
complexes were washed twice with wash buffer (50 mM Tris HCl pH 7.5, 150 mM NaCl, 
0.1% Triton X-100), twice with wash buffer supplemented with 500 mM LiCl and lastly, 
once with kinase buffer (60 mM Hepes pH 7.5, 3 mM MgCl2, 3 mM MnCl2, 50 mM NaF, 
25 mM dithiothreitol, 125 µM cold ATP and Roche protease inhibitor pellet). Bacterial-
purified, thrombin cleaved GST-PRMT5 protein was incubated with purified immuno-
complexes of Flag-PLK4 constructs. For each kinase reaction, 8 µg of GST-PRMT5 and 
10 µCi of [γ-
32
P] [Perkin Elmer] were supplemented to the kinase buffer. Reactions were 
incubated at 30°C for 30 min. Protein samples were resolved by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis and subjected to autoradiography. Phosphorylated 
bands were visualized using Cyclone Plus Phosphor Imager (Perkin Elmer) and the 
Optiquant software Version 5.0.  
 
Immunofluorescence 
Mouse embryonic fibroblasts were grown on glass slides in 6-well plates to 80-90% 
confluency. Transfections in MEFs were carried out at 60% confluency and incubated for 
24hours before collection. Cells on the slides were fixed in 3.7% pFa + 0.1% triton X-
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100. The cells were then incubated with PRMT5 antibody at a 1:50 dilution for 16 hours 
at 4˚C. Anti-flag and anti-γ-tubulin antibodies (Sigma) staining was incubated for an hour 
at room temperature at a dilution of 1:100. Secondary antibodies Alexa Fluor
®
 568 
(Invitrogen) and FITC (Vector laboratories) staining was also conducted at room 
temperature for 1 hour at a dilution of 1:500.  Cells were then stained using Hoescht 
33342 at a dilution of 1:10,000 for 2 minutes at room temperature. Images were resolved 
on a Zeiss Axioskop 2 mot plus using Northern Eclipse software. 
 
Statistical anaylsis 
Statisical analysis was conducted using Statsoft Statistica software Version 7. A One-way 
ANOVA was carried out to determine p-value. * represent a p<0.01. The results are the 
mean values obtained from three independent experiments. The error bars represent the 
standard deviation of the mean (SD) from three independent experiments.  
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Introduction 
 In a myriad of tumour types, hypermethylation of promoter associated CpG 
islands, histone modifications, and dynamic reassembly of chromatin architecture seem to 
be common mechanisms triggered to deregulate critical genes, including tumour 
suppressors [1].  B-cell lymphomas, along with other hematological malignancies 
including myelodysplastic syndromes and associated leukemias, for example, acute 
myelogenous leukemia (AML), are clinically and molecularly heterogeneous and harbour 
a variety of genetic and epigenetic abnormalities [2-4].  Gene expression profiling helps t 
identify novel biomarkers and potential prognostic indicators [5, 6]. Recently, the 
importance of epigenetics in the genesis of blood neoplasms has come to the forefront. 
The deregulation of gene expression is a hallmark of tumourigenesis and increasing 
evidence suggests that there are DNA methylation signatures that are highly associated 
with specific hematological malignancies [7-10].   All of the members of the Polo-like 
kinases (Plks), proteins with critical functions in cellular processes, often display aberrant 
methylation at their respective gene promoter regions, culminating in transcriptional 
modifications and abnormal gene expression in malignant cells [10-13]. More 
specifically, in the context of hematological disorders, Syed et al. (2006) previously 
reported aberrant cytosine methylation at the promoter region of PLK2, followed by 
167 
 
transcriptional silencing, as a common epigenetic phenomenon that may be driving the 
development and pathogenesis of B-cell neoplasms [14].   In addition, PLK2 promoter 
hypermethylation has also been detected in almost 70% of AML and approximately 90% 
of MDS cases studied [10].  PLK2 is one of five known members of the highly conserved 
family of serine/threonine kinases, the Polo-like kinases. The PLKs are essential in 
specific cell cycle events which include centrosome maturation, spindle-pole formation, 
the DNA damage response, and cytokinesis [15, 16]. Abnormal expression of these 
proteins has been associated with tumourigenesis,  for example, over-expression of PLK1 
has been detected in head and neck squamous carcinoma [17], hepatocellular carcinoma 
[12, 13] and colorectal cancers [18]. More importantly, aberrant promoter methylation of 
PLK1, PLK4, and PLK5 along with PLK2, have been implicated in a variety of tumour 
types such as ovarian cancer, hepatocellular carcinoma, and glioblastoma [10, 12, 13, 19, 
20].  The epigenetic profiling of PLK2 promoter methylation has revealed clinically 
valuable patterns in MDS, AML, and ovarian cancers [14, 19].  In ovarian cancer, an 
epigenetic mark on PLK2 was associated with a greater risk of relapse for post-operative 
patients  [19].  While, in MDS and AML cases, PLK2 hypermethylation trended towards 
a correlation with longer overall survival [10].  These studies indicate that examining the 
promoter methylation of the PLKs can have clinical applications. Thus far, the PLK 
methylation studies in hematologic malignancies have been limited to PLK2 and PLK3 
and have not been inclusive of the other Polo-like kinases. Given their importance in cell 
cycle regulation and their implication in carcinogenesis, we sought to expand on these 
studies and examine the methylation status of the remaining PLKs within the context of 
hematologic malignancies. The overarching aim of our study was to investigate the extent 
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of epigenetic deregulation of the polo-like kinase family in a variety of blood neoplasms 
such as myelodysplasia, leukemia, and lymphoma and understand whether these lesions 
play a role in the development and progression of blood neoplasm. Here we show that the 
PLKs are differentially methylated between normal and neoplastic samples and these 
changes in methylotype are detectable in standard bone marrow aspirates which are 
routinely collected as part of the diagnostic procedures for hematological malignancies  
In addition, we demonstrate the impact of the physiologic microenvironment and the 
effect of common epigenetic therapies on PLK expression using a variety of patient-
derived MDS and lymphoma cell lines.   
Results/Discussion 
PLK promoter methylation in hematological malignancies 
 Epigenetics is defined as the stable modifications of gene expression at the DNA 
and histone level without modification to the primary sequence of a gene. There are two 
distinct mechanisms whose end result greatly impact gene expression: DNA methylation 
and histone modifications. At the DNA level, dense regions of CG dinucleotides 
upstream of gene promoters, called CpG islands, are targeted by DNA methyltransferase 
(DNMTs) enzymes for the addition of methyl groups to the 5’ position of cytosines, 
leading to DNA methylation. Using PLK-specific primers we embarked on the screening 
of the methylation status of the PLKs in human bone marrow aspirates using methylation 
specific PCR (MSP). In normal samples, of those bone marrow aspirates which did not 
exhibit any detectable pathologies, the methylation pattern for PLK1promoter region was 
methylated, while the PLK2 and PLK4 CpG islands remained largely unmethylated. The 
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methylation status for PLK3 was undetectable in approximately 50% of these samples 
(Figure 5.1a,b). Interestingly, when examining samples from patients with hematological 
malignancies, this pattern was reversed. For PLK1, approximately 15% of malignancies 
displayed a loss of PLK1 promoter methylation (Fig. 5.1a,b). In our previous studies, we 
determined that loss of PLK1 promoter methylation is associated with an increase in 
protein levels [13]. Recently, Plk1 over-expression was observed in both acute myeloid 
leukemia (AML) and chronic myelogenous leukemia (CML) [21, 22]. Importantly, 
increased PLK1 protein is a poor prognostic indicator in several malignancies [23]). It 
was therefore of interest to determine whether individual Plk promoter methylation status 
was correlated with protein levels in a spectrum of blood neoplasms. We thus examined 
individual PLK protein levels in whole cell lysates from bone marrow aspirates. In the 
case of Plk1, in the majority (80%) of the cases, where there was a loss of promoter 
methylation there was a corresponding increase at the protein level (Fig. 5.1 c,d).  We 
saw an inverse pattern for Plk4 where 82.0% and 80.5% of lymphoma and 
MDS/Leukemia samples displayed hypermethylation at the PLK4 promoter region 
respectively (Fig. 5.1 a,b). PLK4 hypermethylation was consistently associated with a 
decrease in its protein levels [13, 24]. On average, in lymphoproliferative neoplasms, 
there was a significant decrease in PLK4 protein by 35% (Fig. 5.1e). A similar trend was 
observed in MDS/Leukemia samples (Fig. 5.1e). Strikingly, in more than 90% of the 
cases, PLK4 promoter methylation status correlated to protein expression (Fig. 5.1d), 
suggesting that in blood neoplasms aberrant promoter methylation of Plk4 is an important 
method of regulating  
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Figure 5.1 Promoter methylation analysis of the PLKs in hematological 
malignancies. (a) PLK promoter methylation profiles in MDS and lymphoma samples as 
determined by MSP. This is representative data. U=unmethylated, M=methylated. 
Genomic, fully methylated HeLa cell DNA was used as a positive control. (b) 
Graphically representation of the data obtained from all MSPs conducted in a many types 
of blood neoplasms. * 4 samples did not show amplication for PLK2 with either 
methylated or unmenthylated primers. **2 samples did not show amplification for PLK4 
with either methylated or unmethylated primers.  (c) PLK4 and PLK1 protein analysis 
from whole cell lysates prepared from bone marrow aspirates. This is representative data. 
(d) The correlation between methylation status and the protein expression of PLK1 and 
PLK4 in all samples analysed. (e) Graphical representation of the densitometry 
quantification of PLK4 protein levels among those samples that displayed down-
regulation of PLK4. * represents statistical significance p<0.05. Error bars represent the 
standard deviation from the raw values obtained from densitometry analysis.  
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its expression. Aberrant levels of Plk4 may have profound effects on a cell as PLK4 is an 
important mitotic regulator with reduced levels of PLK4 directly impacting centrosome 
maturation resulting in centrosome abnormalities, aneuploidy and thus contributing to 
genomic instability in dividing cells [25, 26]. Consistent with our observations, PLK4 
down-regulation along with centrosome amplification was previously described in 
multiple myeloma [27] and in plasma cell neoplasms, centrosome amplification was 
correlated with a poor prognosis and shortened survival [28]. Lower Plk4 levels may also 
have an effect on the cellular response to cellular stress and DNA damage as  reduced 
PLK4 levels are associated with decreased p53 activity, a factor which likely contributes 
towards the progression of carcinogenesis [24, 25].   
 For PLK2 we found that approximately 70% of lymphoma samples were positive 
for promoter hypermethylation, similar to the findings of Syed et al (2006) for primary B-
cell neoplasms and cell lines.  We obtained a slightly lower proportion of  PLK2 
hypermethylation in our combined samples of MDS and leukemia with 72.2% 
methylation detected, compared to 88.4% methylation in MDS samples as previously 
reported [10, 11]. This difference is attributed to the heterogeneity of MDS, but more 
likely, due to the MDS subtype examined. The vast majority of the samples examined by 
Benetatos et al. (2011) were MDS classified as refractory cytopenia with multi-lineage 
dysplasia (RCMD) or refractory anemia with excess blasts-1 or -2 (RAEB-1, or RAEB-2) 
with intermediate to very high risk, suggestive of a more aggressive MDS subtypes. The 
available clinical data from our samples classified the majority of our cases as low risk 
(data not shown). In MDS, abnormal DNA methylation present in low-risk cases only 
increases with disease aggressiveness or progression [10].  Likewise, in ovarian 
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carcinoma cells, PLK2 hypermethylation proportionally increased with increased drug 
resistance to paclitaxel and carboplatin [19].  
 Previous reports indicated that in B-cell malignancies, the PLK3 promoter region 
remained unmethylated [11]. Interestingly, we observed changes in PLK3 promoter 
methylation and in contrast to Syed et al. (2006) we detected PLK3 promoter methylation 
in 55% of normal samples. This proportion increased in both lymphoma and 
MDS/Leukemia samples, where 78.2% and 86.1% were positive for methylation (Fig. 
5.1a,b). This is the first report of aberrant PLK3 promoter methylation in hematological 
malignancies. Our study differed from Syed et al. (2006) in that they conducted their 
analysis primarily in vitro with several B-cell neoplasm-derived cell lines and a limited 
number of clinical samples consisting of primarily of mantle cell lymphomas [11].  Our 
DNA samples were obtained directly from 78 bone marrow aspirates which included 
several lymphoma subtypes: B-cell, non-Hodgkins, Hodgkins, and follicular lymphomas.   
PLK promoter methylation in familial MDS 
 We also examined the PLK promoter methylation profile in a family that had all 
been diagnosed with MDS. This small group consisted of three females: twin sisters with 
one of them having a daughter. We obtained peripheral blood samples and the bone 
marrow biopsy for the mother, along with bone marrow biopsies for the other family 
members.  In the blood sample from the mother, PLK1 was demethylated and the PLK4 
promoter was hypermethylated (Fig. 5.2a). Bone marrow biopsies for all three family 
members revealed the same promoter methylation profile in all three individuals: a 
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hypomethylated PLK1 promoter and an increase in PLK4 promoter methylation (Fig. 
5.2b), the same methylation profile as the initial peripheral blood sample.  
PLK levels with respect to current protein markers of hematological malignancies 
 Presently, a number of biomarkers have emerged as important indicators of 
prognosis and pathogenicity in hematological malignancies. Examining the extent to 
which PLK4 hypermethylation and expression relates to these biomarkers may provide 
some insight into its translational value. Janus kinase 2 (JAK2) overexpression dovetails 
disease entities and is deregulated in both myeloid and lymphoid neoplasias [29-32].  
JAK2 is a tyrosine kinase integrated into signalling pathways that have a wide-breadth of 
cellular effects which include the proliferation, survival and normal functioning of 
hematopoietic cells [33].  JAK2 undergoes several activating mutations, including a gain 
of copy number at chromosomes 9p.24 [31], an oncogenic point mutation at residue 617 
and several mutations within exon 12 at residues 537-543, all of which generate a 
constitutively active JAK2 [32].  We examined JAK2 protein levels, and overall, JAK2 
was elevated in malignant versus normal samples in lymphoproliferative disorders (Fig. 
5.3a, b). However, we noticed there was a great deal of variation in expression levels, 
with some samples displaying JAK2 overexpression and others displaying reduced JAK2 
levels (Fig. 5.3b). We divided the polarized levels of JAK2 into elevated or down-
regulated expression and paired them with corresponding PLK4 levels.  PLK4 and JAK2 
appear to have an inverse relationship: when JAK2 was overexpressed, PLK4 levels were 
significantly reduced (p<0.05), and inversely, when JAK2 levels were at their lowest, 
PLK4 levels were comparable to- or exceeded the levels found in normal samples (Fig. 
5.3a,c). This is suggestive of a regulatory relationship between these two proteins. We  
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Figure 5.2 PLK promoter analyses of familial MDS cases. (a) Individual PLK 
promoter methylation status as determined by MSP for peripheral blood. 
U=unmethylated, M=methylated. (b) Individual PLK promoter methylation profile as 
determined by MSP of genomic DNA extracted from bone marrow biopsies. The 
comparative normal samples are highlighted by a red box.  U=unmethylated, 
M=methylated. Genomic, fully methylated HeLa cell DNA was used as a positive 
control. 
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also examined a validated substrate of JAK2, protein arginine methyltransferase 5 
(PRMT5). PRMT5 is often down-regulated in hematological malignancies as a result of 
constitutively active JAK2 [34]. On average, there was a trend of PRMT5 being down-
regulated by almost 20% in neoplastic samples in comparison to the normal (Fig. 5.3b).  
JAK2 down-regulation of PRMT5 in hematological malignancies has been linked to the 
promotion of cellular proliferation and colony formation in vitro [34]. Recent work from 
our lab has shown that PRMT5 is also a substrate of PLK4 (Ward et al, Chapter 4 
dissertation) and perhaps JAK2 and PLK4 are antagonistic to each other in the context of 
blood neoplasias.  
We also examined the levels of myeloperoxidase (MPO) and ten-eleven-
translocation 2 (TET2) due to their association with myeloproliferative neoplasms [29, 
30, 35].  TET2, a homologue of the TET family of proteins, along with TET1 and TET3 
are responsible for converting 5-methylcytosine to 5-hydroxymethylcytosine thus 
resulting in DNA demethylation[36]. TET2 frequently undergoes inactivating mutations 
or chromosomal deletions at location 4q.24 in myeloid neoplasias [37] and is down-
regulated in approximately 10-15% of MDS and acute myelogenous leukemias (AML) 
[29].  Interestingly, we found that several MDS and leukemia samples had lowered or 
depleted levels of TET2 (Fig. 5.4a,b) This was also evident in the familial cases of MDS 
(Fig. 5.4b). The lowest levels of PLK4 were associated with the most depleted levels of 
TET2 (Fig. 5.4a-c). The mutations and subsequent reduction of TET2 has been linked to 
an increase in global methylation and genomic methylation errors in regions of genes 
involved in hematopoietic differentiation and cell cycling, suggesting that deregulation of 
methylation marks are not random but are specifically targeted [37]. Perhaps , PLK4 may  
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Figure 5.3 Expression of the PLKs, JAK2, and PRMT5 in blood neoplasms. (a) 
Representative Western blot analysis for protein levels from several lymphoproliferative 
malignancies. Normal lysates were obtained from bone marrow aspirates with no 
detectable pathology. U=unmethylated, M=methylated representing the methylation state 
of respective PLK for that sample. (b) Protein levels for PLK1, JAK2, and PRMT5. 
Densitometry was conducted on a total of 64 samples for each of the proteins noted. 
GAPDH was used as an internal loading control and all samples were normalized to the 
ratio of the normal protein value/GAPDH. Error bars represent the standard deviation 
from raw densitometry values. (c) A comparative analysis of JAK2 expresion with 
respect to corresponding PLK4 levels. *represents the statistical significance with 
p<0.05. Error bars represent the standard deviation for the raw values generated from 
densitometry analysis.  
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be a recipient of these methylation errors in conjunction with increases in methylation at 
the genome level. To examine this, we performed an ELISA-based global methylation 
assay and determined that all malignant samples assayed displayed at least a two-fold 
increase in global methylation compared to the normal (Fig. 5.4c). We previously 
demonstrated that initial Plk4 CpG island hypermethylation is also associated with an 
increase in global methylation in young Plk 4
+/- 
mice [13]. This may be indicative of an 
arms- length relationship between TET2 and PLK4.  
 MPO is an enzyme specific to the myeloid lineage of cells and is often 
dergulataed in MDS and acute myelogenous leukemia (AML) and used as a diagnostic 
marker [38]. It has been associated with disease-free survival and post-transplant 
prognosis in AML [38]. However, we found no distinct pattern between the normal and 
the diseased state (Fig. 5.4a,b). We did have a limited number of MDS and AML 
samples, perhaps with a larger samples size, and a greater variability in disease stages, a 
pattern may have emerged.   
Our results show that PLK4 levels may be tethered to important biomarkers of 
lymphoid and myeloid malignancies, JAK2 and TET2 respectively. However, to further 
determine the impactof this, statistical analysis using correlation co-efficients may 
determine the extent of correlation between PLK4 and JAK2 and TET2 protein levels. 
This suggests that PLK4 expression may be impacted in the progression of hematological 
neoplasms. 
Hypermethylation of the PLK promoter regions in cell-lines derived from hematological 
malignancies  
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To further understand the dysregulation of Polo-like kinases in hematological 
malignancies, we considered the significance of the low oxygen tension innate to the 
bone marrow (BM) microenvironment in both normal and diseased conditions. While the  
 
 
 
Figure 5.4 Analysis of protein levels from MDS/Leukemia-derived bone marrow 
aspirates. (a) Representative Western blot analysis for key markers of myeloid disorders  
U=unmethylated, M=methylated representing the methylation state of respective PLK for 
that sample (b) Western blot analysis of familial MDS samples compared to unrelated 
MDS samples. U=unmethylated, M=methylated representing the methylation state of 
respective PLK for that sample (c) Quantitative levels of TET2 protein compared to 
PLK4 protein expression in normal and MDS/leukemia samples. Error bars represent 
standard deviation. (d) An ELISA-based global methylation assay of genomic DNA from 
familial MDS samples compared to unrelated MDS samples. Relative levels are 
represented with normal global methylation given the arbitrary value of 1.  
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BM hypoxia is important for normal marrow hematopoiesis and stem cell maintenance, 
the unique milieu of the BM provides a reserve rich with growth factors and cytokines, 
augmenting proliferation, survival, and malignancy of blood-derived neoplastic cells 
[39]. Although many have described the methylation-dependent silencing of genes 
involved in cell cycle regulation, DNA damage repair, or apoptosis using in vitro study 
models, very few have examined the methylation status under biologically relevant 
conditions. A number of studies have revealed the microenvironment as a causative 
factor for inducing alterations to the epigenetic landscape, consequently, modulating the 
expression of gene products. Considering that previous work from our lab has 
demonstrated the ability of environmental stimuli to mediate epigenetic marks of the 
PLKs in a cell type-dependent manner [24], we sought to determine whether the hypoxic 
nature of the BM could confer similar aberrant epigenetic features in malignant cells via 
changes in PLK promoter methylation.  
Initially, we screened the methylation status of nine patient-derived 
MDS/leukemia and lymphoma cell lines under standard cell culture conditions via 
methylation-specific PCR analysis (Fig. 5.5a) (Supplementary Table 5.1). Remarkably, 
examination of patient-derived leukemia and lymphoma cell lines in vitro largely 
identified the PLKs as genes subject to methylation-dependent deregulation, seemingly a 
prevalent epigenetic signature in various subtypes of blood neoplasia. All MDS and 
lymphoma cell lines displayed hypermethylation of the PLK2 promoter-associated CpG 
islands in accordance with the previous findings by Benetatos et al. (2011)[10]. However, 
uncharacteristic of most malignant cells, PLK1 promoter methylation was detectable in 
these in vitro models of neoplasia. Moreover, 7/9 and 5/9 of neoplastic cell lines had  
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Figure 5.5 Methylation profiles of MDS/leukemia- and lymphoma-derived cell lines 
at the PLK promoter regions pre- and post-hypoxia. (a) MDS and lymphoma cell lines 
were screened for basal levels of methylation at the PLK promoter CpG islands under 
standard conditions via methylation-specific PCR (MSP) analysis. U = unmethylated, M 
= methylated. Fully methylated HeLa DNA was used as a positive control. (b) Blood 
neoplastic cells were exposed to hypoxia to determine whether PLK promoter regions 
were susceptible to changes in methylation status as a result of the low oxygen 
environment. The effect of hypoxia on mRNA levels was determined by real-time PCR to 
examine HIF1α transcript levels post-hypoxic treatment. (c) Profiling of PLK methylation 
marks was performed via MSP to determine whether hypoxia induced hypermethylation 
in promoter regions in cell lines derived from blood neoplasms. Con = normoxic 
conditions Hyp = hypoxic conditions; U = unmethylated, M = methylated. Fully 
methylated HeLa DNA was used as a positive control. 
 
 
 
 
 
 
185 
 
 
186 
 
 
 
 
 
 
 
Figure 5.6 Hypoxia-induced changes in PLK protein levels. (a) To ascertain whether 
the hypoxic conditions of the BM affect individual PLK protein levels, proteins extracted 
from hypoxia-treated cells were analyzed for changes in PLK protein levels. Western blot 
analysis revealed changes in PLK expression. GAPDH is used as a loading control. (b) 
Changes in PLK1 and PLK4 expression were quantified using densitometry. Error bars 
represent the standard deviation of three independent experiments. * represents statistical 
significance with p<0.05.  
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detectable PLK3 and PLK4 methylation, respectively. To determine whether low oxygen 
tension can target PLK promoter regions, cells were grown in a hypoxia chamber flooded 
with 5% O2, the biologically relevant oxygen level of the bone marrow, for a period of 48 
hours. Post-hypoxia treatment, HIF1a transcript levels were examined to confirm cellular 
response to hypoxic conditions (Fig. 5.5b). Subsequently, the methylation statuses of 
PLK promoter regions were re-evaluated using MSP analysis. Interestingly, all promoter 
areas of PLK3 and PLK4 that were unmethylated prior to hypoxia exposure acquired 
abnormal methylation post-treatment (Fig. 5.5c). Out of all the samples that gained 
promoter methylation post-hypoxia, Meg-01 and Z-138 lymphoma cells were the only 
ones whose gain of PLK4 methylation translated into decreased PLK4 protein levels. 
Intriguingly, a strong inverse relationship between PLK1 and PLK4 protein levels was 
seen in a number of cell lines post-hypoxia (Fig. 5.6a, b). This antagonistic correlation 
between the notorious oncogene and tumor suppressor has been previously reported, as 
aforementioned [13].  
While it is uncertain whether the collective epigenetic lesions of the Polo-like 
kinases is an early event associated with the development and progression of these 
disorders or possibly, a downstream result of transformation which further propagates 
carcinogenesis, insight into PLK methylotype profile can produce valuable information to 
effectively monitor and treat cancer patients. This data, in combination with our in vivo 
bone marrow study, provides evidence that the PLKs are epigenetically deregulated and 
consequently, have perturbed expression levels in hematological malignancies. In 
addition, we also show that upon changes to oxygen tension, the PLK promoter 
associated CpG islands become sensitive to DNA methylation. More than likely, the PLK 
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promoter hypermethylation associated with hypoxia is a progressive process during the 
transformation and pathogenesis of cancer cells. Our experimental results emphasize the 
importance of performing studies under physiologically relevant conditions and suggest 
that hypoxia, a micro-environmental stressor, may prompt changes to PLK promoter 
methylation profile.  
In previous work, we have demonstrated that the PLKs become down-regulated 
with exposure to oxidative stress, whether in the form of hypoxia or reactive oxygen 
species [24]. In our in vitro studies, short term exposure to these environmental stressors 
was sufficient to induce promoter methylation in the PLKs. The life history of a subset of 
B-cell lymphoma patients, with a mean age of 64.8 years, was collected. We examined 
the smoking history and oxygen saturation data of these individuals and noticed that 47% 
of the patients had a history of heavy smoking or were current smokers (Supplementary 
Table 5.2). In addition, there were several non-smokers that also exhibited low oxygen 
saturation rates (<95%). Smoking results in lowered oxygen saturation rates [40] and 
decreased oxygen saturation has been associated with physiologic hypoxic conditions. 
The metabolites generated from smoking can also create reactive oxygen species [41].  
Interestingly, a large-scale study with a cohort of over one million women demonstrated 
chronic cigarette consumption to significantly augment the risk of Hodgkin’s lymphoma, 
mature T-cell malignancies, and myelodysplastic diseases [42]. Perhaps, reduced oxygen 
levels and ROS in these individuals mediate aberrant epigenetic modifications of the 
PLKs.    
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Effect of epigenome-targeting drugs on the methylotype and expression of the Polo-like 
kinases 
 
Blood syndromes, in particular myelodysplasia, are speculated to be 
epigenetically-driven in nature [7].  This paradigm stems in part from the serendipitous 
response, recovery, and improved survival rates seen in MDS patients administered with 
therapies aimed at the reversal of aberrant epigenetic marks [43]. Naturally, considering 
the epigenetic plasticity of cells, large efforts have been directed towards demonstrating 
the efficacy of epigenome-modifying drugs in reversing epigenetic defects and restoring 
expression of specific anti-tumour proteins [44]. Hypomethylating agents have been used 
to reverse aberrantly methylated promoters of the tumour suppressors p15
INK4B
, p73, and 
E-cadherin in myeloid leukemia cells [Farinha et al 2004 Activation of expression of p15, 
p73, and E cadherin in leukemic cells]. Because of the therapeutic benefits associated 
with these drugs, chemical agents targeting the epigenetic machinery are being used 
concurrently with conventional chemotherapy, and importantly, are the mainstay 
treatment regimen for high-risk MDS and lymphoma patients with poor prognosis [43].  
 Low-dose decitabine (5-aza-2'-deoxycytidine) has been approved for the 
treatment of myelodysplastic patients. A cytosine analogue, decitabine (DAC), is able to 
reverse epigenetic mutations by incorporating itself into the newly synthesized daughter 
strand during replication. When DNA methyltransferases (DNMTs) interact with the 
DNA to place methyl groups on CpG dinucleotides, decitabine is able to covalently bind 
and arrest these enzymes [45]. With subsequent rounds of replication, DNMTs become 
depleted within the cell, allowing for a genome-wide decrease in methylation levels and 
reactivation of methylated genes. In contrast, trichostatin A (TSA) and valproic acid 
(VPA) potentiate gene re-expression by inhibiting histone deacetylases (HDACs) which 
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remove acetyl groups from histone tails to repress transcription [46].  By allowing for 
greater persistence of these acetyl groups on histones, HDACs can remodel the chromatin 
structure into a relaxed, open state and initiate gene transcription. Although it may seem 
that DNMT and HDAC inhibitors work independently of another, methylation and 
histone modifications synergistically impact gene expression. Inhibiting DNA 
methylation prevents methyl-binding protein 2-dependent recruitment of histone 
deacetylases and restores gene expression. Sarkar et al. (2011) have also shown inhibitors 
of HDACs to revert promoter CpG methylation via suppression of MAPK1/ERK 
signalling pathway which ultimately results in reduced DNMT1 levels [47].     
It was therefore of interest to determine whether such therapy could potentially 
modulate the epigenetic and transcriptional state of the Polo-like kinases during therapy 
through an in vitro model. MDS/leukemia and lymphoma-derived cells were treated with 
DAC, TSA, and VPA chronically for a period of 5 days under both standard and 
biologically relevant oxygen conditions. In the clinical setting, DAC is administered over 
a period of several months, with clinical symptoms abating by the second round of 
treatment (Anecdotal, Dr. Kanjeekal) Drugs were administered chronically in order to 
characterize the long-term effects of such treatments. Cell viability and global 
methylation assays were performed throughout the period of drug treatment to optimize 
drug dosage and ensure that changes in global methylation take place before cell death 
(Supplementary Fig. 5.1a-c). To highlight the heterogeneity of blood-derived neoplasms, 
drug treatment data from two leukemia and two lymphoma cell lines have been shown 
here. 
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Figure 5.7 Epigenome-targeting drugs affect PLK expression in leukemia-derived 
cells. (a) Leukemic cell lines, Jurkats and K-562, were chronically treated with histone-
modifying drugs, Trichostatin A (TSA) and Valproic Acid (VPA) and a hypomethylating 
agent, Decitabine (DAC) under standard and hypoxic conditions. Expression levels of the 
PLKs, PLK4-associated proteins p53, PRMT5, and DNMT3a, and biomarkers of 
hematological malignancies, TET2 and JAK2, were analysed post-drug treatment. 
GAPDH is used as a loading control. DNA methylation marks on PLK1 and PLK4 
promoters were also examined via MSP. U = unmethylated, M = methylated. Fully 
methylated HeLa DNA was used as a positive control.  
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Post-drug administration, there was a remarkable sensitivity of the polo-like kinases to 
these drugs largely at the functional protein level. Treatment of Jurkats, a T-cell leukemia 
cell line, under normoxic conditions with TSA, VPA, or DAC resulted in decreased 
PLK4 protein levels; in fact, PLK4 is depleted with chronic exposure to decitabine (Fig. 
5.7a). A similar trend is observed in hypoxia where treatment with epigenome-targeting 
drugs results in lower levels of endogenous PLK4. Interestingly, the decrease in PLK4 
protein levels also corresponds with the expression of its known target, PRMT5, as 
reported previously (Ward et al. Chapter 4 dissertation). We have also previously shown 
a converse relationship between p53 and PLK4 (Ward et al. Chapter 4 dissertation). p53 
has been implicated in the transcriptional repression of PLK, potentially by recruitment 
of HDACs and DNMT3a, and consequently, high levels of p53 are associated with low 
levels of PLK4  [48]. Interestingly, this pattern is observed in drug- treated Jurkats under 
both normoxic and hypoxic conditions: upon exposure to any drug, while PLK4 protein 
levels become reduced in comparison to its untreated counterpart, p53 levels increase 
noticeably. As aforementioned, TET2 and JAK2 are important biomarkers of 
hematological malignancies. In accordance with results obtained from our in vivo study, 
high levels of the demethylating enzyme, TET2, is associated with increased levels of 
PLK4 while JAK2 up-regulation is correlated with suppression of PLK4. Derived from 
chronic myelogenous leukemia, K-562 cells, displayed a similar trend with TET2 and 
JAK2 expression in relation to PLK4 levels. As seen in the Jurkats, K-562 had reduced 
PLK4 levels with TSA, VPA, and DAC treatment under hypoxia (Fig. 5.7b). In contrast 
to the Jurkats, under normoxia, PLK4 protein expression in K-562 was up-regulated with 
administration of each drug. The differed response to drugs via PLK4 expression in these  
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leukemic cells is indicative of the heterogeneity of blood disorders. K-562 cells are p53-
deficient and in this case, perhaps, the varied PLK4 response induced by drugs is tethered 
to the p53 status of the cell line.   
The heterogenicity of these blood diseases is further reiterated by the unique 
responses to DNA-modifying drugs in lymphoma-derived cell lines. ST-486 is a cell line 
derived from a patient with Burkitt’s Lymphoma. Chronic treatment of these cells with 
TSA, VPA, and DAC did not alter PLK4 transcriptional activity under hypoxia as PLK4 
expression was comparable to the untreated control (Fig. 5.8a). Intriguingly, TET2 levels 
were also stable throughout the duration of drug treatment in the low oxygen 
environment. Under standard conditions, however, PLK4 protein levels increased 
specifically with decitabine treatment. Moreover, the same inverse relationship between 
PLK1 and PLK4 protein levels was observed in the ST-486 line under normoxia (Fig. 
5.8a). PLK1 is down-regulated when PLK4 levels are the elevated and vice versa. A 
mantle cell lymphoma, Z-138, was the only cell line examined which responded 
significantly to treatment with trichostatin-A in an oxygen-independent manner. The 
efficacy of TSA in increasing acetylation marks and promoting transcription in in vitro 
models has been established previously [3, 49]. In fact, a TSA-analog, vorinostat, is 
currently in phase I and II of clinical trials for the treatment of acute myeloid leukemias 
and lymphomas. Although it has shown tremendous anti-tumor activity with minimal side 
effects in patients [50], perhaps, the efficacy of TSA is augmented in the treatment of 
distinct subtypes of blood neoplasms. In the examined leukemia and lymphoma cell lines, 
PLK2 and PLK3 protein levels seem largely unperturbed by these epigenetic drugs. The 
most notable response 
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Figure 5.8 Impact of DNA-modifying drugs on PLK protein levels in lymphoma 
cells. (a) PLK4 responded to the long-term five-day treatment with epigenome-modifying 
drugs in ST-486 and Z-138 lymphoma cell lines as indicated by changes in protein levels. 
Varied responses to drugs were observed in hypoxia in comparison to normoxia. p53, 
PRMT5, TET2, and JAK2 levels were also examined. MSP analysis was performed to 
determine whether changes in PLK expression occurred via modifications to the PLK 
epigenetic status. U = unmethylated, M = methylated. Fully methylated HeLa DNA was 
used as a positive control.  
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was seen in ST-486 where administration of decitabine resulted in gene silencing of 
PLK2 and PLK3, as noted by depletion of these proteins under standard and hypoxic 
conditions (Fig. 5.8a). It is interesting that a drug is able to evoke either a robust 
expression or complete suppression of PLK4 in a particular subtype of blood disorder but 
not in another. In this study, we also sought to determine whether these DNA-modifying 
drugs targeted the epigenetic status of the PLKs. Surprisingly, MSP analysis of the PLK 
promoter region showed little to no change in the methylation status, even with exposure 
to the DNA methyltransferase inhibitor, decitabine. As our results show distinct changes 
to PLK4 expression under varying treatments, more than likely, it may be that changes in 
methylation of the PLK promoter regions are taking place outside of the region amplified 
by the MSP primers. Bisulfite sequencing may be necessary to identify changes in the 
methylation marks of CpG dinucleotides. There is also potential for modulation of PLK 
expression to be driven through histone modifications rather than DNA methylation. 
Another possibility may be that the baseline transcription of PLK4 has not changed, but 
there may be a change in the protein’s stability. Epigenetic modifying treatments are not 
targeted to specific genes, but rather confer their effects at a global level. Perhaps, as a 
by-product of treatment, an upstream regulator of PLK4 may be activated. This, in 
conjunction with DNA hypermethylation, may further contribute to changes in PLK4 at 
the protein level. 
Our results demonstrate that hypomethylating and histone deacetylase inhibitors 
indeed modulate PLK expression, however, the extent of this regulation seems to be 
dependent on oxygen conditions and likely, on the molecular background of these cell 
lines. Specifically, it is important to recognize that these cells have aberrant cytogenetics 
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and a myriad of biochemical imbalances (Supplementary Table 5.1). For instance, a 
majority of the cell lines used in this study are polyploid, harbour multiple chromosomal 
deletions and translocations, and have irregular molecular behaviours such as perpetual 
secretion of cytokines and inappropriate expression of numerous antigens (ATCC) 
(Supplementary Table 5.1).  In consideration of the nature of these neoplasms, crosstalk 
between genetic alterations and epigenetic state may play an important role in dictating 
the efficacy of these drugs in re-activating tumor suppressors.  
 
Conclusions 
MDS, leukemia, and lymphoma cells are derived from stem cells of the bone 
marrow and it is thought that the heterogeneity seen in these disorders is likely a 
reverberation of the genetic, epigenetic, and molecular heterogeneity within the resulting 
cancer cell population [51]. Inter- and intra-tumor heterogeneity has been extensively 
studied in several tumor types to understand phenotypic and functional differences 
among cancer cells and as well as provide insight into the complex clinical outcomes 
seen during therapy [52, 53]. Our in vitro drug study identifies the PLKs as responsive to 
these epigenome-targeting agents, however, the ability of methyltransferase and HDAC 
inhibitors to target CpG island hypermethylation of the PLKs and the subsequent 
reactivation of these genes varies between subtypes of blood disorders, but more so, 
between normoxia and hypoxia. The diversity of the patients’ profiles presages the 
unique range of responses observed in cell lines at the protein level. This observation is 
also in consistent with the well-described model which posits that many cancers undergo 
clonal evolution and tumorigenic cell differentiation that independently or synergistically 
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contribute to heterogeneity within a cancer population [51]. While this enigma continues 
to be a hindrance in the effective treatment of patients with blood disorders, 
understanding the effect of DNA-modifying drugs on the epigenetic profile of PLKs and 
their expression may provide some insight as to how these highly conserved and essential 
cell cycle-dependent kinases are impacted during therapy. As shown here, under 
particular conditions, drugs have a negative impact on the tumor suppressors PLK2-4 and 
promote the elevation of the oncogenic PLK1. Understanding how epigenetic therapy can 
influences the underlying epigenetic lesions of the PLKs in leukemia and lymphoma-
diseased patients may be a valuable biological predictor in the clinical setting Though 
more studies need to be carried out at this point. 
At the methylome level, there are distinct signatures that are specific to the 
tumour phenotype.  In diffuse large B-cell lymphomas (DLBCL), 15 differentially 
methylated genes were identified, whereas in another subset of aggressive B-cell 
lymphomas, 56 hypermethylated genes were discovered using epigenomic profiling [54, 
55]. At the individual gene level for example, the gene O
6
-methylguanine DNA 
methyltransferase (MGMT), important for genomic stability, is methylated in 39% of 
cases of DLBCLs [56]. Epigenetic studies in blood neoplasms have also been important 
in the identification of DLBCL and AML subtypes, which other than through DNA 
methylation signatures, had no other molecular means of distinction [9, 57].  
Interestingly, the most well-studied methylation-regulated genes in hematologic 
malignancies are tumour suppressors and cyclin-dependent kinase inhibitors like p15
INK4B
 
and p16
INK4A
, which are hypermethylated at a rate of 60% in leukemia and lymphoma 
respectively (reviewed in Esteller 2003).  Prognostic models of MDS methylotype have 
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been proposed in an effort to predict important clinical outcomes like disease-free- and 
overall survival [58]. Our data suggests that the methylation phenotype of the PLKs, is 
associated with a tumourigenic state in hematological malignancies. Moreover, with 
deregulated PLK4 expression affiliated with proteins commonly deregulated in blood 
neoplasms, JAK2 and TET2, the PLK methylation and expression profile may have some 
clinical value as a biomarker.     
 
Materials and Methods 
 
Bone marrow aspirates 
 
 The collection of bone marrow aspirates from patients was conducted under the 
approval of the ethics committee at Windsor Metropolitan Hospital and the research 
ethics committee at the University of Windsor.  
 
DNA Extraction 
 
 DNA from bone marrow aspirates was extracted under sterile conditions. Several 
washes of 1XSSC buffer were used to remove the serum from the blood cells after which 
samples were incubated in proteinase K enzyme for 90 min at 55˚C, followed by a 
standard phenol/chloroform extraction.  Similarly, DNA extractions from cells grown in 
vitro also employed the use of proteinase K, however, samples were incubated at 55˚C 
for 24 hours prior to phenol/chloroform extractions. DNA concentrations were quantified 
using the NanoDrop® ND-1000 spectrophotometer (Thermo Scientific).  
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Methylation specific PCR 
 
 Initially, 2ug of DNA were bisulfite treated as per Herman et al, 1996 [59]. In the 
case where low yields of DNA were recovered from bone marrow aspirates, 200-500ng 
of DNA was used as the starting material and the EZ DNA Methylation-Gold™ kit was 
used to perform the bisulfite conversions (Zymo Research). The bisulfite converted DNA 
was then PCR amplified using PLK-specific primers. PLK1 and PLK4 primer sequences 
are found in [13]. For PLK2 and PLK3 primers sequences, these are the same sequences 
used by Syed et al. 2006 and Ward et al. 2011[13, 14].    
 
Cell culture  
The following cell lines were used in the study: chronic myelogenous leukemia: K-562 
and Meg-01; acute lymphocytic leukemia: Reh; B cell non-Hodgkin’s lymphoma: Z-138; 
and Burkitt’s lymphoma: ST-486, Ramos, Ramos-2G6. The aforementioned cell lines 
were purchased from ATCC (Manassas, VA). Jurkats (T-cell leukemia) were also 
employed in the study and was kindly donated to us by S. Pandey (U of Windsor). The 
cells were cultured in cell-line specific growth media, as recommended by ATCC, 
supplemented with 10% fetal  bovine  or horse serum at 20% O2/5% CO2 (normoxia) or 
at 5% O /5% CO2 (hypoxia).  
Hypomethylation and histone-modifying treatments 
 To perform treatments with epigenome-targeting agents, cells were treated with 
either 0.5 µM 5-aza-2’deoxycytidine (Decitabine -DAC; Sigma), 1 mM valproic acid 
(VPA; Sigma), or 0.5 µM trichostatin A (TSA; Sigma) for a period of 5 days to observe 
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their effects on PLK promoter methylation status. TSA was administered to cells every 
other day, while cells were treated with DAC and VPA every day of the treatment period. 
Cells were passaged every 24 hours with the supplementation of fresh media and if 
necessary, the drugs. After the treatment period, cells were harvested for DNA and 
protein extraction. 
Western blot analysis 
 Whole cell lysates from both bone marrow aspirates and in vitro cultured cells 
were used to quantify protein expression. Samples and cells were lysed using lysis buffer  
(50mM Tris-Cl, 150mM NaCl 1% Triton-X, 0.1% SDS) supplemented with complete 
EDTA-free protease inhibitor cocktail tablets at a ratio of 1:10000 (Roche). The 
following primary antibodies were used to examine respective protein levels PLK4, 
GAPDH, PRMT5 (Cell Signalling); PLK2, PLK3, TET2 (Santa Cruz), PLK1 (Abcam), 
MPO (OWL), and JAK2 (Millipore). Secondary antibodies used were anti-rabbit HRP at 
a ratio of 1:10000(Cell Signalling) and anti-mouse HRP at a ratio of 1:50000 (Sigma) 
 Global methylation assay 
 Genomic DNA from samples was subjected to global methylation analysis using 
the Methylamp Global Methylation quantification kit (Epigentek). Experiments were 
carried out according to manufacturer’s recommendations using 30 ug of DNA. 
Colourimetric analysis was carried out on a Wallac Victor3 140 multilabel counter at 
450nm.  
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Statistical analysis 
 Statistical analyses were carried out using Statistica software version 7.1. Error 
bars represented here are reflective of the standard deviation from the sample size 
indicated or from three independent experiments. * denotes statistical significance 
p<0.05.  
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Supplementary figure 5.1. Cell viability and global methylation changes take place 
in cells upon drug treatment in a dose- and time-dependent manner. Jurkat cells were 
chosen as the standard cell line to determine optimal drug dosage for TSA, VPA, and 
DAC for all cell lines. Cell viability and an ELISA-based global methylation assays were 
performed to ensure that changes in methylation marks were accumulating prior to drug-
induced apoptosis. After 24 hours of each drug treatment, cells were collected for 
Tryphan Blue staining to measure cell death and DNA was extracted for methylation 
assays. Viability and changes in global methylation were assessed each day for a period 
of five days for a) TSA, b) VPA, and c) DAC treatment. 
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Supplementary Table 5.1. Description of MDS/leukemia and lymphoma cell lines. 
Background information of patient-derived MDS/leukemia and lymphoma cell lines 
(ATCC) used in the study including description of disease type, gender, and abnormal 
cell characteristics. All information provided here was obtained from ATCC.     
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Supplementary Table 5.2 Summary of smoking history and oxygen saturation of 
patients. A summary of the patients with lymphoproliferative disorders and their 
smoking history and oxygen saturation levels. The bone marrow for all these patients 
were included in our methylation analysis for the PLKs    
 
 
 
 
 
 
 
 
 
 
 
Population information n=51 % 
Avearage age 
64.75 
 
Number of patients with a 
smoking history 
24 47.0 
Patients with low O2 
Saturation 
9 17.6 
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Supplementary Materials and Methods 
Cell Viability Assay 
Various dosages of demethylating and histone-modifying drugs were administered for a 
period of 5 days to determine the optimal as well as toxic doses. Tryphan Blue staining 
was performed to discriminate between viable and non-viable cells post-drug treatment. 
To do this, a sample of the cell suspension was re-suspended in filter-sterilized Tryphan 
Blue stain at 1:1 ratio. From this mixture, 10 µl of the sample was added to the BioRad 
cell counting chamber slides and placed into the BioRad TC10 Automated Cell Counter 
to measure cell viability. This assay was performed each day of the drug treatment to 
monitor changes in cell survival over time. 
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Chapter 6 
Towards a model for the polo-like kinases and epigenetic regulation: Overall 
summary of conclusions and future directions 
This chapter includes data generated by Gayathri Sivakumar (Plk1 BSP) 
 
 In the last decade, the role of epigenetic modifications as contributors of 
malignancy has been cemented. These reversible modifications have become the 
protagonists in the narrative of cancer research and treatment, with the epigenome 
developing into a liaison of sorts between the environment and the changes in gene 
expression that lead to tumourigenesis. Specific epigenomic aberrancies are often used as 
biomarkers and are paving the way towards personalized medicine, with deregulated 
DNA methylation as the most commonly used epigenetic indicator. The DNA 
hypermethylation profile found in cancers has been dubbed the “hypermethylome” by the 
likes of Manel Esteller and Stephen Baylin [1, 2]. These hypermethylomes include 
several commonly methylated genes in cancers like E-cadherin, p16, and BRCA1; 
hypermethylomes have been assessed within many of the most prevalent cancer types [2]. 
Although these analyses included many genes encoding known tumour suppressors and 
other cell cycle regulators, they are not exhaustive.  The aberrant DNA methylation of the 
Plk family of cell-cycle regulated serine/threonine kinases is emerging as a new and 
potentially important indicator and contributor to tumourigenesis. Here I outline the 
current understanding for the PLKs and epigenetic regulation. The information, based on 
both my results, and the current literature, leads towards a model in which epigenetics 
and the PLKs have a bi-directional  exchange, a  key relationship that has impact at the 
both a basic research and clinical level. This chapter thus includes a systematic overview 
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of the individual PLKs and their association with specific epigenetic marks, with a focus 
on PLK4 as the crux between PLK signalling and the dissemination of epigenetic marks.  
PLK1 
Recent evidence supports a model in which Plk1 levels in normal tissue from 
mice and humans, are maintained at relatively low levels  by an epigenetic mechanism as 
noted by the presence of detectable methylation within its promoter [3, 4] (Ward et al. 
unpublished Chapter 4).  PLK1 is commonly augmented in a myriad of cancer types.  
More specifically, PLK1 becomes upregulated in both human and mouse hepatocellular 
carcinoma (HCC) [4, 5] and in hematological malignancies (Ward et al. Chapter 5 
dissertation). We were the first to identify the loss of promoter methylation of PLK1 
correlated to an increase in its expression. Specifically, in human HCC, samples that 
displayed hypomethylation of PLK1 had almost a 10-fold increase in PLK1 transcripts 
[4].  Using a Plk4
+/- 
mouse model with an inherently high rate of developing HCC, we 
also observed DNA hypomethylation of Plk1 in more than 70% of the HCC samples 
assayed, this was in contrast to normal liver samples which were strongly methylated [4]. 
This loss of methylation directly correlated to Plk1 overexpression at the protein level in 
HCC [4].  In addition, these mice develop several different tumour types other than liver 
cancer, such as soft tissue sarcoma, along with lung and colon tumours. We examined 
these tumours for promoter methylation of Plk1 by MSP and BSP.  These analyses 
revealed a loss of methylation in lung and colon tumours, and soft tissue sarcoma (data 
not published), with 100% of the 14 CpG sites examined within the Plk1 CpG island 
completely hypomethylated. In contrast, in normal tissue and in the normal positive 
control a loss of methylation was not detected (Fig 1).  
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Figure 6.1 Plk1 distribution of methylation marks in 3T3, normal liver and tumor 
samples. Both the 3T3 mouse fibroblast cell line and normal mice liver samples 
exhibited 100% methylation of CpG  sites in the Plk1 promoter region. In contrast, Plk1 
promoter CpG sites were unmethylated in all tumour samples 
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We also observed PLK1 promoter hypomethylation in blood neoplasms with almost 20% 
of malignant human bone marrow aspirates analyzed displaying PLK1 promoter 
hypomethylation with a subsequent increase in PLK1protein levels (Ward et al, Chapter 5 
dissertation). Brauninger et al. (1995) identified the 2.3 kb region immediately upstream 
of the transcriptional start site of PLK1 as sufficient for its transcriptional regulation [6].  
Within this region, PLK1 harbours a 909 base pair CpG island identified in silico [7]. 
This CpG island also overlaps a recognition sequence for the forkhead transcription 
factor, FoxM1 [8].  p53 targets FoxM1 for downregulation, and in cells where there was a 
loss of p53 function, FoxM1 was elevated [9, 10]. FoxM1 is a known transcriptional 
activator for PLK1[5] and its overexpression is followed by PLK1 amplification in 
human HCC, esophageal, and other cancers [5, 11, 12]. At the protein level, PLK1 
phosphorylates FoxM1, increasing its activity, creating a positive feedback loop that 
ultimately promotes the cellular transition through G2/M [13]. It therefore will be of 
interest to examine the FoxM1 levels in tumours that display hypomethylation of the 
PLK1 promoter region.  
PLK1 also has two distinct p53 responsive elements within this region that p53 
binds to, thus, directly leading to the transcriptional repression of PLK1 [14].  
Interestingly, PLK1 promoter methylation responds to oxidative stress in a p53-
dependent manner. Cells exposed to reactive oxygen species harbouring a defective p53 
response displayed promoter hypomethylation with a subsequent increase in PLK1 
protein [3]. This suggests that p53 in conjunction with promoter hypermethylation help to 
downregulate PLK1 expression. In a scenario where there is both promoter 
hypomethylation of PLK1 along with a defective p53 response, the natural consequence 
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would inevitably be the upregulation of PLK1. We also examined the effect of Plk4 
heterozygosity on Plk1 promoter methylation. Plk4 heterozygosity results in a deficiency 
in the p53 response [3, 15] (Ward et al, Chapter 5 dissertation) and in tumours derived 
from Plk4
+/-
 mice, there is a loss of Plk1 promoter methylation [4]. This suggests that 
Plk4 heterozygosity provides the scaffold necessary for the inadvertent upregulation of 
Plk1.  
PLK2 
 PLK2 was the first of the PLKs to be characterized with promoter methylation 
aberrancies in malignancies. Its hypermethylation is a potentially valuable clinical marker 
in that approximately 60-90% of B-cell lymphoma, myelodysplastic syndromes, acute 
myelogenous leukemia, and multiple myeloma display PLK2 DNA hypermethylation 
[16] (Ward et al. Chapter 5 dissertation). PLK2 hypermethylation has been associated 
with better over-all survival in hematological malignancies, more specifically, in the case 
of multiple multiple myeloma this translated to a 48% lowered risk of death [17]. In a 
broad spectrum of hematological malignancies, we were able to detect PLK2 methylation 
in bone marrow aspirates, a procedure which is performed routinely in bone marrow 
biopsies. We were fortunate in that there is more material in aspirates than actual bone 
marrow biopsies and more importantly the aspirates display the same methylation profile.  
The use of the aspirate negates the need for additional bone marrow samples and may be 
of use clinically in that there is less of a burden on patients (Ward et al, Chapter 5 
dissertation).  Consistent with this, others have detected PLK2 promoter 
hypermethylation in the patient’s sera for ovarian cancer cases [18].  PLK2’s methylation 
status as a clinical indicator varies with tumour type. For example, unlike the case for 
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hematological malignancies, in ovarian cancer PLK2 hypermethylation is a poor 
prognostic indicator and is associated with a shorter time to relapse and resistance to the 
commonly used chemotherapeutic agent, paclitaxel [19]. Epigenetically reduced levels of 
PLK2 abrogate the paclitaxel-induced blockade of the transition from the G2 to M phases 
of the cell cycle [18, 19]. 
Oxidative stress, like hypoxia and reactive oxygen species are known to be 
causative agents that induce aberrant epigenetic marks in several tumour types [20-22].  
With the PLKs frequently deregulated by promoter hypermethylation in malignancies, we 
sought to determine if these micro-environmental factors did in fact contribute to PLK 
expression changes. My research found that PLK2 CpG island methylation status is 
subject to changes in the microenvironment in a p53-dependent manner. When HCC and 
osteosarcoma cells with an intact p53 response were exposed to oxidative stress, PLK2 
underwent promoter demethylation paired with an increase in transcripts. However, this 
was not observed in cells where p53 was abrogated [3]. In p53 null cells, like Hep3b and 
Saos-2, PLK2 had a detectable gain in promoter methylation accompanied by a 
corresponding decrease at the protein level [3]. PLK2 hypermethylation has also been 
described in human HCC, an organ that is often subjected to high levels of oxidative 
stress [5]. In these cases, PLK2 downregulation was associated with increased cell 
growth and shorten survival [5].   
 PLK3 
Several CpG islands exist in human PLK3 within the first 2000 base pairs of the 
gene, and the largest is 687 bp in length [3, 7]. However, the mouse Plk3 gene lacks a 
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CpG island within its promoter region [4]. Based on the current literature available to 
date and data generated from our lab, irregular patterns of human PLK3 promoter 
methylation are not as prevalent compared to PLK2. The initial studies implicating 
changes in Plk3 methyaltion status associated with malignancy were conducted by 
Pellegrino et al. (2010). Here they found that in  human HCC that 37.3% of HCCs had an 
increase in PLK3 promoter methylation, which, like PLK2, also correlated to poorer 
patient outcome [5]. An analysis of PLK3 promoter methylation profiles in normal 
human liver tissue and bone marrow aspirates determined that PLK3 promoter 
methylation is detectable in a subset of samples [4, 5] (Ward et al. Chapter 5 
dissertation). These studies suggest that PLK3 promoter methylation may be tissue 
specific.  
Our initial investigation of potentially aberrant PLK3 methylation patterns was  
conducted in B-cell malignancies, with no promoter hypermethylation detected in vitro or 
in primary tumour samples [16].   More recently, we found that PLK3 was 
hypermethylated in almost 80% of lymphoid and myeloid derived neoplasms (Ward et al, 
Chapter 5 Dissertation). This represented a proportional increase of 30% detectable 
promoter methylation in malignancies compared to the methylation patterns observed in 
normal tissue. This difference could be attributed to the larger sample size that we 
examined (n=114) and a greater number of hematological subtypes (Ward et al. Chapter 5 
dissertation).   
The microenvironment also has an effect of Plk3 promoter methylation status. 
Previously, we determined that PLK promoter methylation marks are dynamic and are 
susceptible to change upon exposure to oxidative stress [3]. In vitro, cells derived from 
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human HCC and osteosarcoma display PLK3 promoter methylation, however, unlike the 
other PLKs, post treatment with ROS and hypoxia, no difference in promoter methylation 
was detected, [3]. .  This was also the case in cells derived from blood neoplasms, which 
showed no significant change in presence of hypoxia (Ward et al Chapter 5 dissertation). 
Across a variety of cellular types and with different stressors, little change in the 
promoter methylation of PLK3 has been observed when comparing samples prior to- and 
post-treatment. Even with primers designed to examine different CpG islands, the 
methylation status of PLK3 remained constant [3]. Although there were no detectable 
differences in promoter methylation between treated and untreated cells, the expression at 
the transcript and protein levels was significantly different. Under oxidative stress, 
dramatic changes in PLK3 expression are observed [3].  PLK3 transcript and protein 
levels with cellular exposure to reactive oxygen species in osteosarcoma cells were 
almost undetectable, regardless of the p53 status of the cells. Whereas,  in HCC cells with 
intact p53, ROS exposure triggered an increase in PLK3 levels, regardless of promoter 
methylation status [3]. This suggests that PLK3’s expression may not be tightly tied to its 
promoter methylation, but in fact may be regulated through other mechanisms.  
Another important epigenetic mechanism that may play a role in Plk3 regulation 
is via  microRNAs. MicroRNAs are short, non-coding oligos composed of 21-25 
nucleotides. They mediate the post-transcriptional repression of mRNAs in a sequence-
specific manner [23]. Interestingly, in silico analysis of the PLK3 mRNA sequence, using 
the database Target Scan Human, revealed a very high likely-hood that PLK3’s RNA 
product may be targeted for degradation by microRNAs.  One of the micro-RNAs with a 
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high context score percentile (82%) was miR-24. This miRNA has been associated with 
the silencing of other DNA repair proteins during DNA damage, such as H2AX [24].  
PLK4 
We were the first to describe the regulation of PLK4 expression via promoter 
methylation with age, and in the context of carcinogenesis [4]. We found that, not only is 
Plk4 promoter region targeted for hypermethylation with age in mice, but Plk4
+/-
 mice 
displayed an even further increase in hypermethylation at 9 months of age compared to 
their wild type littermates [4]. Furthermore, 75% of HCC tumours extracted from Plk4
+/-
 
mice were hypermethylated at the CpG island upstream of the Plk4 promoter region with 
an corresponding decrease in Plk4 transcripts and protein compared to age-matched wild 
type mice [4]. This phenotype was also observed in a small sample of human HCC 
samples [4]. Interestingly, at 9 months of age, Plk4
+/-
 mice, displayed a significantly 
higher level of global methylation compared to the wild type mice (Ward et al. 2011) and 
in general Plk4 heterozygosity pre-disposes these mice to abnormal epigenetic 
modifications. For example, When examining the methyltransferases in Plk4
+/-
 MEFs, 
DNMT3a levels were elevated compared to wild type MEFs [3]. DNMT3a is a 
methyltransferase responsible for the establishment of de novo methylation marks. Other 
PLK4 interacting partners, like PRMT5 and p53, which can directly or indirectly mediate 
epigenetic changes, are also deregulated in Plk4 heterozygous cells [3, 4, 15, 25](Ward et 
al, Chapter 4 dissertation). These will be discussed in more detail later on.  
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PLK4 methylation in hematological malignancy 
Haematological malignancies often display aberrant promoter methylation of key 
genes. In the context of the present study, this includes tumour suppressors such as PLK2.  
This along with our results for Plk4 and Plk1 in HCC, led us to examine the methylation 
status for PLK4 in hematological malignancies. We found that PLK4 was 
hypermethylated in almost 80% of lymphomas, myelodysplastic syndromes (MDS), and 
leukemias, while in normal bone marrow aspirates, no promoter methylation was 
observed (Ward et al. Chapter 5 dissertation). PLK4 hypermethylation was accompanied 
by a significant overall decrease in PLK4 protein. This striking shift in PLK4 
downregulation in these malignancies indicated that perhaps the PLK4 promoter 
methylation status may be of value as a clinical or prognostic biomarker. If so, one would 
expect that PLK4 methylation status and levels may be correlated with some of the 
known markers. We therefore screened these samples and assessed the levels of some 
proteins commonly deregulated in hematological malignancies. This included the 
clinically relevant proteins, JAK2 and TET2.  JAK2 expression was inversely correlated 
with PLK4 levels, while TET2 and PLK4 follow similar patterns of downregulation in 
blood neoplasms (Ward et al, Chapter 5 dissertation). These observations support our 
notion that PLK4 may have merit as a biomarker in hematological malignancies.  
PLK4 promoter hypermethylation in vitro and in response to environmental stressors 
PLK4  hypermethylation has been detected in cell lines from diverse cancer types 
including leukemia, lymphoma, hepatocellular carcinoma, and osteosarcoma [3](Ward et 
al, Chapter 5 dissertation). Within these cell types, we have found that the cellular 
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microenvironment plays a significant role in the promoter methylation status of PLK4. 
The PLK4 promoter region is targeted for hypermethylation in response to oxidative 
stressors commonly found in tumourigenesis, such as hypoxia and ROS [3].  This 
hypermethylation of PLK4 is dependent on the p53 status of cells with the p53 null 
sarcoma cell line Saos-2 and the hepatocellular carcinoma cell line Hep3B, displaying a 
loss of PLK4 methylation and an increase at the protein level [3]. These results are 
indicative of the importance of p53’s regulatory effect on PLK4.  We thus explored the 
relationship between PLK4 and p53.  
PLK4 is dynamic, and has a role in the DNA damage response and as a pro-
mitotic protein. Acute stress temporarily stabilizes PLK4, however, sustained stress 
triggers p53 activation accompanied by p53-dependent downregulation of PLK4 at the 
protein level along with promoter hypermethylation at the DNA level [3, 26](Sepal 
Bonni, 2007 Master’s thesis). In normal cells, mechanisms that regulate PLK4 at the 
DNA and protein level provide an efficient approach by which to delay the transition to 
mitosis until the stressor has abated, prompting the repair of DNA damage, or triggering 
the apoptotic response if the damage is too great. Indeed, flow cytometric analysis of 
Plk4 heterozygous MEFs reveal a higher proportion of cells accumulated at the G2/M 
phase of the cell cycle and in an even greater accumulation in response to UV damage 
[27] (Sepal Bonni Master’s thesis; Ward unpublished).  
PLK4 and its novel interacting partner PRMT5 
In chapter 4, I described the characterization of a novel PLK4 interacting partner, 
PRMT5. PRMT5 is evolutionarily conserved and is the only methyltransferase that 
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mediates the symmetric dimethylation of arginine residues at histone and non-histone 
proteins [28].  These methylation marks regulate the expression and activity of many 
proteins, including the master guardian of the genome, p53 [28, 29]. We determined that 
PRMT5 is a substrate of PLK4 and that in normal MEFs, Plk4 and Prmt5 co-localize to 
the centrosomes (Ward et al. Chapter 4 dissertation).  Plk4 levels directly impact Prmt5 
localization, levels, and activity in Plk4
+/- 
MEFs (Ward et al. Chapter 4 dissertation). 
Prmt5’s deregulation in Plk4+/- MEFs leads to mislocalization of Prmt5 and loss of 
arginine methylation marks.  This loss of symmetric arginine methylation marks 
potentially could contribute to an insufficient p53 response in Plk4
+/- 
MEFs exposed to 
DNA damaging agents (Ward et al. Chapter 4 dissertation).  In order for p53 to be 
properly activated, it requires the symmetric methylation of arginine residues at its C-
terminal domain; p53 is also targeted for activation by PLK4 at S392 [25]  [29].  My 
findings revealed that in vitro, Plk4
+/- 
MEFs exposed to a variety of stressors have 
depressed levels of p53 along with decreased p53 activity [3, 15] (Ward et al. Chapter 5 
dissertation ).  In the context of Plk4 heterozygosity, both PRMT5 and p53 are aberrantly 
expressed, suggesting that PLK4 may be a liaison between PRMT5 and p53. The normal 
expression and activity of all three of these proteins is often compromised in a multitude 
of cancers. 
PLK4 at the intersection of epigenetics and cell signalling: a model 
In order to gain a better understanding of how Plk4 heterozosity impacts global 
epigenetic patterns, we should consider PLK4’s known and potential interacting partners. 
Thus far it has been determined that PLK4 phosphorylates several cell cycle regulatory 
proteins such as Cdc25C, Chk2, and p53 [15, 30, 31]. Work presented here also suggests 
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that PLK4 may have a relationship with JAK2 and TET2 (Ward et al. Chapter 5 
dissertation), but there are also several epigenetic modifiers that are targets of PLK4. We 
propose a model where PLK4 is central to the dissemination of several important 
epigenetic modifications through its interaction with PRMT5 and DNMT3a (Fig. 6.2). 
Thus far we have characterized the interaction between PLK4 and PRMT5 (Ward et al. 
Chapter 4 dissertation). In addition, we know Plk4
+/- 
MEFs harbour deregulated levels of 
PRMT5 and DNMT3a [3](Ward et al. Chapter 4 dissertation). Although we have 
established a relationship with PRMT5 and PLK4, we still need to elucidate the specific 
phase of the cell cycle when this interaction occurs. PLK4 is expressed throughout the 
cell cycle, and its abundance is low in  early G1, and peaks in late G1, remaining elevated 
through S and G2/M [32]. It could be that PRMT5 interacts with PLK4 when PLK4 levels 
are at their highest. Beyond the PLK4 and PRMT5’s interaction, the question then 
becomes how are symmetric arginine methylation marks impacted by PLK4 
phosphorylating PRMT5? With Prmt5 primarily localizing to the nucleus in Plk4 
heterozygous MEFs, but more so at the centrosomes and cytoplasm in wild type MEFs, it 
suggests that its interaction with Plk4 may be required for proper cellular localization. 
This can in turn impact its activity and the deposition of arginine methylation (Ward et al. 
Chapter 4 dissertation). Lastly, PLK4 and PRMT5 are involved in the DNA damage 
response and both PLK4 and PRMT5 mediate post-translational modifications on p53 at 
sites associated with p53 activation (Nakamura, et al. Ko et al dissertation). This prompts 
us to ask whether the nature of their interaction changes with DNA damage?  
Plk4 heterozygous MEFs display elevated levels of DNMT3a compared to wild 
type MEFs [3], raising the question of whether this increase is merely a symptom of Plk4 
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heterozygosity, or whether Plk4 and DNMT3a have a direct relationship? Preliminary 
work from our lab has established that PLK4 and DNMT3a are interacting partners as 
indicated in their co-immunoprecipitation from cellular extracts (Ward and Cerghet 
unpublished). However, we have not as yet, determined the nature of this interaction; 
whether DNMT3a is a substrate for phosphorylation by PLK4.   
Future directions 
To address the above questions and scenarios, I propose several experiments. To further 
elucidate the PLK4-DNMT3a interaction, one would employ approaches including kinase 
assays to determine if DNMT3a is a substrate of PLK4; as well as using DNMT3a 
truncation mutants in co-immunoprecipitation experiments to determine the regions 
required for PLK4 and DNMT3a to interact;  ChIP assays with DNMT3a and PLK4 may 
help determine if DNMT3a is responsible for the increase in PLK4 promoter 
hypermethylation seen in malignancy [3, 4]. It will also be valuable to examine the extent 
of DNMT3a deregulation in Plk4 heterozygous MEFs. Is the protein elevation also 
accompanied by an increase in activity, as well as broad-spread changes in sites of 
methylation? Initially, to rule out any false results due to interference from the other 
DNMTs, cells would be treated with mahanine, a plant-derived carbazole alkyloid which 
specifically inhibits DNMT1 and DNMT3b, but not DNMT3a [33]. Post treatment, an 
analysis of genome-wide methylation using a non-isotopic cytosine extensions assay. 
This technique takes advantage of methylation sensitive restriction enzymes, which 
cleave genomic DNA strictly at unmethylated sites, creating 5’guanine overhangs. Then, 
using a single primer extension, Cy5 fluorescently labeled dCTP is incorporated into the 
cleaved site [34]. Recognition sites which have methylated cystosine do not get cleaved  
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Figure 6.2. Downstream implications of downregulation of PLK4 via promoter 
methylation. This diagram incorporates several of the known targets of PLK4 and those 
proteins whose interaction have yet to be fully elucidate (Represented by a dotted line 
and a question mark). It is evident that aberrant downregulation of PLK4 has a domino 
effect that ultimately ends in tumourigenesis.  Of most profound interest is PLK4’s 
interaction with p53, PRMT5 and DNMT3a. The deregulation of these specific pathways 
have global implications resulting in improper DNA damage response, aberrant global 
epigenetic marks and the subsequent deregulation of gene expression.   
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and labeled dCTP is not incorporated. This technique could provide an overall view of 
the global methylation between Plk4 heterozygosity, compared to Plk4 wild type MEFs. 
Dimethylation of histone 3 at arginine 4 (H3R4me2) by PRMT5 acts as a recruiting mark 
for DNMT3a to mediate de novo methylation [35]. In PRMT5 knockdown experiments, 
loss of H3R4me2 resulted in the loss of DNMT3a binding [35]. It is of note that since 
Plk4
+/- 
MEFs lack symmetric dimethylation marks due to reduced Prmt5 levels (Ward et 
al. Chapter 4 dissertation), it is likely that DNMT3a activity may not be guided to 
specific sites of histone methylation resulting in irregular DNA methylation patterns, 
potentially deregulating the expression of important cell cycle regulatory genes. This 
could collectively contribute towards  tumourigenesis. Interestingly, both PRMT5 and 
DNMT3a jointly function in regulating gene expression in erythroid progenitor cells [35]. 
PRMT5 levels are generally reduced in blood neoplasms whose PLK4 promoters are 
hypermethylated (Ward et al, chapter 5 dissertation) and DNMT3a is often deregulated in 
a broad spectrum of hematological malignancies from both lymphoid and myeloid origins 
[36].  It may therefore be prudent to examine DNMT3a levels in hematological 
malignancies that displayed aberrant PLK4 methylation patterns.  
Further elucidating the nature of the interaction triangle among PLK4, PRMT5, 
and p53 would be of scientific and clinical interest. In the case of Prmt5, it is 
mislocalized in Plk4
+/- 
MEFs. Therefore, at a more functional level, determining their 
spatial and temporal association in the cell cycle, with the use of co-immunoprecipitation, 
flow cytometry, and in the context of Plk4 heterozygosity would provide insight into the 
necessity of this pairing as part of normal cell functioning. With regards to the PLK4-
PRMT5-p53 interaction axis, a tri-fluor immunofluorescence approach using Plk4
+/+
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MEFS would provide an in vitro snapshot of how these proteins interact. This assay, in 
combination with cell cycle synchronization and DNA damage, would use antibodies 
specific for phosphorylated residues on p53, such as S15 and S392. Additionally, in the 
presence of DNA damaging agents (UV), immunoprecipitation with an anti-arginine 
methylated p53 antibody in lysates from MEFs, would determine whether Plk4 
heterozygosity does indeed impede Prmt5-mediated p53 activations via arginine 
methylation.   
Additionally, in reviewing the genes deregulated by insufficient Plk4, an 
interesting pattern is emerging.  Recent work from out lab has also identified decreased 
levels of gadd45a, another epigenetic modifier (Sivakumar, G, Master’s thesis). In human 
cells, gadd45a has been validated as a substrate of PLK4, although the full extent of its 
biological significance still remains at large (Sivakum G Master’s thesis and Wu B 
Master’s thesis). Moreover, microarray data also revealed that Plk4 heterozygosity was 
associated with the upregulation of 143 genes, many of which have p53 responsive 
elements in their respective promoter regions  and several are also epigenetic modifiers 
like sap30 (Sin3) and setdb1[27]. These genes were increased by more than 2-fold 
compared to wild type MEFs, and both function as transcriptional regulators in 
conjunction with histone modifying proteins [27, 37, 38].  This suggests that PLK4 has a 
direct impact on the expression of several important disseminators of epigenetic marks, 
and one may even be so bold as to suggest that PLK4 may be a master regulator of 
epigenetic modifications.  Conceivably, CpG island hypermethylation of PLK4 and its 
accompanied depression in tumourigenesis trigger broad-reaching undulations that could 
result in the destabilization of many key epigenetic regulatory pathways.  Here we 
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provide a model by which downregulation of PLK4 can have a potentially devastating 
results on cellular integrity. 
Collectively, these studies highlight the importance of the regulatory pathways of 
the polo-like kinases, and how epigenetic modifications to their respective promoters can 
impact downstream proteins and ultimately, conventional cell cycle dynamics.  
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Date: 12 April 2014 
 
I, Sharon Yong, hereby give my consent to R. Alejandra Ward to use data I generated in 
Chapter 4-PRMT5, A novel substrate of PLK4 is deregulated in Plk4 heterozygous MEFs 
in her dissertation. I am aware that she has given me credit for my contributions.  
Specifically, I contributed the following data: Chapter 4 MEF localization studies in Wild 
type and Plk4 heterozygous MEFs. Figure 5.3 panels a-c. 
 
Sincerely, 
 
Sharon Yong 
Research Assistant 
University of Windsor 
Room 300, Biological Sciences 
yongs@uwindsor.ca 
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Date: 11/04/2014 
 
 
I, Gayathri Sivakumar, hereby give my consent to R. Alejandra Ward to use data I 
generated in (Chapter 4-PRMT5, A novel substrate of PLK4 is deregulated in Plk4 
heterozygous MEFs or Chapter 5- The deregulated methylation of the PLKs in 
hematological malignancies as a potential clinical biomarker) in her dissertation. I am 
aware that she has given me credit for my contributions.  
Specifically, I contributed the following data:  
Chapter 4 Kinase assays with PRMT5 and PLK4; Co-immunoprecipitations of PRMT5 
truncation mutants with PLK4 
Chapter 5 In vitro analysis of PLK methylation profile and protein levels in neoplastic 
cell lines (pre- and post-hypoxia); effect of epigenome-targeting drugs on PLK 
expression in MDS/leukemia and lymphoma cells in standard and hypoxic conditions 
 
Sincerely, 
 
Gayathri Sivakumar 
MSc. Candidate 
University of Windsor 
sivakum@uwindsor.ca 
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Date: 12 April 2014 
 
I, Alan Morettin, hereby give my consent to Rosa Alejandra Ward to use data I generated 
in Chapter 2-Aberrant methylation of Polo-like kinase CpG methylation islands in Plk4 
heterozygous mice in her dissertation.  I am aware that she has given me credit for my 
contributions.  
Specifically, I performed the experiements which are included in Chapter 2 of her PhD 
dissertation. I performed all the MSP analysis in human tissue and isolated murine 
embryonic fibroblasts for the experiments performed.  
 
Sincerely, 
 
 
 
Alan Morettin 
PhD Candidate 
University of Ottawa 
 1535 Alta Vista Dr. Apt. 614 
Ottawa ON 
K1G 3N9 
amore091@uottawa.ca 
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Date: 11/04/2014 
 
 
I, Anna Kozarova, hereby give my consent to R. Alejandra Ward to use data I generated 
in (Chapter 4-PRMT5, A novel substrate of PLK4 is deregulated in Plk4 heterozygous 
MEFs ) in her dissertation. I am aware that she has given me credit for my contributions.  
Specifically, I contributed the following data:  
Chapter 4 Mass spectrometry data that first identified PRMT5 as a potential substrate of 
PLK4 
 
Sincerely, 
Anna Kozarova, PhD 
University of Windsor 
kozarova@uwindsor.ca 
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Date: 11/04/2014 
 
 
I, Brayden Labute, hereby give my consent to R. Alejandra Ward to use data I generated 
in Chapter 5- The deregulated methylation of the PLKs in hematological malignancies as 
a potential clinical biomarker in her dissertation. I am aware that she has given me credit 
for my contributions.  
Specifically, I contributed the following data:  
Chapter 5 – Western blot analysis of p53 protein levels in human bone marrow aspirates 
Sincerely, 
Brayden Labute 
MSc. Candidate 
University of Windsor 
labuteb@uwindsor.ca 
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